id	sid	tid	token	lemma	pos
cord-293860-6kz0iws6	1	1	key	key	NN
cord-293860-6kz0iws6	1	2	:	:	:
cord-293860-6kz0iws6	2	1	cord-293860	cord-293860	NNP
cord-293860-6kz0iws6	2	2	-	-	HYPH
cord-293860-6kz0iws6	2	3	6kz0iws6	6kz0iws6	CD
cord-293860-6kz0iws6	2	4	authors	author	NNS
cord-293860-6kz0iws6	2	5	:	:	:
cord-293860-6kz0iws6	3	1	Qutayba	Qutayba	NNP
cord-293860-6kz0iws6	3	2	Almerie	Almerie	NNP
cord-293860-6kz0iws6	3	3	,	,	,
cord-293860-6kz0iws6	3	4	Muhammad	Muhammad	NNP
cord-293860-6kz0iws6	3	5	;	;	:
cord-293860-6kz0iws6	3	6	Daniel	Daniel	NNP
cord-293860-6kz0iws6	3	7	Kerrigan	Kerrigan	NNP
cord-293860-6kz0iws6	3	8	,	,	,
cord-293860-6kz0iws6	3	9	David	David	NNP
cord-293860-6kz0iws6	3	10	title	title	NN
cord-293860-6kz0iws6	3	11	:	:	:
cord-293860-6kz0iws6	3	12	The	the	DT
cord-293860-6kz0iws6	3	13	Association	Association	NNP
cord-293860-6kz0iws6	3	14	between	between	IN
cord-293860-6kz0iws6	3	15	Obesity	Obesity	NNP
cord-293860-6kz0iws6	3	16	and	and	CC
cord-293860-6kz0iws6	3	17	Poor	Poor	NNP
cord-293860-6kz0iws6	3	18	Outcome	Outcome	NNP
cord-293860-6kz0iws6	3	19	after	after	IN
cord-293860-6kz0iws6	3	20	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	3	21	Indicates	indicate	VBZ
cord-293860-6kz0iws6	3	22	a	a	DT
cord-293860-6kz0iws6	3	23	Potential	potential	JJ
cord-293860-6kz0iws6	3	24	Therapeutic	therapeutic	JJ
cord-293860-6kz0iws6	3	25	Role	role	NN
cord-293860-6kz0iws6	3	26	for	for	IN
cord-293860-6kz0iws6	3	27	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	3	28	date	date	NN
cord-293860-6kz0iws6	3	29	:	:	:
cord-293860-6kz0iws6	3	30	2020	2020	CD
cord-293860-6kz0iws6	3	31	-	-	HYPH
cord-293860-6kz0iws6	3	32	05	05	CD
cord-293860-6kz0iws6	3	33	-	-	HYPH
cord-293860-6kz0iws6	3	34	27	27	CD
cord-293860-6kz0iws6	3	35	journal	journal	NN
cord-293860-6kz0iws6	3	36	:	:	:
cord-293860-6kz0iws6	4	1	Med	Med	NNP
cord-293860-6kz0iws6	4	2	Hypotheses	Hypotheses	NNP
cord-293860-6kz0iws6	4	3	DOI	DOI	NNP
cord-293860-6kz0iws6	4	4	:	:	:
cord-293860-6kz0iws6	4	5	10.1016	10.1016	CD
cord-293860-6kz0iws6	4	6	/	/	SYM
cord-293860-6kz0iws6	4	7	j.mehy.2020.109883	j.mehy.2020.109883	NN
cord-293860-6kz0iws6	4	8	sha	sha	NNP
cord-293860-6kz0iws6	4	9	:	:	:
cord-293860-6kz0iws6	4	10	d1cbc62cd5ebb30669dcc01b5b535d880a96be7f	d1cbc62cd5ebb30669dcc01b5b535d880a96be7f	NNP
cord-293860-6kz0iws6	4	11	doc_id	doc_id	CD
cord-293860-6kz0iws6	4	12	:	:	:
cord-293860-6kz0iws6	4	13	293860	293860	CD
cord-293860-6kz0iws6	5	1	cord_uid	cord_uid	NN
cord-293860-6kz0iws6	5	2	:	:	:
cord-293860-6kz0iws6	6	1	6kz0iws6	6kz0iws6	CD
cord-293860-6kz0iws6	7	1	It	-PRON-	PRP
cord-293860-6kz0iws6	7	2	is	be	VBZ
cord-293860-6kz0iws6	7	3	widely	widely	RB
cord-293860-6kz0iws6	7	4	believed	believe	VBN
cord-293860-6kz0iws6	7	5	that	that	IN
cord-293860-6kz0iws6	7	6	infection	infection	NN
cord-293860-6kz0iws6	7	7	with	with	IN
cord-293860-6kz0iws6	7	8	the	the	DT
cord-293860-6kz0iws6	7	9	SARS	SARS	NNP
cord-293860-6kz0iws6	7	10	-	-	HYPH
cord-293860-6kz0iws6	7	11	CoV2	CoV2	NNP
cord-293860-6kz0iws6	7	12	virus	virus	NN
cord-293860-6kz0iws6	7	13	triggers	trigger	VBZ
cord-293860-6kz0iws6	7	14	a	a	DT
cord-293860-6kz0iws6	7	15	disproportionate	disproportionate	JJ
cord-293860-6kz0iws6	7	16	immune	immune	JJ
cord-293860-6kz0iws6	7	17	response	response	NN
cord-293860-6kz0iws6	7	18	which	which	WDT
cord-293860-6kz0iws6	7	19	causes	cause	VBZ
cord-293860-6kz0iws6	7	20	a	a	DT
cord-293860-6kz0iws6	7	21	devastating	devastating	JJ
cord-293860-6kz0iws6	7	22	systemic	systemic	JJ
cord-293860-6kz0iws6	7	23	injury	injury	NN
cord-293860-6kz0iws6	7	24	,	,	,
cord-293860-6kz0iws6	7	25	particularly	particularly	RB
cord-293860-6kz0iws6	7	26	in	in	IN
cord-293860-6kz0iws6	7	27	individuals	individual	NNS
cord-293860-6kz0iws6	7	28	with	with	IN
cord-293860-6kz0iws6	7	29	obesity	obesity	NN
cord-293860-6kz0iws6	7	30	,	,	,
cord-293860-6kz0iws6	7	31	itself	-PRON-	PRP
cord-293860-6kz0iws6	7	32	a	a	DT
cord-293860-6kz0iws6	7	33	chronic	chronic	JJ
cord-293860-6kz0iws6	7	34	,	,	,
cord-293860-6kz0iws6	7	35	multi	multi	JJ
cord-293860-6kz0iws6	7	36	-	-	JJ
cord-293860-6kz0iws6	7	37	organ	organ	JJ
cord-293860-6kz0iws6	7	38	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	7	39	disease	disease	NN
cord-293860-6kz0iws6	7	40	.	.	.
cord-293860-6kz0iws6	8	1	Immune	immune	JJ
cord-293860-6kz0iws6	8	2	cells	cell	NNS
cord-293860-6kz0iws6	8	3	accumulate	accumulate	VBP
cord-293860-6kz0iws6	8	4	in	in	IN
cord-293860-6kz0iws6	8	5	visceral	visceral	JJ
cord-293860-6kz0iws6	8	6	adipose	adipose	JJ
cord-293860-6kz0iws6	8	7	tissue	tissue	NN
cord-293860-6kz0iws6	8	8	and	and	CC
cord-293860-6kz0iws6	8	9	together	together	RB
cord-293860-6kz0iws6	8	10	with	with	IN
cord-293860-6kz0iws6	8	11	paracrine	paracrine	JJ
cord-293860-6kz0iws6	8	12	adipocytes	adipocyte	NNS
cord-293860-6kz0iws6	8	13	release	release	VBP
cord-293860-6kz0iws6	8	14	a	a	DT
cord-293860-6kz0iws6	8	15	wide	wide	JJ
cord-293860-6kz0iws6	8	16	range	range	NN
cord-293860-6kz0iws6	8	17	of	of	IN
cord-293860-6kz0iws6	8	18	biologically	biologically	RB
cord-293860-6kz0iws6	8	19	active	active	JJ
cord-293860-6kz0iws6	8	20	cytokines	cytokine	NNS
cord-293860-6kz0iws6	8	21	(	(	-LRB-
cord-293860-6kz0iws6	8	22	including	include	VBG
cord-293860-6kz0iws6	8	23	IL-1β	il-1β	ADD
cord-293860-6kz0iws6	8	24	,	,	,
cord-293860-6kz0iws6	8	25	IL5	IL5	NNP
cord-293860-6kz0iws6	8	26	,	,	,
cord-293860-6kz0iws6	8	27	IL6	il6	NN
cord-293860-6kz0iws6	8	28	and	and	CC
cord-293860-6kz0iws6	8	29	IL8	IL8	NNP
cord-293860-6kz0iws6	8	30	)	)	-RRB-
cord-293860-6kz0iws6	8	31	that	that	WDT
cord-293860-6kz0iws6	8	32	can	can	MD
cord-293860-6kz0iws6	8	33	result	result	VB
cord-293860-6kz0iws6	8	34	in	in	IN
cord-293860-6kz0iws6	8	35	both	both	DT
cord-293860-6kz0iws6	8	36	local	local	JJ
cord-293860-6kz0iws6	8	37	,	,	,
cord-293860-6kz0iws6	8	38	pulmonary	pulmonary	JJ
cord-293860-6kz0iws6	8	39	and	and	CC
cord-293860-6kz0iws6	8	40	systemic	systemic	JJ
cord-293860-6kz0iws6	8	41	inflammation	inflammation	NN
cord-293860-6kz0iws6	8	42	.	.	.
cord-293860-6kz0iws6	9	1	A	a	DT
cord-293860-6kz0iws6	9	2	more	more	RBR
cord-293860-6kz0iws6	9	3	intense	intense	JJ
cord-293860-6kz0iws6	9	4	‘	'	``
cord-293860-6kz0iws6	9	5	cytokine	cytokine	NN
cord-293860-6kz0iws6	9	6	storm	storm	NN
cord-293860-6kz0iws6	9	7	’	'	''
cord-293860-6kz0iws6	9	8	is	be	VBZ
cord-293860-6kz0iws6	9	9	postulated	postulate	VBN
cord-293860-6kz0iws6	9	10	as	as	IN
cord-293860-6kz0iws6	9	11	the	the	DT
cord-293860-6kz0iws6	9	12	mechanism	mechanism	NN
cord-293860-6kz0iws6	9	13	behind	behind	IN
cord-293860-6kz0iws6	9	14	the	the	DT
cord-293860-6kz0iws6	9	15	extreme	extreme	JJ
cord-293860-6kz0iws6	9	16	immune	immune	JJ
cord-293860-6kz0iws6	9	17	response	response	NN
cord-293860-6kz0iws6	9	18	seen	see	VBN
cord-293860-6kz0iws6	9	19	in	in	IN
cord-293860-6kz0iws6	9	20	severe	severe	JJ
cord-293860-6kz0iws6	9	21	COVID-19	covid-19	NN
cord-293860-6kz0iws6	9	22	.	.	.
cord-293860-6kz0iws6	10	1	It	-PRON-	PRP
cord-293860-6kz0iws6	10	2	is	be	VBZ
cord-293860-6kz0iws6	10	3	striking	strike	VBG
cord-293860-6kz0iws6	10	4	how	how	WRB
cord-293860-6kz0iws6	10	5	dangerous	dangerous	JJ
cord-293860-6kz0iws6	10	6	the	the	DT
cord-293860-6kz0iws6	10	7	combination	combination	NN
cord-293860-6kz0iws6	10	8	of	of	IN
cord-293860-6kz0iws6	10	9	obesity	obesity	NN
cord-293860-6kz0iws6	10	10	and	and	CC
cord-293860-6kz0iws6	10	11	COVID-19	covid-19	NN
cord-293860-6kz0iws6	10	12	is	be	VBZ
cord-293860-6kz0iws6	10	13	,	,	,
cord-293860-6kz0iws6	10	14	resulting	result	VBG
cord-293860-6kz0iws6	10	15	in	in	IN
cord-293860-6kz0iws6	10	16	a	a	DT
cord-293860-6kz0iws6	10	17	greater	great	JJR
cord-293860-6kz0iws6	10	18	risk	risk	NN
cord-293860-6kz0iws6	10	19	of	of	IN
cord-293860-6kz0iws6	10	20	ICU	ICU	NNP
cord-293860-6kz0iws6	10	21	admission	admission	NN
cord-293860-6kz0iws6	10	22	and	and	CC
cord-293860-6kz0iws6	10	23	a	a	DT
cord-293860-6kz0iws6	10	24	higher	high	JJR
cord-293860-6kz0iws6	10	25	mortality	mortality	NN
cord-293860-6kz0iws6	10	26	.	.	.
cord-293860-6kz0iws6	11	1	Furthermore	furthermore	RB
cord-293860-6kz0iws6	11	2	,	,	,
cord-293860-6kz0iws6	11	3	patients	patient	NNS
cord-293860-6kz0iws6	11	4	from	from	IN
cord-293860-6kz0iws6	11	5	a	a	DT
cord-293860-6kz0iws6	11	6	BAME	BAME	NNP
cord-293860-6kz0iws6	11	7	background	background	NN
cord-293860-6kz0iws6	11	8	appear	appear	VBP
cord-293860-6kz0iws6	11	9	to	to	TO
cord-293860-6kz0iws6	11	10	have	have	VB
cord-293860-6kz0iws6	11	11	increased	increase	VBN
cord-293860-6kz0iws6	11	12	mortality	mortality	NN
cord-293860-6kz0iws6	11	13	after	after	IN
cord-293860-6kz0iws6	11	14	SARS	SARS	NNP
cord-293860-6kz0iws6	11	15	-	-	HYPH
cord-293860-6kz0iws6	11	16	CoV2	cov2	NN
cord-293860-6kz0iws6	11	17	infection	infection	NN
cord-293860-6kz0iws6	11	18	;	;	:
cord-293860-6kz0iws6	11	19	they	-PRON-	PRP
cord-293860-6kz0iws6	11	20	also	also	RB
cord-293860-6kz0iws6	11	21	have	have	VBP
cord-293860-6kz0iws6	11	22	a	a	DT
cord-293860-6kz0iws6	11	23	higher	high	JJR
cord-293860-6kz0iws6	11	24	prevalence	prevalence	NN
cord-293860-6kz0iws6	11	25	of	of	IN
cord-293860-6kz0iws6	11	26	central	central	JJ
cord-293860-6kz0iws6	11	27	obesity	obesity	NN
cord-293860-6kz0iws6	11	28	and	and	CC
cord-293860-6kz0iws6	11	29	its	-PRON-	PRP$
cord-293860-6kz0iws6	11	30	metabolic	metabolic	JJ
cord-293860-6kz0iws6	11	31	complications	complication	NNS
cord-293860-6kz0iws6	11	32	.	.	.
cord-293860-6kz0iws6	12	1	In	in	IN
cord-293860-6kz0iws6	12	2	the	the	DT
cord-293860-6kz0iws6	12	3	absence	absence	NN
cord-293860-6kz0iws6	12	4	of	of	IN
cord-293860-6kz0iws6	12	5	an	an	DT
cord-293860-6kz0iws6	12	6	effective	effective	JJ
cord-293860-6kz0iws6	12	7	vaccine	vaccine	NN
cord-293860-6kz0iws6	12	8	,	,	,
cord-293860-6kz0iws6	12	9	the	the	DT
cord-293860-6kz0iws6	12	10	therapeutic	therapeutic	JJ
cord-293860-6kz0iws6	12	11	potential	potential	NN
cord-293860-6kz0iws6	12	12	of	of	IN
cord-293860-6kz0iws6	12	13	immune	immune	NN
cord-293860-6kz0iws6	12	14	-	-	HYPH
cord-293860-6kz0iws6	12	15	modulating	modulate	VBG
cord-293860-6kz0iws6	12	16	drugs	drug	NNS
cord-293860-6kz0iws6	12	17	is	be	VBZ
cord-293860-6kz0iws6	12	18	a	a	DT
cord-293860-6kz0iws6	12	19	priority	priority	NN
cord-293860-6kz0iws6	12	20	,	,	,
cord-293860-6kz0iws6	12	21	but	but	CC
cord-293860-6kz0iws6	12	22	the	the	DT
cord-293860-6kz0iws6	12	23	development	development	NN
cord-293860-6kz0iws6	12	24	of	of	IN
cord-293860-6kz0iws6	12	25	new	new	JJ
cord-293860-6kz0iws6	12	26	drugs	drug	NNS
cord-293860-6kz0iws6	12	27	is	be	VBZ
cord-293860-6kz0iws6	12	28	expensive	expensive	JJ
cord-293860-6kz0iws6	12	29	and	and	CC
cord-293860-6kz0iws6	12	30	time	time	NN
cord-293860-6kz0iws6	12	31	-	-	HYPH
cord-293860-6kz0iws6	12	32	consuming	consume	VBG
cord-293860-6kz0iws6	12	33	.	.	.
cord-293860-6kz0iws6	13	1	A	a	DT
cord-293860-6kz0iws6	13	2	more	more	RBR
cord-293860-6kz0iws6	13	3	pragmatic	pragmatic	JJ
cord-293860-6kz0iws6	13	4	solution	solution	NN
cord-293860-6kz0iws6	13	5	would	would	MD
cord-293860-6kz0iws6	13	6	be	be	VB
cord-293860-6kz0iws6	13	7	to	to	TO
cord-293860-6kz0iws6	13	8	seek	seek	VB
cord-293860-6kz0iws6	13	9	to	to	TO
cord-293860-6kz0iws6	13	10	repurpose	repurpose	VB
cord-293860-6kz0iws6	13	11	existing	existing	JJ
cord-293860-6kz0iws6	13	12	drugs	drug	NNS
cord-293860-6kz0iws6	13	13	,	,	,
cord-293860-6kz0iws6	13	14	particularly	particularly	RB
cord-293860-6kz0iws6	13	15	those	those	DT
cord-293860-6kz0iws6	13	16	that	that	WDT
cord-293860-6kz0iws6	13	17	might	may	MD
cord-293860-6kz0iws6	13	18	suppress	suppress	VB
cord-293860-6kz0iws6	13	19	the	the	DT
cord-293860-6kz0iws6	13	20	heightened	heighten	VBN
cord-293860-6kz0iws6	13	21	cytokine	cytokine	NN
cord-293860-6kz0iws6	13	22	activity	activity	NN
cord-293860-6kz0iws6	13	23	seen	see	VBN
cord-293860-6kz0iws6	13	24	in	in	IN
cord-293860-6kz0iws6	13	25	obesity	obesity	NN
cord-293860-6kz0iws6	13	26	,	,	,
cord-293860-6kz0iws6	13	27	the	the	DT
cord-293860-6kz0iws6	13	28	major	major	JJ
cord-293860-6kz0iws6	13	29	risk	risk	NN
cord-293860-6kz0iws6	13	30	factor	factor	NN
cord-293860-6kz0iws6	13	31	for	for	IN
cord-293860-6kz0iws6	13	32	a	a	DT
cord-293860-6kz0iws6	13	33	poor	poor	JJ
cord-293860-6kz0iws6	13	34	prognosis	prognosis	NN
cord-293860-6kz0iws6	13	35	in	in	IN
cord-293860-6kz0iws6	13	36	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	13	37	.	.	.
cord-293860-6kz0iws6	14	1	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	14	2	is	be	VBZ
cord-293860-6kz0iws6	14	3	a	a	DT
cord-293860-6kz0iws6	14	4	cysteinyl	cysteinyl	NNP
cord-293860-6kz0iws6	14	5	leukotriene	leukotriene	NN
cord-293860-6kz0iws6	14	6	receptor	receptor	NN
cord-293860-6kz0iws6	14	7	antagonist	antagonist	NN
cord-293860-6kz0iws6	14	8	licensed	license	VBN
cord-293860-6kz0iws6	14	9	to	to	TO
cord-293860-6kz0iws6	14	10	treat	treat	VB
cord-293860-6kz0iws6	14	11	asthma	asthma	NN
cord-293860-6kz0iws6	14	12	and	and	CC
cord-293860-6kz0iws6	14	13	allergic	allergic	JJ
cord-293860-6kz0iws6	14	14	rhinitis	rhinitis	NN
cord-293860-6kz0iws6	14	15	.	.	.
cord-293860-6kz0iws6	15	1	It	-PRON-	PRP
cord-293860-6kz0iws6	15	2	has	have	VBZ
cord-293860-6kz0iws6	15	3	been	be	VBN
cord-293860-6kz0iws6	15	4	shown	show	VBN
cord-293860-6kz0iws6	15	5	to	to	TO
cord-293860-6kz0iws6	15	6	diminish	diminish	VB
cord-293860-6kz0iws6	15	7	pulmonary	pulmonary	JJ
cord-293860-6kz0iws6	15	8	response	response	NN
cord-293860-6kz0iws6	15	9	to	to	IN
cord-293860-6kz0iws6	15	10	antigen	antigen	NN
cord-293860-6kz0iws6	15	11	,	,	,
cord-293860-6kz0iws6	15	12	tissue	tissue	NN
cord-293860-6kz0iws6	15	13	eosinophilia	eosinophilia	NN
cord-293860-6kz0iws6	15	14	and	and	CC
cord-293860-6kz0iws6	15	15	IL-5	IL-5	NNP
cord-293860-6kz0iws6	15	16	expression	expression	NN
cord-293860-6kz0iws6	15	17	in	in	IN
cord-293860-6kz0iws6	15	18	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	15	19	cells	cell	NNS
cord-293860-6kz0iws6	15	20	.	.	.
cord-293860-6kz0iws6	16	1	It	-PRON-	PRP
cord-293860-6kz0iws6	16	2	has	have	VBZ
cord-293860-6kz0iws6	16	3	also	also	RB
cord-293860-6kz0iws6	16	4	been	be	VBN
cord-293860-6kz0iws6	16	5	shown	show	VBN
cord-293860-6kz0iws6	16	6	to	to	TO
cord-293860-6kz0iws6	16	7	decrease	decrease	VB
cord-293860-6kz0iws6	16	8	elevated	elevated	JJ
cord-293860-6kz0iws6	16	9	levels	level	NNS
cord-293860-6kz0iws6	16	10	of	of	IN
cord-293860-6kz0iws6	16	11	IL-1β	il-1β	NN
cord-293860-6kz0iws6	16	12	and	and	CC
cord-293860-6kz0iws6	16	13	IL8	il8	NN
cord-293860-6kz0iws6	16	14	in	in	IN
cord-293860-6kz0iws6	16	15	humans	human	NNS
cord-293860-6kz0iws6	16	16	with	with	IN
cord-293860-6kz0iws6	16	17	viral	viral	JJ
cord-293860-6kz0iws6	16	18	upper	upper	JJ
cord-293860-6kz0iws6	16	19	respiratory	respiratory	JJ
cord-293860-6kz0iws6	16	20	tract	tract	NN
cord-293860-6kz0iws6	16	21	infections	infection	NNS
cord-293860-6kz0iws6	16	22	compared	compare	VBN
cord-293860-6kz0iws6	16	23	with	with	IN
cord-293860-6kz0iws6	16	24	placebo	placebo	NN
cord-293860-6kz0iws6	16	25	-	-	HYPH
cord-293860-6kz0iws6	16	26	treated	treat	VBN
cord-293860-6kz0iws6	16	27	patients	patient	NNS
cord-293860-6kz0iws6	16	28	.	.	.
cord-293860-6kz0iws6	17	1	In	in	IN
cord-293860-6kz0iws6	17	2	addition	addition	NN
cord-293860-6kz0iws6	17	3	,	,	,
cord-293860-6kz0iws6	17	4	in	in	IN
cord-293860-6kz0iws6	17	5	silico	silico	NN
cord-293860-6kz0iws6	17	6	studies	study	NNS
cord-293860-6kz0iws6	17	7	have	have	VBP
cord-293860-6kz0iws6	17	8	demonstrated	demonstrate	VBN
cord-293860-6kz0iws6	17	9	a	a	DT
cord-293860-6kz0iws6	17	10	high	high	JJ
cord-293860-6kz0iws6	17	11	binding	bind	VBG
cord-293860-6kz0iws6	17	12	affinity	affinity	NN
cord-293860-6kz0iws6	17	13	of	of	IN
cord-293860-6kz0iws6	17	14	the	the	DT
cord-293860-6kz0iws6	17	15	montelukast	montelukast	NN
cord-293860-6kz0iws6	17	16	molecule	molecule	NN
cord-293860-6kz0iws6	17	17	to	to	IN
cord-293860-6kz0iws6	17	18	the	the	DT
cord-293860-6kz0iws6	17	19	terminal	terminal	JJ
cord-293860-6kz0iws6	17	20	site	site	NN
cord-293860-6kz0iws6	17	21	of	of	IN
cord-293860-6kz0iws6	17	22	the	the	DT
cord-293860-6kz0iws6	17	23	virus	virus	NN
cord-293860-6kz0iws6	17	24	’s	’s	POS
cord-293860-6kz0iws6	17	25	main	main	JJ
cord-293860-6kz0iws6	17	26	protease	protease	NN
cord-293860-6kz0iws6	17	27	enzyme	enzyme	NN
cord-293860-6kz0iws6	17	28	which	which	WDT
cord-293860-6kz0iws6	17	29	is	be	VBZ
cord-293860-6kz0iws6	17	30	needed	need	VBN
cord-293860-6kz0iws6	17	31	for	for	IN
cord-293860-6kz0iws6	17	32	virus	virus	NN
cord-293860-6kz0iws6	17	33	RNA	RNA	NNP
cord-293860-6kz0iws6	17	34	synthesis	synthesis	NN
cord-293860-6kz0iws6	17	35	and	and	CC
cord-293860-6kz0iws6	17	36	replication	replication	NN
cord-293860-6kz0iws6	17	37	.	.	.
cord-293860-6kz0iws6	18	1	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	18	2	,	,	,
cord-293860-6kz0iws6	18	3	which	which	WDT
cord-293860-6kz0iws6	18	4	is	be	VBZ
cord-293860-6kz0iws6	18	5	cheap	cheap	JJ
cord-293860-6kz0iws6	18	6	,	,	,
cord-293860-6kz0iws6	18	7	safe	safe	JJ
cord-293860-6kz0iws6	18	8	and	and	CC
cord-293860-6kz0iws6	18	9	widely	widely	RB
cord-293860-6kz0iws6	18	10	available	available	JJ
cord-293860-6kz0iws6	18	11	would	would	MD
cord-293860-6kz0iws6	18	12	appear	appear	VB
cord-293860-6kz0iws6	18	13	to	to	TO
cord-293860-6kz0iws6	18	14	have	have	VB
cord-293860-6kz0iws6	18	15	the	the	DT
cord-293860-6kz0iws6	18	16	potential	potential	NN
cord-293860-6kz0iws6	18	17	to	to	TO
cord-293860-6kz0iws6	18	18	be	be	VB
cord-293860-6kz0iws6	18	19	an	an	DT
cord-293860-6kz0iws6	18	20	ideal	ideal	JJ
cord-293860-6kz0iws6	18	21	candidate	candidate	NN
cord-293860-6kz0iws6	18	22	drug	drug	NN
cord-293860-6kz0iws6	18	23	for	for	IN
cord-293860-6kz0iws6	18	24	clinical	clinical	JJ
cord-293860-6kz0iws6	18	25	trials	trial	NNS
cord-293860-6kz0iws6	18	26	,	,	,
cord-293860-6kz0iws6	18	27	particularly	particularly	RB
cord-293860-6kz0iws6	18	28	in	in	IN
cord-293860-6kz0iws6	18	29	early	early	JJ
cord-293860-6kz0iws6	18	30	stage	stage	NN
cord-293860-6kz0iws6	18	31	disease	disease	NN
cord-293860-6kz0iws6	18	32	before	before	IN
cord-293860-6kz0iws6	18	33	irreparable	irreparable	JJ
cord-293860-6kz0iws6	18	34	tissue	tissue	NN
cord-293860-6kz0iws6	18	35	damage	damage	NN
cord-293860-6kz0iws6	18	36	has	have	VBZ
cord-293860-6kz0iws6	18	37	already	already	RB
cord-293860-6kz0iws6	18	38	occurred	occur	VBN
cord-293860-6kz0iws6	18	39	.	.	.
cord-293860-6kz0iws6	19	1	HYPOTHESIS	hypothesis	NN
cord-293860-6kz0iws6	19	2	:	:	:
cord-293860-6kz0iws6	20	1	Through	through	IN
cord-293860-6kz0iws6	20	2	a	a	DT
cord-293860-6kz0iws6	20	3	direct	direct	JJ
cord-293860-6kz0iws6	20	4	anti	anti	JJ
cord-293860-6kz0iws6	20	5	-	-	JJ
cord-293860-6kz0iws6	20	6	viral	viral	JJ
cord-293860-6kz0iws6	20	7	effect	effect	NN
cord-293860-6kz0iws6	20	8	,	,	,
cord-293860-6kz0iws6	20	9	or	or	CC
cord-293860-6kz0iws6	20	10	by	by	IN
cord-293860-6kz0iws6	20	11	suppression	suppression	NN
cord-293860-6kz0iws6	20	12	of	of	IN
cord-293860-6kz0iws6	20	13	heightened	heightened	JJ
cord-293860-6kz0iws6	20	14	cytokine	cytokine	NN
cord-293860-6kz0iws6	20	15	release	release	NN
cord-293860-6kz0iws6	20	16	in	in	IN
cord-293860-6kz0iws6	20	17	response	response	NN
cord-293860-6kz0iws6	20	18	to	to	IN
cord-293860-6kz0iws6	20	19	SARS	SARS	NNP
cord-293860-6kz0iws6	20	20	-	-	HYPH
cord-293860-6kz0iws6	20	21	CoV2	CoV2	NNP
cord-293860-6kz0iws6	20	22	,	,	,
cord-293860-6kz0iws6	20	23	montelukast	montelukast	NNP
cord-293860-6kz0iws6	20	24	will	will	MD
cord-293860-6kz0iws6	20	25	reduce	reduce	VB
cord-293860-6kz0iws6	20	26	the	the	DT
cord-293860-6kz0iws6	20	27	severity	severity	NN
cord-293860-6kz0iws6	20	28	of	of	IN
cord-293860-6kz0iws6	20	29	immune	immune	NN
cord-293860-6kz0iws6	20	30	-	-	HYPH
cord-293860-6kz0iws6	20	31	mediated	mediate	VBN
cord-293860-6kz0iws6	20	32	multiorgan	multiorgan	NN
cord-293860-6kz0iws6	20	33	damage	damage	NN
cord-293860-6kz0iws6	20	34	resulting	result	VBG
cord-293860-6kz0iws6	20	35	from	from	IN
cord-293860-6kz0iws6	20	36	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	20	37	,	,	,
cord-293860-6kz0iws6	20	38	particularly	particularly	RB
cord-293860-6kz0iws6	20	39	in	in	IN
cord-293860-6kz0iws6	20	40	patients	patient	NNS
cord-293860-6kz0iws6	20	41	with	with	IN
cord-293860-6kz0iws6	20	42	central	central	JJ
cord-293860-6kz0iws6	20	43	obesity	obesity	NN
cord-293860-6kz0iws6	20	44	and	and	CC
cord-293860-6kz0iws6	20	45	metabolic	metabolic	JJ
cord-293860-6kz0iws6	20	46	syndrome	syndrome	NN
cord-293860-6kz0iws6	20	47	.	.	.
cord-293860-6kz0iws6	21	1	In	in	IN
cord-293860-6kz0iws6	21	2	the	the	DT
cord-293860-6kz0iws6	21	3	absence	absence	NN
cord-293860-6kz0iws6	21	4	of	of	IN
cord-293860-6kz0iws6	21	5	an	an	DT
cord-293860-6kz0iws6	21	6	effective	effective	JJ
cord-293860-6kz0iws6	21	7	vaccine	vaccine	NN
cord-293860-6kz0iws6	21	8	,	,	,
cord-293860-6kz0iws6	21	9	the	the	DT
cord-293860-6kz0iws6	21	10	therapeutic	therapeutic	JJ
cord-293860-6kz0iws6	21	11	potential	potential	NN
cord-293860-6kz0iws6	21	12	of	of	IN
cord-293860-6kz0iws6	21	13	immune	immune	NN
cord-293860-6kz0iws6	21	14	-	-	HYPH
cord-293860-6kz0iws6	21	15	modulating	modulate	VBG
cord-293860-6kz0iws6	21	16	drugs	drug	NNS
cord-293860-6kz0iws6	21	17	is	be	VBZ
cord-293860-6kz0iws6	21	18	a	a	DT
cord-293860-6kz0iws6	21	19	priority	priority	NN
cord-293860-6kz0iws6	21	20	,	,	,
cord-293860-6kz0iws6	21	21	but	but	CC
cord-293860-6kz0iws6	21	22	the	the	DT
cord-293860-6kz0iws6	21	23	development	development	NN
cord-293860-6kz0iws6	21	24	of	of	IN
cord-293860-6kz0iws6	21	25	new	new	JJ
cord-293860-6kz0iws6	21	26	drugs	drug	NNS
cord-293860-6kz0iws6	21	27	is	be	VBZ
cord-293860-6kz0iws6	21	28	expensive	expensive	JJ
cord-293860-6kz0iws6	21	29	and	and	CC
cord-293860-6kz0iws6	21	30	time	time	NN
cord-293860-6kz0iws6	21	31	-	-	HYPH
cord-293860-6kz0iws6	21	32	consuming	consume	VBG
cord-293860-6kz0iws6	21	33	.	.	.
cord-293860-6kz0iws6	22	1	A	a	DT
cord-293860-6kz0iws6	22	2	more	more	RBR
cord-293860-6kz0iws6	22	3	pragmatic	pragmatic	JJ
cord-293860-6kz0iws6	22	4	solution	solution	NN
cord-293860-6kz0iws6	22	5	would	would	MD
cord-293860-6kz0iws6	22	6	be	be	VB
cord-293860-6kz0iws6	22	7	to	to	TO
cord-293860-6kz0iws6	22	8	seek	seek	VB
cord-293860-6kz0iws6	22	9	to	to	TO
cord-293860-6kz0iws6	22	10	repurpose	repurpose	VB
cord-293860-6kz0iws6	22	11	existing	existing	JJ
cord-293860-6kz0iws6	22	12	drugs	drug	NNS
cord-293860-6kz0iws6	22	13	,	,	,
cord-293860-6kz0iws6	22	14	particularly	particularly	RB
cord-293860-6kz0iws6	22	15	those	those	DT
cord-293860-6kz0iws6	22	16	that	that	WDT
cord-293860-6kz0iws6	22	17	might	may	MD
cord-293860-6kz0iws6	22	18	suppress	suppress	VB
cord-293860-6kz0iws6	22	19	the	the	DT
cord-293860-6kz0iws6	22	20	heightened	heighten	VBN
cord-293860-6kz0iws6	22	21	cytokine	cytokine	NN
cord-293860-6kz0iws6	22	22	activity	activity	NN
cord-293860-6kz0iws6	22	23	seen	see	VBN
cord-293860-6kz0iws6	22	24	in	in	IN
cord-293860-6kz0iws6	22	25	obesity	obesity	NN
cord-293860-6kz0iws6	22	26	,	,	,
cord-293860-6kz0iws6	22	27	the	the	DT
cord-293860-6kz0iws6	22	28	major	major	JJ
cord-293860-6kz0iws6	22	29	risk	risk	NN
cord-293860-6kz0iws6	22	30	factor	factor	NN
cord-293860-6kz0iws6	22	31	for	for	IN
cord-293860-6kz0iws6	22	32	a	a	DT
cord-293860-6kz0iws6	22	33	poor	poor	JJ
cord-293860-6kz0iws6	22	34	prognosis	prognosis	NN
cord-293860-6kz0iws6	22	35	in	in	IN
cord-293860-6kz0iws6	22	36	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	22	37	.	.	.
cord-293860-6kz0iws6	23	1	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	23	2	is	be	VBZ
cord-293860-6kz0iws6	23	3	a	a	DT
cord-293860-6kz0iws6	23	4	cysteinyl	cysteinyl	NNP
cord-293860-6kz0iws6	23	5	leukotriene	leukotriene	NN
cord-293860-6kz0iws6	23	6	receptor	receptor	NN
cord-293860-6kz0iws6	23	7	antagonist	antagonist	NN
cord-293860-6kz0iws6	23	8	licensed	license	VBN
cord-293860-6kz0iws6	23	9	to	to	TO
cord-293860-6kz0iws6	23	10	treat	treat	VB
cord-293860-6kz0iws6	23	11	asthma	asthma	NN
cord-293860-6kz0iws6	23	12	and	and	CC
cord-293860-6kz0iws6	23	13	allergic	allergic	JJ
cord-293860-6kz0iws6	23	14	rhinitis	rhinitis	NN
cord-293860-6kz0iws6	23	15	.	.	.
cord-293860-6kz0iws6	24	1	It	-PRON-	PRP
cord-293860-6kz0iws6	24	2	has	have	VBZ
cord-293860-6kz0iws6	24	3	been	be	VBN
cord-293860-6kz0iws6	24	4	shown	show	VBN
cord-293860-6kz0iws6	24	5	to	to	TO
cord-293860-6kz0iws6	24	6	diminish	diminish	VB
cord-293860-6kz0iws6	24	7	pulmonary	pulmonary	JJ
cord-293860-6kz0iws6	24	8	response	response	NN
cord-293860-6kz0iws6	24	9	to	to	IN
cord-293860-6kz0iws6	24	10	antigen	antigen	NN
cord-293860-6kz0iws6	24	11	,	,	,
cord-293860-6kz0iws6	24	12	tissue	tissue	NN
cord-293860-6kz0iws6	24	13	eosinophilia	eosinophilia	NN
cord-293860-6kz0iws6	24	14	and	and	CC
cord-293860-6kz0iws6	24	15	IL-5	IL-5	NNP
cord-293860-6kz0iws6	24	16	expression	expression	NN
cord-293860-6kz0iws6	24	17	in	in	IN
cord-293860-6kz0iws6	24	18	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	24	19	cells	cell	NNS
cord-293860-6kz0iws6	24	20	.	.	.
cord-293860-6kz0iws6	25	1	It	-PRON-	PRP
cord-293860-6kz0iws6	25	2	has	have	VBZ
cord-293860-6kz0iws6	25	3	also	also	RB
cord-293860-6kz0iws6	25	4	been	be	VBN
cord-293860-6kz0iws6	25	5	shown	show	VBN
cord-293860-6kz0iws6	25	6	to	to	TO
cord-293860-6kz0iws6	25	7	decrease	decrease	VB
cord-293860-6kz0iws6	25	8	elevated	elevated	JJ
cord-293860-6kz0iws6	25	9	levels	level	NNS
cord-293860-6kz0iws6	25	10	of	of	IN
cord-293860-6kz0iws6	25	11	IL-1	IL-1	NNP
cord-293860-6kz0iws6	25	12	and	and	CC
cord-293860-6kz0iws6	25	13	IL8	il8	VB
cord-293860-6kz0iws6	25	14	in	in	IN
cord-293860-6kz0iws6	25	15	humans	human	NNS
cord-293860-6kz0iws6	25	16	with	with	IN
cord-293860-6kz0iws6	25	17	viral	viral	JJ
cord-293860-6kz0iws6	25	18	upper	upper	JJ
cord-293860-6kz0iws6	25	19	respiratory	respiratory	JJ
cord-293860-6kz0iws6	25	20	tract	tract	NN
cord-293860-6kz0iws6	25	21	infections	infection	NNS
cord-293860-6kz0iws6	25	22	compared	compare	VBN
cord-293860-6kz0iws6	25	23	with	with	IN
cord-293860-6kz0iws6	25	24	placebo	placebo	NN
cord-293860-6kz0iws6	25	25	-	-	HYPH
cord-293860-6kz0iws6	25	26	treated	treat	VBN
cord-293860-6kz0iws6	25	27	patients	patient	NNS
cord-293860-6kz0iws6	25	28	.	.	.
cord-293860-6kz0iws6	26	1	In	in	IN
cord-293860-6kz0iws6	26	2	addition	addition	NN
cord-293860-6kz0iws6	26	3	,	,	,
cord-293860-6kz0iws6	26	4	in	in	IN
cord-293860-6kz0iws6	26	5	silico	silico	NN
cord-293860-6kz0iws6	26	6	studies	study	NNS
cord-293860-6kz0iws6	26	7	have	have	VBP
cord-293860-6kz0iws6	26	8	demonstrated	demonstrate	VBN
cord-293860-6kz0iws6	26	9	a	a	DT
cord-293860-6kz0iws6	26	10	high	high	JJ
cord-293860-6kz0iws6	26	11	binding	bind	VBG
cord-293860-6kz0iws6	26	12	affinity	affinity	NN
cord-293860-6kz0iws6	26	13	of	of	IN
cord-293860-6kz0iws6	26	14	the	the	DT
cord-293860-6kz0iws6	26	15	montelukast	montelukast	NN
cord-293860-6kz0iws6	26	16	molecule	molecule	NN
cord-293860-6kz0iws6	26	17	to	to	IN
cord-293860-6kz0iws6	26	18	the	the	DT
cord-293860-6kz0iws6	26	19	terminal	terminal	JJ
cord-293860-6kz0iws6	26	20	site	site	NN
cord-293860-6kz0iws6	26	21	of	of	IN
cord-293860-6kz0iws6	26	22	the	the	DT
cord-293860-6kz0iws6	26	23	virus	virus	NN
cord-293860-6kz0iws6	26	24	's	's	POS
cord-293860-6kz0iws6	26	25	main	main	JJ
cord-293860-6kz0iws6	26	26	protease	protease	NN
cord-293860-6kz0iws6	26	27	enzyme	enzyme	NN
cord-293860-6kz0iws6	26	28	which	which	WDT
cord-293860-6kz0iws6	26	29	is	be	VBZ
cord-293860-6kz0iws6	26	30	needed	need	VBN
cord-293860-6kz0iws6	26	31	for	for	IN
cord-293860-6kz0iws6	26	32	virus	virus	NN
cord-293860-6kz0iws6	26	33	RNA	RNA	NNP
cord-293860-6kz0iws6	26	34	synthesis	synthesis	NN
cord-293860-6kz0iws6	26	35	and	and	CC
cord-293860-6kz0iws6	26	36	replication	replication	NN
cord-293860-6kz0iws6	26	37	.	.	.
cord-293860-6kz0iws6	27	1	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	27	2	,	,	,
cord-293860-6kz0iws6	27	3	which	which	WDT
cord-293860-6kz0iws6	27	4	is	be	VBZ
cord-293860-6kz0iws6	27	5	cheap	cheap	JJ
cord-293860-6kz0iws6	27	6	,	,	,
cord-293860-6kz0iws6	27	7	safe	safe	JJ
cord-293860-6kz0iws6	27	8	and	and	CC
cord-293860-6kz0iws6	27	9	widely	widely	RB
cord-293860-6kz0iws6	27	10	available	available	JJ
cord-293860-6kz0iws6	27	11	would	would	MD
cord-293860-6kz0iws6	27	12	appear	appear	VB
cord-293860-6kz0iws6	27	13	to	to	TO
cord-293860-6kz0iws6	27	14	have	have	VB
cord-293860-6kz0iws6	27	15	the	the	DT
cord-293860-6kz0iws6	27	16	potential	potential	NN
cord-293860-6kz0iws6	27	17	to	to	TO
cord-293860-6kz0iws6	27	18	be	be	VB
cord-293860-6kz0iws6	27	19	an	an	DT
cord-293860-6kz0iws6	27	20	ideal	ideal	JJ
cord-293860-6kz0iws6	27	21	candidate	candidate	NN
cord-293860-6kz0iws6	27	22	drug	drug	NN
cord-293860-6kz0iws6	27	23	for	for	IN
cord-293860-6kz0iws6	27	24	clinical	clinical	JJ
cord-293860-6kz0iws6	27	25	trials	trial	NNS
cord-293860-6kz0iws6	27	26	,	,	,
cord-293860-6kz0iws6	27	27	particularly	particularly	RB
cord-293860-6kz0iws6	27	28	in	in	IN
cord-293860-6kz0iws6	27	29	early	early	JJ
cord-293860-6kz0iws6	27	30	stage	stage	NN
cord-293860-6kz0iws6	27	31	disease	disease	NN
cord-293860-6kz0iws6	27	32	before	before	IN
cord-293860-6kz0iws6	27	33	irreparable	irreparable	JJ
cord-293860-6kz0iws6	27	34	tissue	tissue	NN
cord-293860-6kz0iws6	27	35	damage	damage	NN
cord-293860-6kz0iws6	27	36	has	have	VBZ
cord-293860-6kz0iws6	27	37	already	already	RB
cord-293860-6kz0iws6	27	38	occurred	occur	VBN
cord-293860-6kz0iws6	27	39	.	.	.
cord-293860-6kz0iws6	28	1	Through	through	IN
cord-293860-6kz0iws6	28	2	a	a	DT
cord-293860-6kz0iws6	28	3	direct	direct	JJ
cord-293860-6kz0iws6	28	4	anti	anti	JJ
cord-293860-6kz0iws6	28	5	-	-	JJ
cord-293860-6kz0iws6	28	6	viral	viral	JJ
cord-293860-6kz0iws6	28	7	effect	effect	NN
cord-293860-6kz0iws6	28	8	,	,	,
cord-293860-6kz0iws6	28	9	or	or	CC
cord-293860-6kz0iws6	28	10	by	by	IN
cord-293860-6kz0iws6	28	11	suppression	suppression	NN
cord-293860-6kz0iws6	28	12	of	of	IN
cord-293860-6kz0iws6	28	13	heightened	heightened	JJ
cord-293860-6kz0iws6	28	14	cytokine	cytokine	NN
cord-293860-6kz0iws6	28	15	release	release	NN
cord-293860-6kz0iws6	28	16	in	in	IN
cord-293860-6kz0iws6	28	17	response	response	NN
cord-293860-6kz0iws6	28	18	to	to	IN
cord-293860-6kz0iws6	28	19	SARS	SARS	NNP
cord-293860-6kz0iws6	28	20	-	-	HYPH
cord-293860-6kz0iws6	28	21	CoV2	CoV2	NNP
cord-293860-6kz0iws6	28	22	,	,	,
cord-293860-6kz0iws6	28	23	montelukast	montelukast	NNP
cord-293860-6kz0iws6	28	24	will	will	MD
cord-293860-6kz0iws6	28	25	reduce	reduce	VB
cord-293860-6kz0iws6	28	26	the	the	DT
cord-293860-6kz0iws6	28	27	severity	severity	NN
cord-293860-6kz0iws6	28	28	of	of	IN
cord-293860-6kz0iws6	28	29	immune	immune	NN
cord-293860-6kz0iws6	28	30	-	-	HYPH
cord-293860-6kz0iws6	28	31	mediated	mediate	VBN
cord-293860-6kz0iws6	28	32	multiorgan	multiorgan	NN
cord-293860-6kz0iws6	28	33	damage	damage	NN
cord-293860-6kz0iws6	28	34	resulting	result	VBG
cord-293860-6kz0iws6	28	35	from	from	IN
cord-293860-6kz0iws6	28	36	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	28	37	,	,	,
cord-293860-6kz0iws6	28	38	particularly	particularly	RB
cord-293860-6kz0iws6	28	39	in	in	IN
cord-293860-6kz0iws6	28	40	patients	patient	NNS
cord-293860-6kz0iws6	28	41	with	with	IN
cord-293860-6kz0iws6	28	42	central	central	JJ
cord-293860-6kz0iws6	28	43	obesity	obesity	NN
cord-293860-6kz0iws6	28	44	and	and	CC
cord-293860-6kz0iws6	28	45	metabolic	metabolic	JJ
cord-293860-6kz0iws6	28	46	syndrome	syndrome	NN
cord-293860-6kz0iws6	28	47	.	.	.
cord-293860-6kz0iws6	29	1	It	-PRON-	PRP
cord-293860-6kz0iws6	29	2	is	be	VBZ
cord-293860-6kz0iws6	29	3	widely	widely	RB
cord-293860-6kz0iws6	29	4	believed	believe	VBN
cord-293860-6kz0iws6	29	5	that	that	IN
cord-293860-6kz0iws6	29	6	infection	infection	NN
cord-293860-6kz0iws6	29	7	with	with	IN
cord-293860-6kz0iws6	29	8	the	the	DT
cord-293860-6kz0iws6	29	9	SARS	SARS	NNP
cord-293860-6kz0iws6	29	10	-	-	HYPH
cord-293860-6kz0iws6	29	11	CoV2	CoV2	NNP
cord-293860-6kz0iws6	29	12	virus	virus	NN
cord-293860-6kz0iws6	29	13	triggers	trigger	VBZ
cord-293860-6kz0iws6	29	14	a	a	DT
cord-293860-6kz0iws6	29	15	disproportionate	disproportionate	JJ
cord-293860-6kz0iws6	29	16	immune	immune	JJ
cord-293860-6kz0iws6	29	17	response	response	NN
cord-293860-6kz0iws6	29	18	which	which	WDT
cord-293860-6kz0iws6	29	19	causes	cause	VBZ
cord-293860-6kz0iws6	29	20	a	a	DT
cord-293860-6kz0iws6	29	21	devastating	devastating	JJ
cord-293860-6kz0iws6	29	22	systemic	systemic	JJ
cord-293860-6kz0iws6	29	23	injury	injury	NN
cord-293860-6kz0iws6	29	24	,	,	,
cord-293860-6kz0iws6	29	25	particularly	particularly	RB
cord-293860-6kz0iws6	29	26	in	in	IN
cord-293860-6kz0iws6	29	27	individuals	individual	NNS
cord-293860-6kz0iws6	29	28	with	with	IN
cord-293860-6kz0iws6	29	29	obesity	obesity	NN
cord-293860-6kz0iws6	29	30	,	,	,
cord-293860-6kz0iws6	29	31	itself	-PRON-	PRP
cord-293860-6kz0iws6	29	32	a	a	DT
cord-293860-6kz0iws6	29	33	chronic	chronic	JJ
cord-293860-6kz0iws6	29	34	,	,	,
cord-293860-6kz0iws6	29	35	multi	multi	JJ
cord-293860-6kz0iws6	29	36	-	-	JJ
cord-293860-6kz0iws6	29	37	organ	organ	JJ
cord-293860-6kz0iws6	29	38	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	29	39	disease	disease	NN
cord-293860-6kz0iws6	29	40	.	.	.
cord-293860-6kz0iws6	30	1	Immune	immune	JJ
cord-293860-6kz0iws6	30	2	cells	cell	NNS
cord-293860-6kz0iws6	30	3	accumulate	accumulate	VBP
cord-293860-6kz0iws6	30	4	in	in	IN
cord-293860-6kz0iws6	30	5	visceral	visceral	JJ
cord-293860-6kz0iws6	30	6	adipose	adipose	JJ
cord-293860-6kz0iws6	30	7	tissue	tissue	NN
cord-293860-6kz0iws6	30	8	and	and	CC
cord-293860-6kz0iws6	30	9	together	together	RB
cord-293860-6kz0iws6	30	10	with	with	IN
cord-293860-6kz0iws6	30	11	paracrine	paracrine	JJ
cord-293860-6kz0iws6	30	12	adipocytes	adipocyte	NNS
cord-293860-6kz0iws6	30	13	release	release	VBP
cord-293860-6kz0iws6	30	14	a	a	DT
cord-293860-6kz0iws6	30	15	wide	wide	JJ
cord-293860-6kz0iws6	30	16	range	range	NN
cord-293860-6kz0iws6	30	17	of	of	IN
cord-293860-6kz0iws6	30	18	biologically	biologically	RB
cord-293860-6kz0iws6	30	19	active	active	JJ
cord-293860-6kz0iws6	30	20	cytokines	cytokine	NNS
cord-293860-6kz0iws6	30	21	(	(	-LRB-
cord-293860-6kz0iws6	30	22	including	include	VBG
cord-293860-6kz0iws6	30	23	IL-1	IL-1	NNP
cord-293860-6kz0iws6	30	24	,	,	,
cord-293860-6kz0iws6	30	25	IL5	IL5	NNP
cord-293860-6kz0iws6	30	26	,	,	,
cord-293860-6kz0iws6	30	27	IL6	il6	NN
cord-293860-6kz0iws6	30	28	and	and	CC
cord-293860-6kz0iws6	30	29	IL8	IL8	NNP
cord-293860-6kz0iws6	30	30	)	)	-RRB-
cord-293860-6kz0iws6	30	31	that	that	WDT
cord-293860-6kz0iws6	30	32	can	can	MD
cord-293860-6kz0iws6	30	33	result	result	VB
cord-293860-6kz0iws6	30	34	in	in	IN
cord-293860-6kz0iws6	30	35	both	both	DT
cord-293860-6kz0iws6	30	36	local	local	JJ
cord-293860-6kz0iws6	30	37	,	,	,
cord-293860-6kz0iws6	30	38	pulmonary	pulmonary	JJ
cord-293860-6kz0iws6	30	39	and	and	CC
cord-293860-6kz0iws6	30	40	systemic	systemic	JJ
cord-293860-6kz0iws6	30	41	inflammation	inflammation	NN
cord-293860-6kz0iws6	30	42	1	1	CD
cord-293860-6kz0iws6	30	43	-	-	SYM
cord-293860-6kz0iws6	30	44	3	3	CD
cord-293860-6kz0iws6	30	45	.	.	.
cord-293860-6kz0iws6	31	1	A	a	DT
cord-293860-6kz0iws6	31	2	more	more	RBR
cord-293860-6kz0iws6	31	3	intense	intense	JJ
cord-293860-6kz0iws6	31	4	'	'	``
cord-293860-6kz0iws6	31	5	cytokine	cytokine	NN
cord-293860-6kz0iws6	31	6	storm	storm	NN
cord-293860-6kz0iws6	31	7	'	'	''
cord-293860-6kz0iws6	31	8	is	be	VBZ
cord-293860-6kz0iws6	31	9	postulated	postulate	VBN
cord-293860-6kz0iws6	31	10	as	as	IN
cord-293860-6kz0iws6	31	11	the	the	DT
cord-293860-6kz0iws6	31	12	mechanism	mechanism	NN
cord-293860-6kz0iws6	31	13	behind	behind	IN
cord-293860-6kz0iws6	31	14	the	the	DT
cord-293860-6kz0iws6	31	15	extreme	extreme	JJ
cord-293860-6kz0iws6	31	16	immune	immune	JJ
cord-293860-6kz0iws6	31	17	response	response	NN
cord-293860-6kz0iws6	31	18	seen	see	VBN
cord-293860-6kz0iws6	31	19	in	in	IN
cord-293860-6kz0iws6	31	20	severe	severe	JJ
cord-293860-6kz0iws6	31	21	COVID-19	covid-19	NN
cord-293860-6kz0iws6	31	22	.	.	.
cord-293860-6kz0iws6	32	1	It	-PRON-	PRP
cord-293860-6kz0iws6	32	2	is	be	VBZ
cord-293860-6kz0iws6	32	3	striking	strike	VBG
cord-293860-6kz0iws6	32	4	how	how	WRB
cord-293860-6kz0iws6	32	5	dangerous	dangerous	JJ
cord-293860-6kz0iws6	32	6	the	the	DT
cord-293860-6kz0iws6	32	7	combination	combination	NN
cord-293860-6kz0iws6	32	8	of	of	IN
cord-293860-6kz0iws6	32	9	obesity	obesity	NN
cord-293860-6kz0iws6	32	10	and	and	CC
cord-293860-6kz0iws6	32	11	COVID-19	covid-19	NN
cord-293860-6kz0iws6	32	12	is	be	VBZ
cord-293860-6kz0iws6	32	13	,	,	,
cord-293860-6kz0iws6	32	14	resulting	result	VBG
cord-293860-6kz0iws6	32	15	in	in	IN
cord-293860-6kz0iws6	32	16	a	a	DT
cord-293860-6kz0iws6	32	17	greater	great	JJR
cord-293860-6kz0iws6	32	18	risk	risk	NN
cord-293860-6kz0iws6	32	19	of	of	IN
cord-293860-6kz0iws6	32	20	ICU	ICU	NNP
cord-293860-6kz0iws6	32	21	admission	admission	NN
cord-293860-6kz0iws6	32	22	and	and	CC
cord-293860-6kz0iws6	32	23	a	a	DT
cord-293860-6kz0iws6	32	24	higher	high	JJR
cord-293860-6kz0iws6	32	25	mortality	mortality	NN
cord-293860-6kz0iws6	32	26	4	4	CD
cord-293860-6kz0iws6	32	27	,	,	,
cord-293860-6kz0iws6	32	28	suggesting	suggest	VBG
cord-293860-6kz0iws6	32	29	that	that	IN
cord-293860-6kz0iws6	32	30	the	the	DT
cord-293860-6kz0iws6	32	31	already	already	RB
cord-293860-6kz0iws6	32	32	heightened	heighten	VBN
cord-293860-6kz0iws6	32	33	background	background	NN
cord-293860-6kz0iws6	32	34	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	32	35	process	process	NN
cord-293860-6kz0iws6	32	36	resulting	result	VBG
cord-293860-6kz0iws6	32	37	from	from	IN
cord-293860-6kz0iws6	32	38	obesity	obesity	NN
cord-293860-6kz0iws6	32	39	might	may	MD
cord-293860-6kz0iws6	32	40	prime	prime	VB
cord-293860-6kz0iws6	32	41	the	the	DT
cord-293860-6kz0iws6	32	42	immune	immune	JJ
cord-293860-6kz0iws6	32	43	system	system	NN
cord-293860-6kz0iws6	32	44	for	for	IN
cord-293860-6kz0iws6	32	45	a	a	DT
cord-293860-6kz0iws6	32	46	more	more	RBR
cord-293860-6kz0iws6	32	47	catastrophic	catastrophic	JJ
cord-293860-6kz0iws6	32	48	response	response	NN
cord-293860-6kz0iws6	32	49	to	to	IN
cord-293860-6kz0iws6	32	50	SAR	SAR	NNP
cord-293860-6kz0iws6	32	51	-	-	HYPH
cord-293860-6kz0iws6	32	52	Cov2	Cov2	NNP
cord-293860-6kz0iws6	32	53	infection	infection	NN
cord-293860-6kz0iws6	32	54	.	.	.
cord-293860-6kz0iws6	33	1	Furthermore	furthermore	RB
cord-293860-6kz0iws6	33	2	,	,	,
cord-293860-6kz0iws6	33	3	patients	patient	NNS
cord-293860-6kz0iws6	33	4	from	from	IN
cord-293860-6kz0iws6	33	5	a	a	DT
cord-293860-6kz0iws6	33	6	BAME	BAME	NNP
cord-293860-6kz0iws6	33	7	background	background	NN
cord-293860-6kz0iws6	33	8	appear	appear	VBP
cord-293860-6kz0iws6	33	9	to	to	TO
cord-293860-6kz0iws6	33	10	have	have	VB
cord-293860-6kz0iws6	33	11	increased	increase	VBN
cord-293860-6kz0iws6	33	12	mortality	mortality	NN
cord-293860-6kz0iws6	33	13	after	after	IN
cord-293860-6kz0iws6	33	14	SARS	SARS	NNP
cord-293860-6kz0iws6	33	15	-	-	HYPH
cord-293860-6kz0iws6	33	16	CoV2	CoV2	NNP
cord-293860-6kz0iws6	33	17	infection	infection	NN
cord-293860-6kz0iws6	33	18	5	5	CD
cord-293860-6kz0iws6	33	19	,	,	,
cord-293860-6kz0iws6	33	20	an	an	DT
cord-293860-6kz0iws6	33	21	observation	observation	NN
cord-293860-6kz0iws6	33	22	that	that	WDT
cord-293860-6kz0iws6	33	23	has	have	VBZ
cord-293860-6kz0iws6	33	24	at	at	IN
cord-293860-6kz0iws6	33	25	least	least	JJS
cord-293860-6kz0iws6	33	26	partly	partly	RB
cord-293860-6kz0iws6	33	27	ben	ben	NNP
cord-293860-6kz0iws6	33	28	explained	explain	VBD
cord-293860-6kz0iws6	33	29	by	by	IN
cord-293860-6kz0iws6	33	30	the	the	DT
cord-293860-6kz0iws6	33	31	higher	high	JJR
cord-293860-6kz0iws6	33	32	prevalence	prevalence	NN
cord-293860-6kz0iws6	33	33	of	of	IN
cord-293860-6kz0iws6	33	34	central	central	JJ
cord-293860-6kz0iws6	33	35	obesity	obesity	NN
cord-293860-6kz0iws6	33	36	and	and	CC
cord-293860-6kz0iws6	33	37	its	-PRON-	PRP$
cord-293860-6kz0iws6	33	38	metabolic	metabolic	JJ
cord-293860-6kz0iws6	33	39	complications	complication	NNS
cord-293860-6kz0iws6	33	40	in	in	IN
cord-293860-6kz0iws6	33	41	this	this	DT
cord-293860-6kz0iws6	33	42	group	group	NN
cord-293860-6kz0iws6	33	43	6,7	6,7	CD
cord-293860-6kz0iws6	33	44	.	.	.
cord-293860-6kz0iws6	34	1	In	in	IN
cord-293860-6kz0iws6	34	2	the	the	DT
cord-293860-6kz0iws6	34	3	absence	absence	NN
cord-293860-6kz0iws6	34	4	of	of	IN
cord-293860-6kz0iws6	34	5	an	an	DT
cord-293860-6kz0iws6	34	6	effective	effective	JJ
cord-293860-6kz0iws6	34	7	vaccine	vaccine	NN
cord-293860-6kz0iws6	34	8	,	,	,
cord-293860-6kz0iws6	34	9	exploring	explore	VBG
cord-293860-6kz0iws6	34	10	the	the	DT
cord-293860-6kz0iws6	34	11	therapeutic	therapeutic	JJ
cord-293860-6kz0iws6	34	12	potential	potential	NN
cord-293860-6kz0iws6	34	13	of	of	IN
cord-293860-6kz0iws6	34	14	immunemodulating	immunemodulate	VBG
cord-293860-6kz0iws6	34	15	drugs	drug	NNS
cord-293860-6kz0iws6	34	16	is	be	VBZ
cord-293860-6kz0iws6	34	17	a	a	DT
cord-293860-6kz0iws6	34	18	priority	priority	NN
cord-293860-6kz0iws6	34	19	,	,	,
cord-293860-6kz0iws6	34	20	but	but	CC
cord-293860-6kz0iws6	34	21	the	the	DT
cord-293860-6kz0iws6	34	22	development	development	NN
cord-293860-6kz0iws6	34	23	of	of	IN
cord-293860-6kz0iws6	34	24	new	new	JJ
cord-293860-6kz0iws6	34	25	drugs	drug	NNS
cord-293860-6kz0iws6	34	26	is	be	VBZ
cord-293860-6kz0iws6	34	27	expensive	expensive	JJ
cord-293860-6kz0iws6	34	28	and	and	CC
cord-293860-6kz0iws6	34	29	time	time	NN
cord-293860-6kz0iws6	34	30	-	-	HYPH
cord-293860-6kz0iws6	34	31	consuming	consume	VBG
cord-293860-6kz0iws6	34	32	.	.	.
cord-293860-6kz0iws6	35	1	A	a	DT
cord-293860-6kz0iws6	35	2	more	more	RBR
cord-293860-6kz0iws6	35	3	pragmatic	pragmatic	JJ
cord-293860-6kz0iws6	35	4	solution	solution	NN
cord-293860-6kz0iws6	35	5	would	would	MD
cord-293860-6kz0iws6	35	6	be	be	VB
cord-293860-6kz0iws6	35	7	to	to	TO
cord-293860-6kz0iws6	35	8	seek	seek	VB
cord-293860-6kz0iws6	35	9	to	to	TO
cord-293860-6kz0iws6	35	10	repurpose	repurpose	VB
cord-293860-6kz0iws6	35	11	existing	existing	JJ
cord-293860-6kz0iws6	35	12	drugs	drug	NNS
cord-293860-6kz0iws6	35	13	,	,	,
cord-293860-6kz0iws6	35	14	particularly	particularly	RB
cord-293860-6kz0iws6	35	15	those	those	DT
cord-293860-6kz0iws6	35	16	that	that	WDT
cord-293860-6kz0iws6	35	17	might	may	MD
cord-293860-6kz0iws6	35	18	suppress	suppress	VB
cord-293860-6kz0iws6	35	19	the	the	DT
cord-293860-6kz0iws6	35	20	heightened	heighten	VBN
cord-293860-6kz0iws6	35	21	cytokine	cytokine	NN
cord-293860-6kz0iws6	35	22	activity	activity	NN
cord-293860-6kz0iws6	35	23	seen	see	VBN
cord-293860-6kz0iws6	35	24	in	in	IN
cord-293860-6kz0iws6	35	25	obesity	obesity	NN
cord-293860-6kz0iws6	35	26	,	,	,
cord-293860-6kz0iws6	35	27	the	the	DT
cord-293860-6kz0iws6	35	28	major	major	JJ
cord-293860-6kz0iws6	35	29	risk	risk	NN
cord-293860-6kz0iws6	35	30	factor	factor	NN
cord-293860-6kz0iws6	35	31	for	for	IN
cord-293860-6kz0iws6	35	32	a	a	DT
cord-293860-6kz0iws6	35	33	poor	poor	JJ
cord-293860-6kz0iws6	35	34	prognosis	prognosis	NN
cord-293860-6kz0iws6	35	35	in	in	IN
cord-293860-6kz0iws6	35	36	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	35	37	.	.	.
cord-293860-6kz0iws6	36	1	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	36	2	is	be	VBZ
cord-293860-6kz0iws6	36	3	a	a	DT
cord-293860-6kz0iws6	36	4	cysteinyl	cysteinyl	NNP
cord-293860-6kz0iws6	36	5	leukotriene	leukotriene	NN
cord-293860-6kz0iws6	36	6	receptor	receptor	NN
cord-293860-6kz0iws6	36	7	antagonist	antagonist	NN
cord-293860-6kz0iws6	36	8	licensed	license	VBN
cord-293860-6kz0iws6	36	9	to	to	TO
cord-293860-6kz0iws6	36	10	treat	treat	VB
cord-293860-6kz0iws6	36	11	asthma	asthma	NN
cord-293860-6kz0iws6	36	12	and	and	CC
cord-293860-6kz0iws6	36	13	allergic	allergic	JJ
cord-293860-6kz0iws6	36	14	rhinitis	rhinitis	NN
cord-293860-6kz0iws6	36	15	.	.	.
cord-293860-6kz0iws6	37	1	It	-PRON-	PRP
cord-293860-6kz0iws6	37	2	has	have	VBZ
cord-293860-6kz0iws6	37	3	been	be	VBN
cord-293860-6kz0iws6	37	4	shown	show	VBN
cord-293860-6kz0iws6	37	5	to	to	TO
cord-293860-6kz0iws6	37	6	diminish	diminish	VB
cord-293860-6kz0iws6	37	7	pulmonary	pulmonary	JJ
cord-293860-6kz0iws6	37	8	response	response	NN
cord-293860-6kz0iws6	37	9	to	to	IN
cord-293860-6kz0iws6	37	10	antigen	antigen	NN
cord-293860-6kz0iws6	37	11	,	,	,
cord-293860-6kz0iws6	37	12	tissue	tissue	NN
cord-293860-6kz0iws6	37	13	eosinophilia	eosinophilia	NN
cord-293860-6kz0iws6	37	14	and	and	CC
cord-293860-6kz0iws6	37	15	IL-5	IL-5	NNP
cord-293860-6kz0iws6	37	16	expression	expression	NN
cord-293860-6kz0iws6	37	17	in	in	IN
cord-293860-6kz0iws6	37	18	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	37	19	cells	cell	NNS
cord-293860-6kz0iws6	37	20	8	8	CD
cord-293860-6kz0iws6	37	21	.	.	.
cord-293860-6kz0iws6	38	1	It	-PRON-	PRP
cord-293860-6kz0iws6	38	2	has	have	VBZ
cord-293860-6kz0iws6	38	3	also	also	RB
cord-293860-6kz0iws6	38	4	been	be	VBN
cord-293860-6kz0iws6	38	5	shown	show	VBN
cord-293860-6kz0iws6	38	6	to	to	TO
cord-293860-6kz0iws6	38	7	decrease	decrease	VB
cord-293860-6kz0iws6	38	8	elevated	elevated	JJ
cord-293860-6kz0iws6	38	9	levels	level	NNS
cord-293860-6kz0iws6	38	10	of	of	IN
cord-293860-6kz0iws6	38	11	IL-1	IL-1	NNP
cord-293860-6kz0iws6	38	12	and	and	CC
cord-293860-6kz0iws6	38	13	IL8	il8	VB
cord-293860-6kz0iws6	38	14	in	in	IN
cord-293860-6kz0iws6	38	15	humans	human	NNS
cord-293860-6kz0iws6	38	16	with	with	IN
cord-293860-6kz0iws6	38	17	viral	viral	JJ
cord-293860-6kz0iws6	38	18	upper	upper	JJ
cord-293860-6kz0iws6	38	19	respiratory	respiratory	JJ
cord-293860-6kz0iws6	38	20	tract	tract	NN
cord-293860-6kz0iws6	38	21	infections	infection	NNS
cord-293860-6kz0iws6	38	22	compared	compare	VBN
cord-293860-6kz0iws6	38	23	with	with	IN
cord-293860-6kz0iws6	38	24	placebo	placebo	NN
cord-293860-6kz0iws6	38	25	-	-	HYPH
cord-293860-6kz0iws6	38	26	treated	treat	VBN
cord-293860-6kz0iws6	38	27	patients	patient	NNS
cord-293860-6kz0iws6	38	28	9	9	CD
cord-293860-6kz0iws6	38	29	.	.	.
cord-293860-6kz0iws6	39	1	In	in	IN
cord-293860-6kz0iws6	39	2	addition	addition	NN
cord-293860-6kz0iws6	39	3	,	,	,
cord-293860-6kz0iws6	39	4	in	in	IN
cord-293860-6kz0iws6	39	5	silico	silico	NN
cord-293860-6kz0iws6	39	6	computer	computer	NN
cord-293860-6kz0iws6	39	7	modelling	modelling	NN
cord-293860-6kz0iws6	39	8	studies	study	NNS
cord-293860-6kz0iws6	39	9	have	have	VBP
cord-293860-6kz0iws6	39	10	demonstrated	demonstrate	VBN
cord-293860-6kz0iws6	39	11	a	a	DT
cord-293860-6kz0iws6	39	12	high	high	JJ
cord-293860-6kz0iws6	39	13	binding	bind	VBG
cord-293860-6kz0iws6	39	14	affinity	affinity	NN
cord-293860-6kz0iws6	39	15	of	of	IN
cord-293860-6kz0iws6	39	16	the	the	DT
cord-293860-6kz0iws6	39	17	montelukast	montelukast	NN
cord-293860-6kz0iws6	39	18	molecule	molecule	NN
cord-293860-6kz0iws6	39	19	to	to	IN
cord-293860-6kz0iws6	39	20	the	the	DT
cord-293860-6kz0iws6	39	21	SARS	SARS	NNP
cord-293860-6kz0iws6	39	22	-	-	HYPH
cord-293860-6kz0iws6	39	23	CoV2	CoV2	NNP
cord-293860-6kz0iws6	39	24	virus	virus	NN
cord-293860-6kz0iws6	39	25	's	's	POS
cord-293860-6kz0iws6	39	26	main	main	JJ
cord-293860-6kz0iws6	39	27	protease	protease	NN
cord-293860-6kz0iws6	39	28	enzyme	enzyme	NN
cord-293860-6kz0iws6	39	29	substrate	substrate	NN
cord-293860-6kz0iws6	39	30	-	-	HYPH
cord-293860-6kz0iws6	39	31	binding	bind	VBG
cord-293860-6kz0iws6	39	32	pocket	pocket	NN
cord-293860-6kz0iws6	39	33	that	that	WDT
cord-293860-6kz0iws6	39	34	is	be	VBZ
cord-293860-6kz0iws6	39	35	involved	involve	VBN
cord-293860-6kz0iws6	39	36	in	in	IN
cord-293860-6kz0iws6	39	37	virus	virus	NN
cord-293860-6kz0iws6	39	38	RNA	RNA	NNP
cord-293860-6kz0iws6	39	39	synthesis	synthesis	NN
cord-293860-6kz0iws6	39	40	and	and	CC
cord-293860-6kz0iws6	39	41	replication	replication	NN
cord-293860-6kz0iws6	39	42	10	10	CD
cord-293860-6kz0iws6	39	43	,	,	,
cord-293860-6kz0iws6	39	44	11	11	CD
cord-293860-6kz0iws6	39	45	.	.	.
cord-293860-6kz0iws6	40	1	Evidence	evidence	NN
cord-293860-6kz0iws6	40	2	supporting	support	VBG
cord-293860-6kz0iws6	40	3	montelukast	montelukast	NNP
cord-293860-6kz0iws6	40	4	as	as	IN
cord-293860-6kz0iws6	40	5	a	a	DT
cord-293860-6kz0iws6	40	6	candidate	candidate	NN
cord-293860-6kz0iws6	40	7	COVID-19	covid-19	CD
cord-293860-6kz0iws6	40	8	therapy	therapy	NN
cord-293860-6kz0iws6	40	9	in	in	IN
cord-293860-6kz0iws6	40	10	individuals	individual	NNS
cord-293860-6kz0iws6	40	11	with	with	IN
cord-293860-6kz0iws6	40	12	obesity	obesity	NN
cord-293860-6kz0iws6	40	13	:	:	:
cord-293860-6kz0iws6	40	14	Patients	patient	NNS
cord-293860-6kz0iws6	40	15	affected	affect	VBN
cord-293860-6kz0iws6	40	16	by	by	IN
cord-293860-6kz0iws6	40	17	severe	severe	JJ
cord-293860-6kz0iws6	40	18	obesity	obesity	NN
cord-293860-6kz0iws6	40	19	share	share	VBP
cord-293860-6kz0iws6	40	20	a	a	DT
cord-293860-6kz0iws6	40	21	common	common	JJ
cord-293860-6kz0iws6	40	22	physiological	physiological	JJ
cord-293860-6kz0iws6	40	23	response	response	NN
cord-293860-6kz0iws6	40	24	with	with	IN
cord-293860-6kz0iws6	40	25	patients	patient	NNS
cord-293860-6kz0iws6	40	26	with	with	IN
cord-293860-6kz0iws6	40	27	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	40	28	as	as	IN
cord-293860-6kz0iws6	40	29	both	both	DT
cord-293860-6kz0iws6	40	30	have	have	VBP
cord-293860-6kz0iws6	40	31	raised	raise	VBN
cord-293860-6kz0iws6	40	32	concentrations	concentration	NNS
cord-293860-6kz0iws6	40	33	of	of	IN
cord-293860-6kz0iws6	40	34	pro	pro	JJ
cord-293860-6kz0iws6	40	35	-	-	JJ
cord-293860-6kz0iws6	40	36	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	40	37	cytokines	cytokine	NNS
cord-293860-6kz0iws6	40	38	(	(	-LRB-
cord-293860-6kz0iws6	40	39	e.g.	e.g.	RB
cord-293860-6kz0iws6	40	40	,	,	,
cord-293860-6kz0iws6	40	41	TNF	TNF	NNP
cord-293860-6kz0iws6	40	42	-	-	HYPH
cord-293860-6kz0iws6	40	43	a	a	NNP
cord-293860-6kz0iws6	40	44	,	,	,
cord-293860-6kz0iws6	40	45	IL1	IL1	NNP
cord-293860-6kz0iws6	40	46	and	and	CC
cord-293860-6kz0iws6	40	47	IL6	IL6	NNP
cord-293860-6kz0iws6	40	48	)	)	-RRB-
cord-293860-6kz0iws6	40	49	and	and	CC
cord-293860-6kz0iws6	40	50	T	T	NNP
cord-293860-6kz0iws6	40	51	-	-	HYPH
cord-293860-6kz0iws6	40	52	helper-2	helper-2	NNP
cord-293860-6kz0iws6	40	53	cytokines	cytokine	NNS
cord-293860-6kz0iws6	40	54	(	(	-LRB-
cord-293860-6kz0iws6	40	55	IL4	il4	NN
cord-293860-6kz0iws6	40	56	,	,	,
cord-293860-6kz0iws6	40	57	IL10	IL10	NNP
cord-293860-6kz0iws6	40	58	)	)	-RRB-
cord-293860-6kz0iws6	41	1	[	[	-LRB-
cord-293860-6kz0iws6	41	2	12	12	CD
cord-293860-6kz0iws6	41	3	]	]	-RRB-
cord-293860-6kz0iws6	41	4	[	[	-LRB-
cord-293860-6kz0iws6	41	5	13	13	CD
cord-293860-6kz0iws6	41	6	]	]	-RRB-
cord-293860-6kz0iws6	42	1	[	[	-LRB-
cord-293860-6kz0iws6	42	2	14	14	CD
cord-293860-6kz0iws6	42	3	]	]	-RRB-
cord-293860-6kz0iws6	42	4	.	.	.
cord-293860-6kz0iws6	43	1	Whilst	whilst	IN
cord-293860-6kz0iws6	43	2	it	-PRON-	PRP
cord-293860-6kz0iws6	43	3	is	be	VBZ
cord-293860-6kz0iws6	43	4	impossible	impossible	JJ
cord-293860-6kz0iws6	43	5	to	to	TO
cord-293860-6kz0iws6	43	6	exclude	exclude	VB
cord-293860-6kz0iws6	43	7	increased	increase	VBN
cord-293860-6kz0iws6	43	8	viral	viral	JJ
cord-293860-6kz0iws6	43	9	burden	burden	NN
cord-293860-6kz0iws6	43	10	as	as	IN
cord-293860-6kz0iws6	43	11	the	the	DT
cord-293860-6kz0iws6	43	12	driver	driver	NN
cord-293860-6kz0iws6	43	13	for	for	IN
cord-293860-6kz0iws6	43	14	this	this	DT
cord-293860-6kz0iws6	43	15	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	43	16	response	response	NN
cord-293860-6kz0iws6	43	17	in	in	IN
cord-293860-6kz0iws6	43	18	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	43	19	,	,	,
cord-293860-6kz0iws6	43	20	there	there	EX
cord-293860-6kz0iws6	43	21	is	be	VBZ
cord-293860-6kz0iws6	43	22	evidence	evidence	NN
cord-293860-6kz0iws6	43	23	that	that	IN
cord-293860-6kz0iws6	43	24	some	some	DT
cord-293860-6kz0iws6	43	25	patients	patient	NNS
cord-293860-6kz0iws6	43	26	develop	develop	VBP
cord-293860-6kz0iws6	43	27	'	'	``
cord-293860-6kz0iws6	43	28	cytokine	cytokine	NN
cord-293860-6kz0iws6	43	29	storm	storm	NN
cord-293860-6kz0iws6	43	30	(	(	-LRB-
cord-293860-6kz0iws6	43	31	release	release	NN
cord-293860-6kz0iws6	43	32	)	)	-RRB-
cord-293860-6kz0iws6	43	33	syndrome	syndrome	NN
cord-293860-6kz0iws6	43	34	'	'	''
cord-293860-6kz0iws6	43	35	,	,	,
cord-293860-6kz0iws6	43	36	described	describe	VBD
cord-293860-6kz0iws6	43	37	as	as	IN
cord-293860-6kz0iws6	43	38	an	an	DT
cord-293860-6kz0iws6	43	39	uncontrolled	uncontrolled	JJ
cord-293860-6kz0iws6	43	40	and	and	CC
cord-293860-6kz0iws6	43	41	overwhelming	overwhelming	JJ
cord-293860-6kz0iws6	43	42	release	release	NN
cord-293860-6kz0iws6	43	43	of	of	IN
cord-293860-6kz0iws6	43	44	proinflammatory	proinflammatory	JJ
cord-293860-6kz0iws6	43	45	mediators	mediator	NNS
cord-293860-6kz0iws6	43	46	by	by	IN
cord-293860-6kz0iws6	43	47	an	an	DT
cord-293860-6kz0iws6	43	48	overly	overly	RB
cord-293860-6kz0iws6	43	49	-	-	HYPH
cord-293860-6kz0iws6	43	50	activated	activate	VBN
cord-293860-6kz0iws6	43	51	immune	immune	JJ
cord-293860-6kz0iws6	43	52	system	system	NN
cord-293860-6kz0iws6	43	53	12	12	CD
cord-293860-6kz0iws6	43	54	,	,	,
cord-293860-6kz0iws6	43	55	13	13	CD
cord-293860-6kz0iws6	43	56	,	,	,
cord-293860-6kz0iws6	43	57	15	15	CD
cord-293860-6kz0iws6	43	58	.	.	.
cord-293860-6kz0iws6	44	1	An	an	DT
cord-293860-6kz0iws6	44	2	overwhelming	overwhelming	JJ
cord-293860-6kz0iws6	44	3	production	production	NN
cord-293860-6kz0iws6	44	4	of	of	IN
cord-293860-6kz0iws6	44	5	proinflammatory	proinflammatory	JJ
cord-293860-6kz0iws6	44	6	mediators	mediator	NNS
cord-293860-6kz0iws6	44	7	in	in	IN
cord-293860-6kz0iws6	44	8	the	the	DT
cord-293860-6kz0iws6	44	9	lungs	lung	NNS
cord-293860-6kz0iws6	44	10	causes	cause	VBZ
cord-293860-6kz0iws6	44	11	localised	localise	VBN
cord-293860-6kz0iws6	44	12	pulmonary	pulmonary	JJ
cord-293860-6kz0iws6	44	13	injury	injury	NN
cord-293860-6kz0iws6	44	14	characterised	characterise	VBN
cord-293860-6kz0iws6	44	15	by	by	IN
cord-293860-6kz0iws6	44	16	diffuse	diffuse	JJ
cord-293860-6kz0iws6	44	17	alveolar	alveolar	JJ
cord-293860-6kz0iws6	44	18	damage	damage	NN
cord-293860-6kz0iws6	44	19	with	with	IN
cord-293860-6kz0iws6	44	20	epithelial	epithelial	JJ
cord-293860-6kz0iws6	44	21	and	and	CC
cord-293860-6kz0iws6	44	22	endothelial	endothelial	JJ
cord-293860-6kz0iws6	44	23	apoptosis	apoptosis	NN
cord-293860-6kz0iws6	44	24	,	,	,
cord-293860-6kz0iws6	44	25	and	and	CC
cord-293860-6kz0iws6	44	26	thrombosis	thrombosis	NN
cord-293860-6kz0iws6	44	27	due	due	IN
cord-293860-6kz0iws6	44	28	to	to	IN
cord-293860-6kz0iws6	44	29	dysregulated	dysregulated	JJ
cord-293860-6kz0iws6	44	30	coagulation	coagulation	NN
cord-293860-6kz0iws6	44	31	and	and	CC
cord-293860-6kz0iws6	44	32	fibrinolysis	fibrinolysis	NN
cord-293860-6kz0iws6	44	33	.	.	.
cord-293860-6kz0iws6	45	1	These	these	DT
cord-293860-6kz0iws6	45	2	mediators	mediator	NNS
cord-293860-6kz0iws6	45	3	may	may	MD
cord-293860-6kz0iws6	45	4	also	also	RB
cord-293860-6kz0iws6	45	5	leak	leak	VB
cord-293860-6kz0iws6	45	6	into	into	IN
cord-293860-6kz0iws6	45	7	systemic	systemic	JJ
cord-293860-6kz0iws6	45	8	circulation	circulation	NN
cord-293860-6kz0iws6	45	9	leading	lead	VBG
cord-293860-6kz0iws6	45	10	to	to	IN
cord-293860-6kz0iws6	45	11	cardiac	cardiac	JJ
cord-293860-6kz0iws6	45	12	,	,	,
cord-293860-6kz0iws6	45	13	renal	renal	JJ
cord-293860-6kz0iws6	45	14	and	and	CC
cord-293860-6kz0iws6	45	15	hepatic	hepatic	JJ
cord-293860-6kz0iws6	45	16	inflammation	inflammation	NN
cord-293860-6kz0iws6	45	17	and	and	CC
cord-293860-6kz0iws6	45	18	multiorgan	multiorgan	NN
cord-293860-6kz0iws6	45	19	failure	failure	NN
cord-293860-6kz0iws6	45	20	16	16	CD
cord-293860-6kz0iws6	45	21	.	.	.
cord-293860-6kz0iws6	46	1	The	the	DT
cord-293860-6kz0iws6	46	2	background	background	NN
cord-293860-6kz0iws6	46	3	chronic	chronic	JJ
cord-293860-6kz0iws6	46	4	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	46	5	state	state	NN
cord-293860-6kz0iws6	46	6	associated	associate	VBN
cord-293860-6kz0iws6	46	7	with	with	IN
cord-293860-6kz0iws6	46	8	obesity	obesity	NN
cord-293860-6kz0iws6	46	9	could	could	MD
cord-293860-6kz0iws6	46	10	act	act	VB
cord-293860-6kz0iws6	46	11	as	as	IN
cord-293860-6kz0iws6	46	12	a	a	DT
cord-293860-6kz0iws6	46	13	catalyst	catalyst	NN
cord-293860-6kz0iws6	46	14	for	for	IN
cord-293860-6kz0iws6	46	15	the	the	DT
cord-293860-6kz0iws6	46	16	a	a	DT
cord-293860-6kz0iws6	46	17	massive	massive	JJ
cord-293860-6kz0iws6	46	18	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	46	19	response	response	NN
cord-293860-6kz0iws6	46	20	to	to	IN
cord-293860-6kz0iws6	46	21	SARS	SARS	NNP
cord-293860-6kz0iws6	46	22	-	-	HYPH
cord-293860-6kz0iws6	46	23	CoV2	CoV2	NNS
cord-293860-6kz0iws6	46	24	by	by	IN
cord-293860-6kz0iws6	46	25	priming	prime	VBG
cord-293860-6kz0iws6	46	26	the	the	DT
cord-293860-6kz0iws6	46	27	immune	immune	JJ
cord-293860-6kz0iws6	46	28	system	system	NN
cord-293860-6kz0iws6	46	29	,	,	,
cord-293860-6kz0iws6	46	30	triggered	trigger	VBN
cord-293860-6kz0iws6	46	31	by	by	IN
cord-293860-6kz0iws6	46	32	the	the	DT
cord-293860-6kz0iws6	46	33	'	'	``
cord-293860-6kz0iws6	46	34	second	second	JJ
cord-293860-6kz0iws6	46	35	hit	hit	NN
cord-293860-6kz0iws6	46	36	'	'	''
cord-293860-6kz0iws6	46	37	of	of	IN
cord-293860-6kz0iws6	46	38	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	46	39	,	,	,
cord-293860-6kz0iws6	46	40	and	and	CC
cord-293860-6kz0iws6	46	41	explaining	explain	VBG
cord-293860-6kz0iws6	46	42	why	why	WRB
cord-293860-6kz0iws6	46	43	those	those	DT
cord-293860-6kz0iws6	46	44	with	with	IN
cord-293860-6kz0iws6	46	45	obesity	obesity	NN
cord-293860-6kz0iws6	46	46	are	be	VBP
cord-293860-6kz0iws6	46	47	more	more	RBR
cord-293860-6kz0iws6	46	48	likely	likely	JJ
cord-293860-6kz0iws6	46	49	to	to	TO
cord-293860-6kz0iws6	46	50	become	become	VB
cord-293860-6kz0iws6	46	51	severely	severely	RB
cord-293860-6kz0iws6	46	52	ill	ill	JJ
cord-293860-6kz0iws6	46	53	,	,	,
cord-293860-6kz0iws6	46	54	require	require	VB
cord-293860-6kz0iws6	46	55	ICU	ICU	NNP
cord-293860-6kz0iws6	46	56	care	care	NN
cord-293860-6kz0iws6	46	57	and	and	CC
cord-293860-6kz0iws6	46	58	die	die	VBP
cord-293860-6kz0iws6	46	59	.	.	.
cord-293860-6kz0iws6	47	1	Severe	severe	JJ
cord-293860-6kz0iws6	47	2	lymphopenia	lymphopenia	NNP
cord-293860-6kz0iws6	47	3	with	with	IN
cord-293860-6kz0iws6	47	4	hyperactivated	hyperactivated	JJ
cord-293860-6kz0iws6	47	5	proinflammatory	proinflammatory	NNP
cord-293860-6kz0iws6	47	6	T	T	NNP
cord-293860-6kz0iws6	47	7	cells	cell	NNS
cord-293860-6kz0iws6	47	8	and	and	CC
cord-293860-6kz0iws6	47	9	decreased	decrease	VBD
cord-293860-6kz0iws6	48	1	regulatory	regulatory	JJ
cord-293860-6kz0iws6	48	2	T	T	NNP
cord-293860-6kz0iws6	48	3	cells	cell	NNS
cord-293860-6kz0iws6	48	4	are	be	VBP
cord-293860-6kz0iws6	48	5	commonly	commonly	RB
cord-293860-6kz0iws6	48	6	seen	see	VBN
cord-293860-6kz0iws6	48	7	in	in	IN
cord-293860-6kz0iws6	48	8	critically	critically	RB
cord-293860-6kz0iws6	48	9	ill	ill	JJ
cord-293860-6kz0iws6	49	1	COVID-19	covid-19	JJ
cord-293860-6kz0iws6	49	2	patients	patient	NNS
cord-293860-6kz0iws6	49	3	supporting	support	VBG
cord-293860-6kz0iws6	49	4	the	the	DT
cord-293860-6kz0iws6	49	5	likelihood	likelihood	NN
cord-293860-6kz0iws6	49	6	of	of	IN
cord-293860-6kz0iws6	49	7	a	a	DT
cord-293860-6kz0iws6	49	8	dysregulated	dysregulate	VBN
cord-293860-6kz0iws6	49	9	immune	immune	JJ
cord-293860-6kz0iws6	49	10	response	response	NN
cord-293860-6kz0iws6	49	11	to	to	IN
cord-293860-6kz0iws6	49	12	the	the	DT
cord-293860-6kz0iws6	49	13	viral	viral	JJ
cord-293860-6kz0iws6	49	14	infection	infection	NN
cord-293860-6kz0iws6	49	15	12	12	CD
cord-293860-6kz0iws6	49	16	.	.	.
cord-293860-6kz0iws6	50	1	Leukotrienes	leukotriene	NNS
cord-293860-6kz0iws6	50	2	(	(	-LRB-
cord-293860-6kz0iws6	50	3	LTC4	LTC4	NNP
cord-293860-6kz0iws6	50	4	,	,	,
cord-293860-6kz0iws6	50	5	LTD4	LTD4	NNP
cord-293860-6kz0iws6	50	6	,	,	,
cord-293860-6kz0iws6	50	7	and	and	CC
cord-293860-6kz0iws6	50	8	LTE4	LTE4	NNP
cord-293860-6kz0iws6	50	9	)	)	-RRB-
cord-293860-6kz0iws6	50	10	are	be	VBP
cord-293860-6kz0iws6	50	11	peptide	peptide	NN
cord-293860-6kz0iws6	50	12	-	-	HYPH
cord-293860-6kz0iws6	50	13	conjugated	conjugate	VBN
cord-293860-6kz0iws6	50	14	lipids	lipid	NNS
cord-293860-6kz0iws6	50	15	that	that	WDT
cord-293860-6kz0iws6	50	16	are	be	VBP
cord-293860-6kz0iws6	50	17	prominent	prominent	JJ
cord-293860-6kz0iws6	50	18	products	product	NNS
cord-293860-6kz0iws6	50	19	of	of	IN
cord-293860-6kz0iws6	50	20	activated	activate	VBN
cord-293860-6kz0iws6	50	21	eosinophils	eosinophil	NNS
cord-293860-6kz0iws6	50	22	,	,	,
cord-293860-6kz0iws6	50	23	basophils	basophil	NNS
cord-293860-6kz0iws6	50	24	,	,	,
cord-293860-6kz0iws6	50	25	mast	mast	NN
cord-293860-6kz0iws6	50	26	cells	cell	NNS
cord-293860-6kz0iws6	50	27	and	and	CC
cord-293860-6kz0iws6	50	28	macrophages	macrophage	NNS
cord-293860-6kz0iws6	50	29	17	17	CD
cord-293860-6kz0iws6	50	30	,	,	,
cord-293860-6kz0iws6	50	31	18	18	CD
cord-293860-6kz0iws6	50	32	.	.	.
cord-293860-6kz0iws6	51	1	They	-PRON-	PRP
cord-293860-6kz0iws6	51	2	are	be	VBP
cord-293860-6kz0iws6	51	3	generated	generate	VBN
cord-293860-6kz0iws6	51	4	de	de	IN
cord-293860-6kz0iws6	51	5	novo	novo	NNP
cord-293860-6kz0iws6	51	6	from	from	IN
cord-293860-6kz0iws6	51	7	cell	cell	NN
cord-293860-6kz0iws6	51	8	membrane	membrane	NN
cord-293860-6kz0iws6	51	9	phospholipid	phospholipid	NN
cord-293860-6kz0iws6	51	10	-	-	HYPH
cord-293860-6kz0iws6	51	11	associated	associate	VBN
cord-293860-6kz0iws6	51	12	arachidonic	arachidonic	NN
cord-293860-6kz0iws6	51	13	acid	acid	NN
cord-293860-6kz0iws6	51	14	via	via	IN
cord-293860-6kz0iws6	51	15	the	the	DT
cord-293860-6kz0iws6	51	16	5-lipoxygenase	5-lipoxygenase	CD
cord-293860-6kz0iws6	51	17	pathway	pathway	NN
cord-293860-6kz0iws6	51	18	.	.	.
cord-293860-6kz0iws6	52	1	Known	know	VBN
cord-293860-6kz0iws6	52	2	to	to	TO
cord-293860-6kz0iws6	52	3	cause	cause	VB
cord-293860-6kz0iws6	52	4	contraction	contraction	NN
cord-293860-6kz0iws6	52	5	of	of	IN
cord-293860-6kz0iws6	52	6	bronchial	bronchial	JJ
cord-293860-6kz0iws6	52	7	smooth	smooth	JJ
cord-293860-6kz0iws6	52	8	muscle	muscle	NN
cord-293860-6kz0iws6	52	9	,	,	,
cord-293860-6kz0iws6	52	10	leukotrienes	leukotriene	NNS
cord-293860-6kz0iws6	52	11	are	be	VBP
cord-293860-6kz0iws6	52	12	now	now	RB
cord-293860-6kz0iws6	52	13	also	also	RB
cord-293860-6kz0iws6	52	14	recognised	recognise	VBN
cord-293860-6kz0iws6	52	15	as	as	RB
cord-293860-6kz0iws6	52	16	potent	potent	JJ
cord-293860-6kz0iws6	52	17	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	52	18	mediators	mediator	NNS
cord-293860-6kz0iws6	52	19	that	that	WDT
cord-293860-6kz0iws6	52	20	initiate	initiate	VBP
cord-293860-6kz0iws6	52	21	and	and	CC
cord-293860-6kz0iws6	52	22	propagate	propagate	VBP
cord-293860-6kz0iws6	52	23	a	a	DT
cord-293860-6kz0iws6	52	24	diverse	diverse	JJ
cord-293860-6kz0iws6	52	25	array	array	NN
cord-293860-6kz0iws6	52	26	of	of	IN
cord-293860-6kz0iws6	52	27	biologic	biologic	JJ
cord-293860-6kz0iws6	52	28	responses	response	NNS
cord-293860-6kz0iws6	52	29	including	include	VBG
cord-293860-6kz0iws6	52	30	macrophage	macrophage	NN
cord-293860-6kz0iws6	52	31	activation	activation	NN
cord-293860-6kz0iws6	52	32	,	,	,
cord-293860-6kz0iws6	52	33	mast	mast	JJ
cord-293860-6kz0iws6	52	34	cell	cell	NN
cord-293860-6kz0iws6	52	35	cytokine	cytokine	NN
cord-293860-6kz0iws6	52	36	secretion	secretion	NN
cord-293860-6kz0iws6	52	37	and	and	CC
cord-293860-6kz0iws6	52	38	dendritic	dendritic	JJ
cord-293860-6kz0iws6	52	39	cell	cell	NN
cord-293860-6kz0iws6	52	40	maturation	maturation	NN
cord-293860-6kz0iws6	52	41	and	and	CC
cord-293860-6kz0iws6	52	42	migration	migration	NN
cord-293860-6kz0iws6	52	43	17	17	CD
cord-293860-6kz0iws6	52	44	,	,	,
cord-293860-6kz0iws6	52	45	18	18	CD
cord-293860-6kz0iws6	52	46	.	.	.
cord-293860-6kz0iws6	53	1	Animal	animal	NN
cord-293860-6kz0iws6	53	2	studies	study	NNS
cord-293860-6kz0iws6	53	3	indicate	indicate	VBP
cord-293860-6kz0iws6	53	4	a	a	DT
cord-293860-6kz0iws6	53	5	significant	significant	JJ
cord-293860-6kz0iws6	53	6	role	role	NN
cord-293860-6kz0iws6	53	7	for	for	IN
cord-293860-6kz0iws6	53	8	leukotrienes	leukotriene	NNS
cord-293860-6kz0iws6	53	9	in	in	IN
cord-293860-6kz0iws6	53	10	adaptive	adaptive	JJ
cord-293860-6kz0iws6	53	11	immunity	immunity	NN
cord-293860-6kz0iws6	53	12	,	,	,
cord-293860-6kz0iws6	53	13	particularly	particularly	RB
cord-293860-6kz0iws6	53	14	the	the	DT
cord-293860-6kz0iws6	53	15	induction	induction	NN
cord-293860-6kz0iws6	53	16	of	of	IN
cord-293860-6kz0iws6	53	17	Th2	th2	CD
cord-293860-6kz0iws6	53	18	response	response	NN
cord-293860-6kz0iws6	53	19	in	in	IN
cord-293860-6kz0iws6	53	20	the	the	DT
cord-293860-6kz0iws6	53	21	lung	lung	NN
cord-293860-6kz0iws6	53	22	via	via	IN
cord-293860-6kz0iws6	53	23	their	-PRON-	PRP$
cord-293860-6kz0iws6	53	24	effect	effect	NN
cord-293860-6kz0iws6	53	25	on	on	IN
cord-293860-6kz0iws6	53	26	dendritic	dendritic	JJ
cord-293860-6kz0iws6	53	27	cells	cell	NNS
cord-293860-6kz0iws6	53	28	and	and	CC
cord-293860-6kz0iws6	53	29	cytokine	cytokine	NN
cord-293860-6kz0iws6	53	30	generation	generation	NN
cord-293860-6kz0iws6	53	31	(	(	-LRB-
cord-293860-6kz0iws6	53	32	mainly	mainly	RB
cord-293860-6kz0iws6	53	33	IL4	il4	JJ
cord-293860-6kz0iws6	53	34	)	)	-RRB-
cord-293860-6kz0iws6	53	35	,	,	,
cord-293860-6kz0iws6	53	36	the	the	DT
cord-293860-6kz0iws6	53	37	recruitment	recruitment	NN
cord-293860-6kz0iws6	53	38	and/or	and/or	CC
cord-293860-6kz0iws6	53	39	activation	activation	NN
cord-293860-6kz0iws6	53	40	of	of	IN
cord-293860-6kz0iws6	53	41	effector	effector	NN
cord-293860-6kz0iws6	53	42	cells	cell	NNS
cord-293860-6kz0iws6	53	43	(	(	-LRB-
cord-293860-6kz0iws6	53	44	especially	especially	RB
cord-293860-6kz0iws6	53	45	eosinophils	eosinophils	NN
cord-293860-6kz0iws6	53	46	and	and	CC
cord-293860-6kz0iws6	53	47	mast	mast	NN
cord-293860-6kz0iws6	53	48	cells	cell	NNS
cord-293860-6kz0iws6	53	49	)	)	-RRB-
cord-293860-6kz0iws6	53	50	,	,	,
cord-293860-6kz0iws6	53	51	pulmonary	pulmonary	JJ
cord-293860-6kz0iws6	53	52	inflammation	inflammation	NN
cord-293860-6kz0iws6	53	53	,	,	,
cord-293860-6kz0iws6	53	54	microvascular	microvascular	JJ
cord-293860-6kz0iws6	53	55	permeability	permeability	NN
cord-293860-6kz0iws6	53	56	and	and	CC
cord-293860-6kz0iws6	53	57	pulmonary	pulmonary	JJ
cord-293860-6kz0iws6	53	58	fibrosis	fibrosis	NN
cord-293860-6kz0iws6	53	59	17	17	CD
cord-293860-6kz0iws6	53	60	,	,	,
cord-293860-6kz0iws6	53	61	19	19	CD
cord-293860-6kz0iws6	53	62	.	.	.
cord-293860-6kz0iws6	54	1	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	54	2	20,21	20,21	CD
cord-293860-6kz0iws6	54	3	(	(	-LRB-
cord-293860-6kz0iws6	54	4	montelukast	montelukast	NNP
cord-293860-6kz0iws6	54	5	sodium	sodium	NN
cord-293860-6kz0iws6	54	6	:	:	:
cord-293860-6kz0iws6	55	1	C	C	NNP
cord-293860-6kz0iws6	55	2	35	35	CD
cord-293860-6kz0iws6	55	3	H	H	NNP
cord-293860-6kz0iws6	55	4	36	36	CD
cord-293860-6kz0iws6	55	5	ClNO	clno	NN
cord-293860-6kz0iws6	55	6	3	3	CD
cord-293860-6kz0iws6	55	7	S	S	NNP
cord-293860-6kz0iws6	55	8	)	)	-RRB-
cord-293860-6kz0iws6	55	9	is	be	VBZ
cord-293860-6kz0iws6	55	10	a	a	DT
cord-293860-6kz0iws6	55	11	leukotriene	leukotriene	NN
cord-293860-6kz0iws6	55	12	receptor	receptor	NN
cord-293860-6kz0iws6	55	13	antagonist	antagonist	NN
cord-293860-6kz0iws6	55	14	which	which	WDT
cord-293860-6kz0iws6	55	15	demonstrates	demonstrate	VBZ
cord-293860-6kz0iws6	55	16	a	a	DT
cord-293860-6kz0iws6	55	17	marked	marked	JJ
cord-293860-6kz0iws6	55	18	affinity	affinity	NN
cord-293860-6kz0iws6	55	19	and	and	CC
cord-293860-6kz0iws6	55	20	selectivity	selectivity	NN
cord-293860-6kz0iws6	55	21	to	to	IN
cord-293860-6kz0iws6	55	22	the	the	DT
cord-293860-6kz0iws6	55	23	cysteinyl	cysteinyl	NNP
cord-293860-6kz0iws6	55	24	leukotriene	leukotriene	NN
cord-293860-6kz0iws6	55	25	receptor	receptor	NN
cord-293860-6kz0iws6	55	26	type-1	type-1	NNP
cord-293860-6kz0iws6	55	27	,	,	,
cord-293860-6kz0iws6	55	28	thus	thus	RB
cord-293860-6kz0iws6	55	29	it	-PRON-	PRP
cord-293860-6kz0iws6	55	30	elicits	elicit	VBZ
cord-293860-6kz0iws6	55	31	substantial	substantial	JJ
cord-293860-6kz0iws6	55	32	blockage	blockage	NN
cord-293860-6kz0iws6	55	33	of	of	IN
cord-293860-6kz0iws6	55	34	any	any	DT
cord-293860-6kz0iws6	55	35	LTD4	LTD4	NNP
cord-293860-6kz0iws6	55	36	leukotriene	leukotriene	NN
cord-293860-6kz0iws6	55	37	-	-	HYPH
cord-293860-6kz0iws6	55	38	mediated	mediate	VBN
cord-293860-6kz0iws6	55	39	effect	effect	NN
cord-293860-6kz0iws6	55	40	,	,	,
cord-293860-6kz0iws6	55	41	resulting	result	VBG
cord-293860-6kz0iws6	55	42	in	in	IN
cord-293860-6kz0iws6	55	43	reduced	reduce	VBN
cord-293860-6kz0iws6	55	44	inflammation	inflammation	NN
cord-293860-6kz0iws6	55	45	and	and	CC
cord-293860-6kz0iws6	55	46	relaxation	relaxation	NN
cord-293860-6kz0iws6	55	47	of	of	IN
cord-293860-6kz0iws6	55	48	smooth	smooth	JJ
cord-293860-6kz0iws6	55	49	muscle	muscle	NN
cord-293860-6kz0iws6	55	50	.	.	.
cord-293860-6kz0iws6	56	1	It	-PRON-	PRP
cord-293860-6kz0iws6	56	2	has	have	VBZ
cord-293860-6kz0iws6	56	3	also	also	RB
cord-293860-6kz0iws6	56	4	been	be	VBN
cord-293860-6kz0iws6	56	5	shown	show	VBN
cord-293860-6kz0iws6	56	6	to	to	TO
cord-293860-6kz0iws6	56	7	diminish	diminish	VB
cord-293860-6kz0iws6	56	8	the	the	DT
cord-293860-6kz0iws6	56	9	pulmonary	pulmonary	JJ
cord-293860-6kz0iws6	56	10	response	response	NN
cord-293860-6kz0iws6	56	11	to	to	IN
cord-293860-6kz0iws6	56	12	antigen	antigen	NN
cord-293860-6kz0iws6	56	13	,	,	,
cord-293860-6kz0iws6	56	14	tissue	tissue	NN
cord-293860-6kz0iws6	56	15	eosinophilia	eosinophilia	NN
cord-293860-6kz0iws6	56	16	and	and	CC
cord-293860-6kz0iws6	56	17	the	the	DT
cord-293860-6kz0iws6	56	18	number	number	NN
cord-293860-6kz0iws6	56	19	of	of	IN
cord-293860-6kz0iws6	56	20	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	56	21	cells	cell	NNS
cord-293860-6kz0iws6	56	22	expressing	express	VBG
cord-293860-6kz0iws6	56	23	IL-5	IL-5	NNP
cord-293860-6kz0iws6	56	24	8	8	CD
cord-293860-6kz0iws6	56	25	.	.	.
cord-293860-6kz0iws6	57	1	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	57	2	decreases	decrease	VBZ
cord-293860-6kz0iws6	57	3	elevated	elevated	JJ
cord-293860-6kz0iws6	57	4	levels	level	NNS
cord-293860-6kz0iws6	57	5	of	of	IN
cord-293860-6kz0iws6	57	6	IL-1	IL-1	NNP
cord-293860-6kz0iws6	57	7	and	and	CC
cord-293860-6kz0iws6	57	8	IL8	il8	VB
cord-293860-6kz0iws6	57	9	in	in	IN
cord-293860-6kz0iws6	57	10	nasal	nasal	NN
cord-293860-6kz0iws6	57	11	washouts	washout	NNS
cord-293860-6kz0iws6	57	12	in	in	IN
cord-293860-6kz0iws6	57	13	humans	human	NNS
cord-293860-6kz0iws6	57	14	with	with	IN
cord-293860-6kz0iws6	57	15	viral	viral	JJ
cord-293860-6kz0iws6	57	16	upper	upper	JJ
cord-293860-6kz0iws6	57	17	respiratory	respiratory	JJ
cord-293860-6kz0iws6	57	18	tract	tract	NN
cord-293860-6kz0iws6	57	19	infections	infection	NNS
cord-293860-6kz0iws6	57	20	compared	compare	VBN
cord-293860-6kz0iws6	57	21	with	with	IN
cord-293860-6kz0iws6	57	22	placebo	placebo	NN
cord-293860-6kz0iws6	57	23	-	-	HYPH
cord-293860-6kz0iws6	57	24	treated	treat	VBN
cord-293860-6kz0iws6	57	25	patients	patient	NNS
cord-293860-6kz0iws6	57	26	9	9	CD
cord-293860-6kz0iws6	57	27	.	.	.
cord-293860-6kz0iws6	58	1	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	58	2	was	be	VBD
cord-293860-6kz0iws6	58	3	first	first	RB
cord-293860-6kz0iws6	58	4	approved	approve	VBN
cord-293860-6kz0iws6	58	5	for	for	IN
cord-293860-6kz0iws6	58	6	clinical	clinical	JJ
cord-293860-6kz0iws6	58	7	use	use	NN
cord-293860-6kz0iws6	58	8	by	by	IN
cord-293860-6kz0iws6	58	9	the	the	DT
cord-293860-6kz0iws6	58	10	US	US	NNP
cord-293860-6kz0iws6	58	11	FDA	FDA	NNP
cord-293860-6kz0iws6	58	12	in	in	IN
cord-293860-6kz0iws6	58	13	1998	1998	CD
cord-293860-6kz0iws6	58	14	.	.	.
cord-293860-6kz0iws6	59	1	It	-PRON-	PRP
cord-293860-6kz0iws6	59	2	is	be	VBZ
cord-293860-6kz0iws6	59	3	currently	currently	RB
cord-293860-6kz0iws6	59	4	licensed	license	VBN
cord-293860-6kz0iws6	59	5	to	to	TO
cord-293860-6kz0iws6	59	6	treat	treat	VB
cord-293860-6kz0iws6	59	7	asthma	asthma	NN
cord-293860-6kz0iws6	59	8	,	,	,
cord-293860-6kz0iws6	59	9	exercise	exercise	NN
cord-293860-6kz0iws6	59	10	-	-	HYPH
cord-293860-6kz0iws6	59	11	induced	induce	VBN
cord-293860-6kz0iws6	59	12	bronchospasm	bronchospasm	JJ
cord-293860-6kz0iws6	59	13	and	and	CC
cord-293860-6kz0iws6	59	14	allergic	allergic	JJ
cord-293860-6kz0iws6	59	15	rhinitis	rhinitis	NN
cord-293860-6kz0iws6	59	16	.	.	.
cord-293860-6kz0iws6	60	1	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	60	2	10	10	CD
cord-293860-6kz0iws6	60	3	mg	mg	NNP
cord-293860-6kz0iws6	60	4	is	be	VBZ
cord-293860-6kz0iws6	60	5	given	give	VBN
cord-293860-6kz0iws6	60	6	orally	orally	RB
cord-293860-6kz0iws6	60	7	once	once	RB
cord-293860-6kz0iws6	60	8	daily	daily	JJ
cord-293860-6kz0iws6	60	9	(	(	-LRB-
cord-293860-6kz0iws6	60	10	oral	oral	JJ
cord-293860-6kz0iws6	60	11	bioavailability	bioavailability	NN
cord-293860-6kz0iws6	60	12	64	64	CD
cord-293860-6kz0iws6	60	13	%	%	NN
cord-293860-6kz0iws6	60	14	)	)	-RRB-
cord-293860-6kz0iws6	60	15	.	.	.
cord-293860-6kz0iws6	61	1	It	-PRON-	PRP
cord-293860-6kz0iws6	61	2	is	be	VBZ
cord-293860-6kz0iws6	61	3	highly	highly	RB
cord-293860-6kz0iws6	61	4	metabolised	metabolise	VBN
cord-293860-6kz0iws6	61	5	in	in	IN
cord-293860-6kz0iws6	61	6	the	the	DT
cord-293860-6kz0iws6	61	7	liver	liver	NN
cord-293860-6kz0iws6	61	8	by	by	IN
cord-293860-6kz0iws6	61	9	cytochrome	cytochrome	NN
cord-293860-6kz0iws6	61	10	P450	p450	NN
cord-293860-6kz0iws6	61	11	.	.	.
cord-293860-6kz0iws6	62	1	The	the	DT
cord-293860-6kz0iws6	62	2	drug	drug	NN
cord-293860-6kz0iws6	62	3	and	and	CC
cord-293860-6kz0iws6	62	4	its	-PRON-	PRP$
cord-293860-6kz0iws6	62	5	metabolites	metabolite	NNS
cord-293860-6kz0iws6	62	6	are	be	VBP
cord-293860-6kz0iws6	62	7	almost	almost	RB
cord-293860-6kz0iws6	62	8	exclusively	exclusively	RB
cord-293860-6kz0iws6	62	9	excreted	excrete	VBN
cord-293860-6kz0iws6	62	10	in	in	IN
cord-293860-6kz0iws6	62	11	the	the	DT
cord-293860-6kz0iws6	62	12	bile	bile	NN
cord-293860-6kz0iws6	62	13	and	and	CC
cord-293860-6kz0iws6	62	14	into	into	IN
cord-293860-6kz0iws6	62	15	the	the	DT
cord-293860-6kz0iws6	62	16	faeces	faece	NNS
cord-293860-6kz0iws6	62	17	.	.	.
cord-293860-6kz0iws6	63	1	With	with	IN
cord-293860-6kz0iws6	63	2	its	-PRON-	PRP$
cord-293860-6kz0iws6	63	3	prominent	prominent	JJ
cord-293860-6kz0iws6	63	4	effect	effect	NN
cord-293860-6kz0iws6	63	5	in	in	IN
cord-293860-6kz0iws6	63	6	reducing	reduce	VBG
cord-293860-6kz0iws6	63	7	leukotriene	leukotriene	NN
cord-293860-6kz0iws6	63	8	-	-	HYPH
cord-293860-6kz0iws6	63	9	mediated	mediate	VBN
cord-293860-6kz0iws6	63	10	cytokine	cytokine	NN
cord-293860-6kz0iws6	63	11	release	release	NN
cord-293860-6kz0iws6	63	12	montelukast	montelukast	NN
cord-293860-6kz0iws6	63	13	would	would	MD
cord-293860-6kz0iws6	63	14	have	have	VB
cord-293860-6kz0iws6	63	15	the	the	DT
cord-293860-6kz0iws6	63	16	potential	potential	NN
cord-293860-6kz0iws6	63	17	to	to	TO
cord-293860-6kz0iws6	63	18	moderate	moderate	VB
cord-293860-6kz0iws6	63	19	the	the	DT
cord-293860-6kz0iws6	63	20	background	background	NN
cord-293860-6kz0iws6	63	21	inflammation	inflammation	NN
cord-293860-6kz0iws6	63	22	associated	associate	VBN
cord-293860-6kz0iws6	63	23	with	with	IN
cord-293860-6kz0iws6	63	24	obesity	obesity	NN
cord-293860-6kz0iws6	63	25	and	and	CC
cord-293860-6kz0iws6	63	26	the	the	DT
cord-293860-6kz0iws6	63	27	body	body	NN
cord-293860-6kz0iws6	63	28	's	's	POS
cord-293860-6kz0iws6	63	29	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	63	30	response	response	NN
cord-293860-6kz0iws6	63	31	to	to	IN
cord-293860-6kz0iws6	63	32	SARS	SARS	NNP
cord-293860-6kz0iws6	63	33	-	-	HYPH
cord-293860-6kz0iws6	63	34	CoV2	CoV2	NNP
cord-293860-6kz0iws6	63	35	.	.	.
cord-293860-6kz0iws6	64	1	Coronaviruses	coronaviruse	NNS
cord-293860-6kz0iws6	64	2	are	be	VBP
cord-293860-6kz0iws6	64	3	enveloped	envelop	VBN
cord-293860-6kz0iws6	64	4	viruses	virus	NNS
cord-293860-6kz0iws6	64	5	with	with	IN
cord-293860-6kz0iws6	64	6	a	a	DT
cord-293860-6kz0iws6	64	7	positive	positive	JJ
cord-293860-6kz0iws6	64	8	RNA	RNA	NNP
cord-293860-6kz0iws6	64	9	genome	genome	NN
cord-293860-6kz0iws6	64	10	.	.	.
cord-293860-6kz0iws6	65	1	The	the	DT
cord-293860-6kz0iws6	65	2	virus	virus	NN
cord-293860-6kz0iws6	65	3	contains	contain	VBZ
cord-293860-6kz0iws6	65	4	at	at	IN
cord-293860-6kz0iws6	65	5	least	least	RBS
cord-293860-6kz0iws6	65	6	four	four	CD
cord-293860-6kz0iws6	65	7	structural	structural	JJ
cord-293860-6kz0iws6	65	8	proteins	protein	NNS
cord-293860-6kz0iws6	65	9	:	:	:
cord-293860-6kz0iws6	65	10	Spike	spike	NN
cord-293860-6kz0iws6	65	11	(	(	-LRB-
cord-293860-6kz0iws6	65	12	S	s	NN
cord-293860-6kz0iws6	65	13	)	)	-RRB-
cord-293860-6kz0iws6	65	14	protein	protein	NN
cord-293860-6kz0iws6	65	15	,	,	,
cord-293860-6kz0iws6	65	16	envelop	envelop	VB
cord-293860-6kz0iws6	65	17	(	(	-LRB-
cord-293860-6kz0iws6	65	18	E	e	NN
cord-293860-6kz0iws6	65	19	)	)	-RRB-
cord-293860-6kz0iws6	65	20	protein	protein	NN
cord-293860-6kz0iws6	65	21	,	,	,
cord-293860-6kz0iws6	65	22	membrane	membrane	NN
cord-293860-6kz0iws6	65	23	(	(	-LRB-
cord-293860-6kz0iws6	65	24	M	M	NNP
cord-293860-6kz0iws6	65	25	)	)	-RRB-
cord-293860-6kz0iws6	65	26	protein	protein	NN
cord-293860-6kz0iws6	65	27	,	,	,
cord-293860-6kz0iws6	65	28	and	and	CC
cord-293860-6kz0iws6	65	29	nucleocapsid	nucleocapsid	NN
cord-293860-6kz0iws6	65	30	(	(	-LRB-
cord-293860-6kz0iws6	65	31	N	N	NNP
cord-293860-6kz0iws6	65	32	)	)	-RRB-
cord-293860-6kz0iws6	65	33	protein	protein	NN
cord-293860-6kz0iws6	65	34	22	22	CD
cord-293860-6kz0iws6	65	35	,	,	,
cord-293860-6kz0iws6	65	36	23	23	CD
cord-293860-6kz0iws6	65	37	.	.	.
cord-293860-6kz0iws6	66	1	SARS	SARS	NNP
cord-293860-6kz0iws6	66	2	-	-	HYPH
cord-293860-6kz0iws6	66	3	CoV-2	CoV-2	NNP
cord-293860-6kz0iws6	66	4	entry	entry	NN
cord-293860-6kz0iws6	66	5	into	into	IN
cord-293860-6kz0iws6	66	6	the	the	DT
cord-293860-6kz0iws6	66	7	host	host	NN
cord-293860-6kz0iws6	66	8	cells	cell	NNS
cord-293860-6kz0iws6	66	9	is	be	VBZ
cord-293860-6kz0iws6	66	10	mediated	mediate	VBN
cord-293860-6kz0iws6	66	11	by	by	IN
cord-293860-6kz0iws6	66	12	an	an	DT
cord-293860-6kz0iws6	66	13	interaction	interaction	NN
cord-293860-6kz0iws6	66	14	between	between	IN
cord-293860-6kz0iws6	66	15	the	the	DT
cord-293860-6kz0iws6	66	16	Spike	Spike	NNP
cord-293860-6kz0iws6	66	17	protein	protein	NN
cord-293860-6kz0iws6	66	18	and	and	CC
cord-293860-6kz0iws6	66	19	angiotensin	angiotensin	NN
cord-293860-6kz0iws6	66	20	-	-	HYPH
cord-293860-6kz0iws6	66	21	converting	convert	VBG
cord-293860-6kz0iws6	66	22	enzyme	enzyme	NN
cord-293860-6kz0iws6	66	23	2	2	CD
cord-293860-6kz0iws6	66	24	(	(	-LRB-
cord-293860-6kz0iws6	66	25	ACE2	ACE2	NNP
cord-293860-6kz0iws6	66	26	)	)	-RRB-
cord-293860-6kz0iws6	66	27	receptors	receptor	NNS
cord-293860-6kz0iws6	66	28	24	24	CD
cord-293860-6kz0iws6	66	29	,	,	,
cord-293860-6kz0iws6	66	30	25	25	CD
cord-293860-6kz0iws6	66	31	,	,	,
cord-293860-6kz0iws6	66	32	cell	cell	NN
cord-293860-6kz0iws6	66	33	surface	surface	NN
cord-293860-6kz0iws6	66	34	proteins	protein	NNS
cord-293860-6kz0iws6	66	35	highly	highly	RB
cord-293860-6kz0iws6	66	36	expressed	express	VBN
cord-293860-6kz0iws6	66	37	in	in	IN
cord-293860-6kz0iws6	66	38	the	the	DT
cord-293860-6kz0iws6	66	39	lung	lung	NN
cord-293860-6kz0iws6	66	40	,	,	,
cord-293860-6kz0iws6	66	41	heart	heart	NN
cord-293860-6kz0iws6	66	42	and	and	CC
cord-293860-6kz0iws6	66	43	kidney	kidney	NN
cord-293860-6kz0iws6	66	44	.	.	.
cord-293860-6kz0iws6	67	1	Wu	Wu	NNP
cord-293860-6kz0iws6	67	2	et	et	NNP
cord-293860-6kz0iws6	67	3	al	al	NNP
cord-293860-6kz0iws6	67	4	10	10	CD
cord-293860-6kz0iws6	67	5	performed	perform	VBD
cord-293860-6kz0iws6	67	6	in	in	IN
cord-293860-6kz0iws6	67	7	silico	silico	NN
cord-293860-6kz0iws6	67	8	,	,	,
cord-293860-6kz0iws6	67	9	target	target	NN
cord-293860-6kz0iws6	67	10	-	-	HYPH
cord-293860-6kz0iws6	67	11	based	base	VBN
cord-293860-6kz0iws6	67	12	virtual	virtual	JJ
cord-293860-6kz0iws6	67	13	ligand	ligand	NN
cord-293860-6kz0iws6	67	14	screening	screening	NN
cord-293860-6kz0iws6	67	15	for	for	IN
cord-293860-6kz0iws6	67	16	SARS	SARS	NNP
cord-293860-6kz0iws6	67	17	-	-	HYPH
cord-293860-6kz0iws6	67	18	CoV-2	CoV-2	NNP
cord-293860-6kz0iws6	67	19	main	main	JJ
cord-293860-6kz0iws6	67	20	proteins	protein	NNS
cord-293860-6kz0iws6	67	21	including	include	VBG
cord-293860-6kz0iws6	67	22	the	the	DT
cord-293860-6kz0iws6	67	23	main	main	JJ
cord-293860-6kz0iws6	67	24	protease	protease	NN
cord-293860-6kz0iws6	67	25	,	,	,
cord-293860-6kz0iws6	67	26	spike	spike	NN
cord-293860-6kz0iws6	67	27	protein	protein	NN
cord-293860-6kz0iws6	67	28	,	,	,
cord-293860-6kz0iws6	67	29	RNA	rna	NN
cord-293860-6kz0iws6	67	30	-	-	HYPH
cord-293860-6kz0iws6	67	31	dependent	dependent	JJ
cord-293860-6kz0iws6	67	32	RNA	RNA	NNP
cord-293860-6kz0iws6	67	33	polymerase	polymerase	NN
cord-293860-6kz0iws6	67	34	and	and	CC
cord-293860-6kz0iws6	67	35	papain	papain	NN
cord-293860-6kz0iws6	67	36	-	-	HYPH
cord-293860-6kz0iws6	67	37	like	like	JJ
cord-293860-6kz0iws6	67	38	protease	protease	NN
cord-293860-6kz0iws6	67	39	.	.	.
cord-293860-6kz0iws6	68	1	The	the	DT
cord-293860-6kz0iws6	68	2	authors	author	NNS
cord-293860-6kz0iws6	68	3	screened	screen	VBD
cord-293860-6kz0iws6	68	4	approved	approve	VBN
cord-293860-6kz0iws6	68	5	drugs	drug	NNS
cord-293860-6kz0iws6	68	6	from	from	IN
cord-293860-6kz0iws6	68	7	a	a	DT
cord-293860-6kz0iws6	68	8	subset	subset	NN
cord-293860-6kz0iws6	68	9	of	of	IN
cord-293860-6kz0iws6	68	10	the	the	DT
cord-293860-6kz0iws6	68	11	ZINC	zinc	NN
cord-293860-6kz0iws6	68	12	database	database	NN
cord-293860-6kz0iws6	68	13	which	which	WDT
cord-293860-6kz0iws6	68	14	contains	contain	VBZ
cord-293860-6kz0iws6	68	15	2924	2924	CD
cord-293860-6kz0iws6	68	16	compounds	compound	NNS
cord-293860-6kz0iws6	68	17	26	26	CD
cord-293860-6kz0iws6	68	18	.	.	.
cord-293860-6kz0iws6	69	1	They	-PRON-	PRP
cord-293860-6kz0iws6	69	2	also	also	RB
cord-293860-6kz0iws6	69	3	screened	screen	VBD
cord-293860-6kz0iws6	69	4	a	a	DT
cord-293860-6kz0iws6	69	5	natural	natural	JJ
cord-293860-6kz0iws6	69	6	product	product	NN
cord-293860-6kz0iws6	69	7	database	database	NN
cord-293860-6kz0iws6	69	8	of	of	IN
cord-293860-6kz0iws6	69	9	1,066	1,066	CD
cord-293860-6kz0iws6	69	10	chemicals	chemical	NNS
cord-293860-6kz0iws6	69	11	separated	separate	VBN
cord-293860-6kz0iws6	69	12	from	from	IN
cord-293860-6kz0iws6	69	13	traditional	traditional	JJ
cord-293860-6kz0iws6	69	14	Chinese	chinese	JJ
cord-293860-6kz0iws6	69	15	herbals	herbal	NNS
cord-293860-6kz0iws6	69	16	and	and	CC
cord-293860-6kz0iws6	69	17	78	78	CD
cord-293860-6kz0iws6	69	18	known	know	VBN
cord-293860-6kz0iws6	69	19	anti	anti	JJ
cord-293860-6kz0iws6	69	20	-	-	JJ
cord-293860-6kz0iws6	69	21	viral	viral	JJ
cord-293860-6kz0iws6	69	22	drugs	drug	NNS
cord-293860-6kz0iws6	69	23	.	.	.
cord-293860-6kz0iws6	70	1	Their	-PRON-	PRP$
cord-293860-6kz0iws6	70	2	computer	computer	NN
cord-293860-6kz0iws6	70	3	modelling	modelling	NN
cord-293860-6kz0iws6	70	4	study	study	NN
cord-293860-6kz0iws6	70	5	found	find	VBD
cord-293860-6kz0iws6	70	6	that	that	IN
cord-293860-6kz0iws6	70	7	montelukast	montelukast	NN
cord-293860-6kz0iws6	70	8	should	should	MD
cord-293860-6kz0iws6	70	9	demonstrate	demonstrate	VB
cord-293860-6kz0iws6	70	10	binding	bind	VBG
cord-293860-6kz0iws6	70	11	energy	energy	NN
cord-293860-6kz0iws6	70	12	to	to	IN
cord-293860-6kz0iws6	70	13	the	the	DT
cord-293860-6kz0iws6	70	14	virus	virus	NN
cord-293860-6kz0iws6	70	15	's	's	POS
cord-293860-6kz0iws6	70	16	main	main	JJ
cord-293860-6kz0iws6	70	17	protease	protease	NN
cord-293860-6kz0iws6	70	18	enzyme	enzyme	NN
cord-293860-6kz0iws6	70	19	.	.	.
cord-293860-6kz0iws6	71	1	It	-PRON-	PRP
cord-293860-6kz0iws6	71	2	fitted	fit	VBD
cord-293860-6kz0iws6	71	3	well	well	RB
cord-293860-6kz0iws6	71	4	into	into	IN
cord-293860-6kz0iws6	71	5	the	the	DT
cord-293860-6kz0iws6	71	6	active	active	JJ
cord-293860-6kz0iws6	71	7	pocket	pocket	NN
cord-293860-6kz0iws6	71	8	of	of	IN
cord-293860-6kz0iws6	71	9	the	the	DT
cord-293860-6kz0iws6	71	10	main	main	JJ
cord-293860-6kz0iws6	71	11	protease	protease	NN
cord-293860-6kz0iws6	71	12	,	,	,
cord-293860-6kz0iws6	71	13	in	in	IN
cord-293860-6kz0iws6	71	14	which	which	WDT
cord-293860-6kz0iws6	71	15	hydrophobic	hydrophobic	JJ
cord-293860-6kz0iws6	71	16	amino	amino	NN
cord-293860-6kz0iws6	71	17	acids	acid	NNS
cord-293860-6kz0iws6	71	18	would	would	MD
cord-293860-6kz0iws6	71	19	create	create	VB
cord-293860-6kz0iws6	71	20	a	a	DT
cord-293860-6kz0iws6	71	21	relatively	relatively	RB
cord-293860-6kz0iws6	71	22	hydrophobic	hydrophobic	JJ
cord-293860-6kz0iws6	71	23	environment	environment	NN
cord-293860-6kz0iws6	71	24	to	to	TO
cord-293860-6kz0iws6	71	25	contain	contain	VB
cord-293860-6kz0iws6	71	26	the	the	DT
cord-293860-6kz0iws6	71	27	drug	drug	NN
cord-293860-6kz0iws6	71	28	and	and	CC
cord-293860-6kz0iws6	71	29	stabilise	stabilise	VB
cord-293860-6kz0iws6	71	30	its	-PRON-	PRP$
cord-293860-6kz0iws6	71	31	conformation	conformation	NN
cord-293860-6kz0iws6	71	32	10	10	CD
cord-293860-6kz0iws6	71	33	.	.	.
cord-293860-6kz0iws6	72	1	Similarly	similarly	RB
cord-293860-6kz0iws6	72	2	,	,	,
cord-293860-6kz0iws6	72	3	a	a	DT
cord-293860-6kz0iws6	72	4	report	report	NN
cord-293860-6kz0iws6	72	5	by	by	IN
cord-293860-6kz0iws6	72	6	Farag	Farag	NNP
cord-293860-6kz0iws6	72	7	et	et	NNP
cord-293860-6kz0iws6	72	8	al	al	NNP
cord-293860-6kz0iws6	72	9	11	11	CD
cord-293860-6kz0iws6	72	10	predicted	predict	VBD
cord-293860-6kz0iws6	72	11	a	a	DT
cord-293860-6kz0iws6	72	12	high	high	JJ
cord-293860-6kz0iws6	72	13	affinity	affinity	NN
cord-293860-6kz0iws6	72	14	of	of	IN
cord-293860-6kz0iws6	72	15	montelukast	montelukast	NN
cord-293860-6kz0iws6	72	16	to	to	IN
cord-293860-6kz0iws6	72	17	the	the	DT
cord-293860-6kz0iws6	72	18	same	same	JJ
cord-293860-6kz0iws6	72	19	binding	bind	VBG
cord-293860-6kz0iws6	72	20	domain	domain	NN
cord-293860-6kz0iws6	72	21	in	in	IN
cord-293860-6kz0iws6	72	22	the	the	DT
cord-293860-6kz0iws6	72	23	main	main	JJ
cord-293860-6kz0iws6	72	24	protease	protease	NN
cord-293860-6kz0iws6	72	25	enzyme	enzyme	NN
cord-293860-6kz0iws6	72	26	with	with	IN
cord-293860-6kz0iws6	72	27	hydrophobic	hydrophobic	JJ
cord-293860-6kz0iws6	72	28	-	-	HYPH
cord-293860-6kz0iws6	72	29	hydrophobic	hydrophobic	JJ
cord-293860-6kz0iws6	72	30	and	and	CC
cord-293860-6kz0iws6	72	31	hydrogen	hydrogen	NN
cord-293860-6kz0iws6	72	32	bond	bond	NN
cord-293860-6kz0iws6	72	33	-	-	HYPH
cord-293860-6kz0iws6	72	34	interactions	interaction	NNS
cord-293860-6kz0iws6	72	35	.	.	.
cord-293860-6kz0iws6	73	1	Farag	Farag	NNP
cord-293860-6kz0iws6	73	2	et	et	NNP
cord-293860-6kz0iws6	73	3	al	al	NNP
cord-293860-6kz0iws6	73	4	11	11	CD
cord-293860-6kz0iws6	73	5	focussed	focusse	VBD
cord-293860-6kz0iws6	73	6	on	on	IN
cord-293860-6kz0iws6	73	7	targeting	target	VBG
cord-293860-6kz0iws6	73	8	the	the	DT
cord-293860-6kz0iws6	73	9	SARS	SARS	NNP
cord-293860-6kz0iws6	73	10	-	-	HYPH
cord-293860-6kz0iws6	73	11	CoV-2	CoV-2	NNP
cord-293860-6kz0iws6	73	12	main	main	JJ
cord-293860-6kz0iws6	73	13	protease	protease	NN
cord-293860-6kz0iws6	73	14	enzyme	enzyme	NN
cord-293860-6kz0iws6	73	15	at	at	IN
cord-293860-6kz0iws6	73	16	its	-PRON-	PRP$
cord-293860-6kz0iws6	73	17	two	two	CD
cord-293860-6kz0iws6	73	18	potential	potential	JJ
cord-293860-6kz0iws6	73	19	binding	bind	VBG
cord-293860-6kz0iws6	73	20	sites	site	NNS
cord-293860-6kz0iws6	73	21	in	in	IN
cord-293860-6kz0iws6	73	22	the	the	DT
cord-293860-6kz0iws6	73	23	main	main	JJ
cord-293860-6kz0iws6	73	24	substrate	substrate	NN
cord-293860-6kz0iws6	73	25	-	-	HYPH
cord-293860-6kz0iws6	73	26	binding	bind	VBG
cord-293860-6kz0iws6	73	27	pocket	pocket	NN
cord-293860-6kz0iws6	73	28	:	:	:
cord-293860-6kz0iws6	73	29	the	the	DT
cord-293860-6kz0iws6	73	30	central	central	JJ
cord-293860-6kz0iws6	73	31	site	site	NN
cord-293860-6kz0iws6	73	32	and	and	CC
cord-293860-6kz0iws6	73	33	terminal	terminal	NN
cord-293860-6kz0iws6	73	34	site	site	NN
cord-293860-6kz0iws6	73	35	.	.	.
cord-293860-6kz0iws6	74	1	The	the	DT
cord-293860-6kz0iws6	74	2	authors	author	NNS
cord-293860-6kz0iws6	74	3	screened	screen	VBD
cord-293860-6kz0iws6	74	4	>	>	XX
cord-293860-6kz0iws6	74	5	2,000	2,000	CD
cord-293860-6kz0iws6	74	6	FDA	FDA	NNP
cord-293860-6kz0iws6	74	7	-	-	HYPH
cord-293860-6kz0iws6	74	8	approved	approve	VBN
cord-293860-6kz0iws6	74	9	drugs	drug	NNS
cord-293860-6kz0iws6	74	10	to	to	TO
cord-293860-6kz0iws6	74	11	identify	identify	VB
cord-293860-6kz0iws6	74	12	potential	potential	JJ
cord-293860-6kz0iws6	74	13	hits	hit	NNS
cord-293860-6kz0iws6	74	14	based	base	VBN
cord-293860-6kz0iws6	74	15	on	on	IN
cord-293860-6kz0iws6	74	16	drug	drug	NN
cord-293860-6kz0iws6	74	17	molecules	molecule	NNS
cord-293860-6kz0iws6	74	18	'	'	POS
cord-293860-6kz0iws6	74	19	binding	bind	VBG
cord-293860-6kz0iws6	74	20	energies	energy	NNS
cord-293860-6kz0iws6	74	21	,	,	,
cord-293860-6kz0iws6	74	22	binding	bind	VBG
cord-293860-6kz0iws6	74	23	modes	mode	NNS
cord-293860-6kz0iws6	74	24	and	and	CC
cord-293860-6kz0iws6	74	25	the	the	DT
cord-293860-6kz0iws6	74	26	predicted	predict	VBN
cord-293860-6kz0iws6	74	27	interaction	interaction	NN
cord-293860-6kz0iws6	74	28	of	of	IN
cord-293860-6kz0iws6	74	29	amino	amino	JJ
cord-293860-6kz0iws6	74	30	acids	acid	NNS
cord-293860-6kz0iws6	74	31	with	with	IN
cord-293860-6kz0iws6	74	32	the	the	DT
cord-293860-6kz0iws6	74	33	enzyme	enzyme	NN
cord-293860-6kz0iws6	74	34	's	's	POS
cord-293860-6kz0iws6	74	35	substrate	substrate	NN
cord-293860-6kz0iws6	74	36	binding	bind	VBG
cord-293860-6kz0iws6	74	37	pockets	pocket	NNS
cord-293860-6kz0iws6	74	38	.	.	.
cord-293860-6kz0iws6	75	1	Whilst	whilst	IN
cord-293860-6kz0iws6	75	2	antiviral	antiviral	JJ
cord-293860-6kz0iws6	75	3	drugs	drug	NNS
cord-293860-6kz0iws6	75	4	unsurprisingly	unsurprisingly	RB
cord-293860-6kz0iws6	75	5	had	have	VBD
cord-293860-6kz0iws6	75	6	the	the	DT
cord-293860-6kz0iws6	75	7	best	good	JJS
cord-293860-6kz0iws6	75	8	binding	binding	NN
cord-293860-6kz0iws6	75	9	to	to	IN
cord-293860-6kz0iws6	75	10	the	the	DT
cord-293860-6kz0iws6	75	11	central	central	JJ
cord-293860-6kz0iws6	75	12	site	site	NN
cord-293860-6kz0iws6	75	13	of	of	IN
cord-293860-6kz0iws6	75	14	the	the	DT
cord-293860-6kz0iws6	75	15	main	main	JJ
cord-293860-6kz0iws6	75	16	protease	protease	NN
cord-293860-6kz0iws6	75	17	enzyme	enzyme	NN
cord-293860-6kz0iws6	75	18	substrate	substrate	NN
cord-293860-6kz0iws6	75	19	-	-	HYPH
cord-293860-6kz0iws6	75	20	binding	bind	VBG
cord-293860-6kz0iws6	75	21	pocket	pocket	NN
cord-293860-6kz0iws6	75	22	,	,	,
cord-293860-6kz0iws6	75	23	montelukast	montelukast	NNP
cord-293860-6kz0iws6	75	24	demonstrated	demonstrate	VBD
cord-293860-6kz0iws6	75	25	a	a	DT
cord-293860-6kz0iws6	75	26	very	very	RB
cord-293860-6kz0iws6	75	27	high	high	JJ
cord-293860-6kz0iws6	75	28	affinity	affinity	NN
cord-293860-6kz0iws6	75	29	for	for	IN
cord-293860-6kz0iws6	75	30	the	the	DT
cord-293860-6kz0iws6	75	31	terminal	terminal	JJ
cord-293860-6kz0iws6	75	32	site	site	NN
cord-293860-6kz0iws6	75	33	,	,	,
cord-293860-6kz0iws6	75	34	better	well	JJR
cord-293860-6kz0iws6	75	35	than	than	IN
cord-293860-6kz0iws6	75	36	any	any	DT
cord-293860-6kz0iws6	75	37	other	other	JJ
cord-293860-6kz0iws6	75	38	drug	drug	NN
cord-293860-6kz0iws6	75	39	tested	test	VBN
cord-293860-6kz0iws6	75	40	at	at	IN
cord-293860-6kz0iws6	75	41	this	this	DT
cord-293860-6kz0iws6	75	42	site	site	NN
cord-293860-6kz0iws6	75	43	Whist	Whist	NNP
cord-293860-6kz0iws6	75	44	drug	drug	NN
cord-293860-6kz0iws6	75	45	binding	bind	VBG
cord-293860-6kz0iws6	75	46	in	in	RP
cord-293860-6kz0iws6	75	47	in	in	IN
cord-293860-6kz0iws6	75	48	silico	silico	NN
cord-293860-6kz0iws6	75	49	modelling	modelling	NN
cord-293860-6kz0iws6	75	50	studies	study	NNS
cord-293860-6kz0iws6	75	51	such	such	JJ
cord-293860-6kz0iws6	75	52	as	as	IN
cord-293860-6kz0iws6	75	53	these	these	DT
cord-293860-6kz0iws6	75	54	may	may	MD
cord-293860-6kz0iws6	75	55	not	not	RB
cord-293860-6kz0iws6	75	56	translate	translate	VB
cord-293860-6kz0iws6	75	57	into	into	IN
cord-293860-6kz0iws6	75	58	clinical	clinical	JJ
cord-293860-6kz0iws6	75	59	effect	effect	NN
cord-293860-6kz0iws6	75	60	,	,	,
cord-293860-6kz0iws6	75	61	the	the	DT
cord-293860-6kz0iws6	75	62	protease	protease	NN
cord-293860-6kz0iws6	75	63	enzyme	enzyme	NN
cord-293860-6kz0iws6	75	64	is	be	VBZ
cord-293860-6kz0iws6	75	65	essential	essential	JJ
cord-293860-6kz0iws6	75	66	for	for	IN
cord-293860-6kz0iws6	75	67	the	the	DT
cord-293860-6kz0iws6	75	68	SARS	SARS	NNP
cord-293860-6kz0iws6	75	69	-	-	HYPH
cord-293860-6kz0iws6	75	70	CoV-2	CoV-2	NNP
cord-293860-6kz0iws6	75	71	virus	virus	NN
cord-293860-6kz0iws6	75	72	RNA	rna	NN
cord-293860-6kz0iws6	75	73	synthesis	synthesis	NN
cord-293860-6kz0iws6	75	74	and	and	CC
cord-293860-6kz0iws6	75	75	replication	replication	NN
cord-293860-6kz0iws6	75	76	and	and	CC
cord-293860-6kz0iws6	75	77	if	if	IN
cord-293860-6kz0iws6	75	78	montelukast	montelukast	NNP
cord-293860-6kz0iws6	75	79	was	be	VBD
cord-293860-6kz0iws6	75	80	shown	show	VBN
cord-293860-6kz0iws6	75	81	to	to	TO
cord-293860-6kz0iws6	75	82	confer	confer	VB
cord-293860-6kz0iws6	75	83	benefit	benefit	NN
cord-293860-6kz0iws6	75	84	in	in	IN
cord-293860-6kz0iws6	75	85	clinical	clinical	JJ
cord-293860-6kz0iws6	75	86	studies	study	NNS
cord-293860-6kz0iws6	75	87	it	-PRON-	PRP
cord-293860-6kz0iws6	75	88	may	may	MD
cord-293860-6kz0iws6	75	89	be	be	VB
cord-293860-6kz0iws6	75	90	,	,	,
cord-293860-6kz0iws6	75	91	at	at	IN
cord-293860-6kz0iws6	75	92	least	least	JJS
cord-293860-6kz0iws6	75	93	in	in	IN
cord-293860-6kz0iws6	75	94	part	part	NN
cord-293860-6kz0iws6	75	95	,	,	,
cord-293860-6kz0iws6	75	96	due	due	JJ
cord-293860-6kz0iws6	75	97	drug	drug	NN
cord-293860-6kz0iws6	75	98	-	-	HYPH
cord-293860-6kz0iws6	75	99	induced	induce	VBN
cord-293860-6kz0iws6	75	100	disruption	disruption	NN
cord-293860-6kz0iws6	75	101	of	of	IN
cord-293860-6kz0iws6	75	102	the	the	DT
cord-293860-6kz0iws6	75	103	virus	virus	NN
cord-293860-6kz0iws6	75	104	replication	replication	NN
cord-293860-6kz0iws6	75	105	cycle	cycle	NN
cord-293860-6kz0iws6	75	106	.	.	.
cord-293860-6kz0iws6	76	1	One	one	CD
cord-293860-6kz0iws6	76	2	of	of	IN
cord-293860-6kz0iws6	76	3	the	the	DT
cord-293860-6kz0iws6	76	4	main	main	JJ
cord-293860-6kz0iws6	76	5	treatment	treatment	NN
cord-293860-6kz0iws6	76	6	strategies	strategy	NNS
cord-293860-6kz0iws6	76	7	for	for	IN
cord-293860-6kz0iws6	76	8	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	76	9	is	be	VBZ
cord-293860-6kz0iws6	76	10	to	to	TO
cord-293860-6kz0iws6	76	11	identify	identify	VB
cord-293860-6kz0iws6	76	12	new	new	JJ
cord-293860-6kz0iws6	76	13	targeted	target	VBN
cord-293860-6kz0iws6	76	14	antiviral	antiviral	JJ
cord-293860-6kz0iws6	76	15	drugs	drug	NNS
cord-293860-6kz0iws6	76	16	based	base	VBN
cord-293860-6kz0iws6	76	17	on	on	IN
cord-293860-6kz0iws6	76	18	the	the	DT
cord-293860-6kz0iws6	76	19	genomic	genomic	JJ
cord-293860-6kz0iws6	76	20	information	information	NN
cord-293860-6kz0iws6	76	21	and	and	CC
cord-293860-6kz0iws6	76	22	pathological	pathological	JJ
cord-293860-6kz0iws6	76	23	characteristics	characteristic	NNS
cord-293860-6kz0iws6	76	24	of	of	IN
cord-293860-6kz0iws6	76	25	SARS	SARS	NNP
cord-293860-6kz0iws6	76	26	-	-	HYPH
cord-293860-6kz0iws6	76	27	CoV-2	CoV-2	NNP
cord-293860-6kz0iws6	76	28	.	.	.
cord-293860-6kz0iws6	77	1	These	these	DT
cord-293860-6kz0iws6	77	2	drugs	drug	NNS
cord-293860-6kz0iws6	77	3	are	be	VBP
cord-293860-6kz0iws6	77	4	likely	likely	JJ
cord-293860-6kz0iws6	77	5	to	to	TO
cord-293860-6kz0iws6	77	6	be	be	VB
cord-293860-6kz0iws6	77	7	the	the	DT
cord-293860-6kz0iws6	77	8	most	most	RBS
cord-293860-6kz0iws6	77	9	effective	effective	JJ
cord-293860-6kz0iws6	77	10	against	against	IN
cord-293860-6kz0iws6	77	11	the	the	DT
cord-293860-6kz0iws6	77	12	virus	virus	NN
cord-293860-6kz0iws6	77	13	.	.	.
cord-293860-6kz0iws6	78	1	However	however	RB
cord-293860-6kz0iws6	78	2	,	,	,
cord-293860-6kz0iws6	78	3	anti	anti	JJ
cord-293860-6kz0iws6	78	4	-	-	JJ
cord-293860-6kz0iws6	78	5	viral	viral	JJ
cord-293860-6kz0iws6	78	6	drug	drug	NN
cord-293860-6kz0iws6	78	7	development	development	NN
cord-293860-6kz0iws6	78	8	and	and	CC
cord-293860-6kz0iws6	78	9	registration	registration	NN
cord-293860-6kz0iws6	78	10	is	be	VBZ
cord-293860-6kz0iws6	78	11	time	time	NN
cord-293860-6kz0iws6	78	12	-	-	HYPH
cord-293860-6kz0iws6	78	13	consuming	consume	VBG
cord-293860-6kz0iws6	78	14	,	,	,
cord-293860-6kz0iws6	78	15	the	the	DT
cord-293860-6kz0iws6	78	16	drug	drug	NN
cord-293860-6kz0iws6	78	17	might	may	MD
cord-293860-6kz0iws6	78	18	not	not	RB
cord-293860-6kz0iws6	78	19	be	be	VB
cord-293860-6kz0iws6	78	20	available	available	JJ
cord-293860-6kz0iws6	78	21	for	for	IN
cord-293860-6kz0iws6	78	22	the	the	DT
cord-293860-6kz0iws6	78	23	current	current	JJ
cord-293860-6kz0iws6	78	24	outbreak	outbreak	NN
cord-293860-6kz0iws6	78	25	and	and	CC
cord-293860-6kz0iws6	78	26	it	-PRON-	PRP
cord-293860-6kz0iws6	78	27	is	be	VBZ
cord-293860-6kz0iws6	78	28	likely	likely	JJ
cord-293860-6kz0iws6	78	29	to	to	TO
cord-293860-6kz0iws6	78	30	be	be	VB
cord-293860-6kz0iws6	78	31	very	very	RB
cord-293860-6kz0iws6	78	32	expensive	expensive	JJ
cord-293860-6kz0iws6	78	33	,	,	,
cord-293860-6kz0iws6	78	34	an	an	DT
cord-293860-6kz0iws6	78	35	important	important	JJ
cord-293860-6kz0iws6	78	36	factor	factor	NN
cord-293860-6kz0iws6	78	37	particularly	particularly	RB
cord-293860-6kz0iws6	78	38	in	in	IN
cord-293860-6kz0iws6	78	39	poorer	poor	JJR
cord-293860-6kz0iws6	78	40	countries	country	NNS
cord-293860-6kz0iws6	78	41	afflicted	afflict	VBN
cord-293860-6kz0iws6	78	42	by	by	IN
cord-293860-6kz0iws6	78	43	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	78	44	.	.	.
cord-293860-6kz0iws6	79	1	An	an	DT
cord-293860-6kz0iws6	79	2	alternative	alternative	NN
cord-293860-6kz0iws6	79	3	,	,	,
cord-293860-6kz0iws6	79	4	faster	fast	JJR
cord-293860-6kz0iws6	79	5	strategy	strategy	NN
cord-293860-6kz0iws6	79	6	is	be	VBZ
cord-293860-6kz0iws6	79	7	'	'	``
cord-293860-6kz0iws6	79	8	drug	drug	NN
cord-293860-6kz0iws6	79	9	repurposing	repurposing	NN
cord-293860-6kz0iws6	79	10	'	'	''
cord-293860-6kz0iws6	79	11	.	.	.
cord-293860-6kz0iws6	80	1	This	this	DT
cord-293860-6kz0iws6	80	2	relies	rely	VBZ
cord-293860-6kz0iws6	80	3	on	on	IN
cord-293860-6kz0iws6	80	4	identification	identification	NN
cord-293860-6kz0iws6	80	5	of	of	IN
cord-293860-6kz0iws6	80	6	potential	potential	JJ
cord-293860-6kz0iws6	80	7	therapeutic	therapeutic	JJ
cord-293860-6kz0iws6	80	8	characteristics	characteristic	NNS
cord-293860-6kz0iws6	80	9	of	of	IN
cord-293860-6kz0iws6	80	10	drugs	drug	NNS
cord-293860-6kz0iws6	80	11	currently	currently	RB
cord-293860-6kz0iws6	80	12	licensed	license	VBN
cord-293860-6kz0iws6	80	13	for	for	IN
cord-293860-6kz0iws6	80	14	other	other	JJ
cord-293860-6kz0iws6	80	15	purposes	purpose	NNS
cord-293860-6kz0iws6	80	16	.	.	.
cord-293860-6kz0iws6	81	1	There	there	EX
cord-293860-6kz0iws6	81	2	are	be	VBP
cord-293860-6kz0iws6	81	3	many	many	JJ
cord-293860-6kz0iws6	81	4	clinical	clinical	JJ
cord-293860-6kz0iws6	81	5	trials	trial	NNS
cord-293860-6kz0iws6	81	6	enrolling	enrol	VBG
cord-293860-6kz0iws6	81	7	patients	patient	NNS
cord-293860-6kz0iws6	81	8	with	with	IN
cord-293860-6kz0iws6	81	9	COVID-19	COVID-19	,
cord-293860-6kz0iws6	81	10	worldwide	worldwide	RB
cord-293860-6kz0iws6	81	11	investigating	investigate	VBG
cord-293860-6kz0iws6	81	12	the	the	DT
cord-293860-6kz0iws6	81	13	potential	potential	JJ
cord-293860-6kz0iws6	81	14	benefits	benefit	NNS
cord-293860-6kz0iws6	81	15	of	of	IN
cord-293860-6kz0iws6	81	16	established	establish	VBN
cord-293860-6kz0iws6	81	17	antimicrobial	antimicrobial	JJ
cord-293860-6kz0iws6	81	18	,	,	,
cord-293860-6kz0iws6	81	19	antiviral	antiviral	JJ
cord-293860-6kz0iws6	81	20	and	and	CC
cord-293860-6kz0iws6	81	21	anti	anti	JJ
cord-293860-6kz0iws6	81	22	-	-	JJ
cord-293860-6kz0iws6	81	23	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	81	24	drugs	drug	NNS
cord-293860-6kz0iws6	81	25	27	27	CD
cord-293860-6kz0iws6	81	26	.	.	.
cord-293860-6kz0iws6	82	1	The	the	DT
cord-293860-6kz0iws6	82	2	strong	strong	JJ
cord-293860-6kz0iws6	82	3	association	association	NN
cord-293860-6kz0iws6	82	4	between	between	IN
cord-293860-6kz0iws6	82	5	the	the	DT
cord-293860-6kz0iws6	82	6	pro	pro	JJ
cord-293860-6kz0iws6	82	7	-	-	JJ
cord-293860-6kz0iws6	82	8	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	82	9	state	state	NN
cord-293860-6kz0iws6	82	10	found	find	VBN
cord-293860-6kz0iws6	82	11	in	in	IN
cord-293860-6kz0iws6	82	12	metabolic	metabolic	JJ
cord-293860-6kz0iws6	82	13	syndrome	syndrome	NN
cord-293860-6kz0iws6	82	14	and	and	CC
cord-293860-6kz0iws6	82	15	obesity	obesity	NN
cord-293860-6kz0iws6	82	16	and	and	CC
cord-293860-6kz0iws6	82	17	a	a	DT
cord-293860-6kz0iws6	82	18	more	more	RBR
cord-293860-6kz0iws6	82	19	aggressive	aggressive	JJ
cord-293860-6kz0iws6	82	20	clinical	clinical	JJ
cord-293860-6kz0iws6	82	21	course	course	NN
cord-293860-6kz0iws6	82	22	in	in	IN
cord-293860-6kz0iws6	82	23	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	82	24	suggests	suggest	VBZ
cord-293860-6kz0iws6	82	25	a	a	DT
cord-293860-6kz0iws6	82	26	potential	potential	JJ
cord-293860-6kz0iws6	82	27	treatment	treatment	NN
cord-293860-6kz0iws6	82	28	role	role	NN
cord-293860-6kz0iws6	82	29	for	for	IN
cord-293860-6kz0iws6	82	30	drugs	drug	NNS
cord-293860-6kz0iws6	82	31	that	that	WDT
cord-293860-6kz0iws6	82	32	inhibit	inhibit	VBP
cord-293860-6kz0iws6	82	33	cytokine	cytokine	NN
cord-293860-6kz0iws6	82	34	release	release	NN
cord-293860-6kz0iws6	82	35	and	and	CC
cord-293860-6kz0iws6	82	36	macrophage	macrophage	NN
cord-293860-6kz0iws6	82	37	activation	activation	NN
cord-293860-6kz0iws6	82	38	.	.	.
cord-293860-6kz0iws6	83	1	There	there	EX
cord-293860-6kz0iws6	83	2	is	be	VBZ
cord-293860-6kz0iws6	83	3	,	,	,
cord-293860-6kz0iws6	83	4	however	however	RB
cord-293860-6kz0iws6	83	5	,	,	,
cord-293860-6kz0iws6	83	6	so	so	RB
cord-293860-6kz0iws6	83	7	far	far	RB
cord-293860-6kz0iws6	83	8	no	no	DT
cord-293860-6kz0iws6	83	9	convincing	convincing	JJ
cord-293860-6kz0iws6	83	10	clinical	clinical	JJ
cord-293860-6kz0iws6	83	11	evidence	evidence	NN
cord-293860-6kz0iws6	83	12	to	to	TO
cord-293860-6kz0iws6	83	13	support	support	VB
cord-293860-6kz0iws6	83	14	the	the	DT
cord-293860-6kz0iws6	83	15	use	use	NN
cord-293860-6kz0iws6	83	16	of	of	IN
cord-293860-6kz0iws6	83	17	corticosteroids	corticosteroid	NNS
cord-293860-6kz0iws6	83	18	,	,	,
cord-293860-6kz0iws6	83	19	one	one	CD
cord-293860-6kz0iws6	83	20	of	of	IN
cord-293860-6kz0iws6	83	21	the	the	DT
cord-293860-6kz0iws6	83	22	most	most	RBS
cord-293860-6kz0iws6	83	23	widely	widely	RB
cord-293860-6kz0iws6	83	24	utilised	utilise	VBN
cord-293860-6kz0iws6	83	25	anti	anti	JJ
cord-293860-6kz0iws6	83	26	-	-	JJ
cord-293860-6kz0iws6	83	27	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	83	28	agents	agent	NNS
cord-293860-6kz0iws6	83	29	.	.	.
cord-293860-6kz0iws6	84	1	If	if	IN
cord-293860-6kz0iws6	84	2	anything	anything	NN
cord-293860-6kz0iws6	84	3	,	,	,
cord-293860-6kz0iws6	84	4	there	there	EX
cord-293860-6kz0iws6	84	5	is	be	VBZ
cord-293860-6kz0iws6	84	6	concern	concern	NN
cord-293860-6kz0iws6	84	7	about	about	IN
cord-293860-6kz0iws6	84	8	patients	patient	NNS
cord-293860-6kz0iws6	84	9	being	be	VBG
cord-293860-6kz0iws6	84	10	harmed	harm	VBN
cord-293860-6kz0iws6	84	11	with	with	IN
cord-293860-6kz0iws6	84	12	such	such	PDT
cord-293860-6kz0iws6	84	13	a	a	DT
cord-293860-6kz0iws6	84	14	treatment	treatment	NN
cord-293860-6kz0iws6	84	15	28	28	CD
cord-293860-6kz0iws6	84	16	,	,	,
cord-293860-6kz0iws6	84	17	29	29	CD
cord-293860-6kz0iws6	84	18	.	.	.
cord-293860-6kz0iws6	85	1	Anti	Anti	NNS
cord-293860-6kz0iws6	85	2	-	-	NNS
cord-293860-6kz0iws6	85	3	cytokines	cytokine	NNS
cord-293860-6kz0iws6	86	1	(	(	-LRB-
cord-293860-6kz0iws6	86	2	interleukin	interleukin	NN
cord-293860-6kz0iws6	86	3	6	6	CD
cord-293860-6kz0iws6	86	4	inhibitors	inhibitor	NNS
cord-293860-6kz0iws6	86	5	,	,	,
cord-293860-6kz0iws6	86	6	e.g.	e.g.	RB
cord-293860-6kz0iws6	86	7	,	,	,
cord-293860-6kz0iws6	86	8	tocilizumab	tocilizumab	NN
cord-293860-6kz0iws6	86	9	)	)	-RRB-
cord-293860-6kz0iws6	86	10	have	have	VBP
cord-293860-6kz0iws6	86	11	also	also	RB
cord-293860-6kz0iws6	86	12	attracted	attract	VBN
cord-293860-6kz0iws6	86	13	much	much	JJ
cord-293860-6kz0iws6	86	14	interest	interest	NN
cord-293860-6kz0iws6	86	15	recently	recently	RB
cord-293860-6kz0iws6	86	16	30	30	CD
cord-293860-6kz0iws6	86	17	with	with	IN
cord-293860-6kz0iws6	86	18	a	a	DT
cord-293860-6kz0iws6	86	19	few	few	JJ
cord-293860-6kz0iws6	86	20	ongoing	ongoing	JJ
cord-293860-6kz0iws6	86	21	clinical	clinical	JJ
cord-293860-6kz0iws6	86	22	trials	trial	NNS
cord-293860-6kz0iws6	86	23	assessing	assess	VBG
cord-293860-6kz0iws6	86	24	their	-PRON-	PRP$
cord-293860-6kz0iws6	86	25	role	role	NN
cord-293860-6kz0iws6	86	26	27	27	CD
cord-293860-6kz0iws6	86	27	.	.	.
cord-293860-6kz0iws6	87	1	However	however	RB
cord-293860-6kz0iws6	87	2	,	,	,
cord-293860-6kz0iws6	87	3	these	these	DT
cord-293860-6kz0iws6	87	4	monoclonal	monoclonal	JJ
cord-293860-6kz0iws6	87	5	antibodies	antibody	NNS
cord-293860-6kz0iws6	87	6	are	be	VBP
cord-293860-6kz0iws6	87	7	expensive	expensive	JJ
cord-293860-6kz0iws6	87	8	and	and	CC
cord-293860-6kz0iws6	87	9	like	like	IN
cord-293860-6kz0iws6	87	10	corticosteroids	corticosteroid	NNS
cord-293860-6kz0iws6	87	11	have	have	VBP
cord-293860-6kz0iws6	87	12	the	the	DT
cord-293860-6kz0iws6	87	13	potential	potential	NN
cord-293860-6kz0iws6	87	14	for	for	IN
cord-293860-6kz0iws6	87	15	promoting	promote	VBG
cord-293860-6kz0iws6	87	16	secondary	secondary	JJ
cord-293860-6kz0iws6	87	17	infections	infection	NNS
cord-293860-6kz0iws6	87	18	.	.	.
cord-293860-6kz0iws6	88	1	Cost	cost	NN
cord-293860-6kz0iws6	88	2	and	and	CC
cord-293860-6kz0iws6	88	3	complications	complication	NNS
cord-293860-6kz0iws6	88	4	are	be	VBP
cord-293860-6kz0iws6	88	5	likely	likely	JJ
cord-293860-6kz0iws6	88	6	to	to	TO
cord-293860-6kz0iws6	88	7	limit	limit	VB
cord-293860-6kz0iws6	88	8	their	-PRON-	PRP$
cord-293860-6kz0iws6	88	9	application	application	NN
cord-293860-6kz0iws6	88	10	on	on	IN
cord-293860-6kz0iws6	88	11	a	a	DT
cord-293860-6kz0iws6	88	12	global	global	JJ
cord-293860-6kz0iws6	88	13	scale	scale	NN
cord-293860-6kz0iws6	88	14	,	,	,
cord-293860-6kz0iws6	88	15	other	other	JJ
cord-293860-6kz0iws6	88	16	than	than	IN
cord-293860-6kz0iws6	88	17	selective	selective	JJ
cord-293860-6kz0iws6	88	18	use	use	NN
cord-293860-6kz0iws6	88	19	in	in	IN
cord-293860-6kz0iws6	88	20	severely	severely	RB
cord-293860-6kz0iws6	88	21	ill	ill	JJ
cord-293860-6kz0iws6	88	22	patients	patient	NNS
cord-293860-6kz0iws6	88	23	30	30	CD
cord-293860-6kz0iws6	88	24	,	,	,
cord-293860-6kz0iws6	88	25	31	31	CD
cord-293860-6kz0iws6	88	26	.	.	.
cord-293860-6kz0iws6	89	1	We	-PRON-	PRP
cord-293860-6kz0iws6	89	2	believe	believe	VBP
cord-293860-6kz0iws6	89	3	there	there	EX
cord-293860-6kz0iws6	89	4	is	be	VBZ
cord-293860-6kz0iws6	89	5	a	a	DT
cord-293860-6kz0iws6	89	6	good	good	JJ
cord-293860-6kz0iws6	89	7	theoretical	theoretical	JJ
cord-293860-6kz0iws6	89	8	basis	basis	NN
cord-293860-6kz0iws6	89	9	to	to	TO
cord-293860-6kz0iws6	89	10	consider	consider	VB
cord-293860-6kz0iws6	89	11	montelukast	montelukast	NNP
cord-293860-6kz0iws6	89	12	as	as	IN
cord-293860-6kz0iws6	89	13	a	a	DT
cord-293860-6kz0iws6	89	14	therapeutic	therapeutic	JJ
cord-293860-6kz0iws6	89	15	candidate	candidate	NN
cord-293860-6kz0iws6	89	16	with	with	IN
cord-293860-6kz0iws6	89	17	a	a	DT
cord-293860-6kz0iws6	89	18	hypothetical	hypothetical	JJ
cord-293860-6kz0iws6	89	19	dual	dual	JJ
cord-293860-6kz0iws6	89	20	mode	mode	NN
cord-293860-6kz0iws6	89	21	of	of	IN
cord-293860-6kz0iws6	89	22	action	action	NN
cord-293860-6kz0iws6	89	23	through	through	IN
cord-293860-6kz0iws6	89	24	suppression	suppression	NN
cord-293860-6kz0iws6	89	25	of	of	IN
cord-293860-6kz0iws6	89	26	cytokine	cytokine	NN
cord-293860-6kz0iws6	89	27	activity	activity	NN
cord-293860-6kz0iws6	89	28	and	and	CC
cord-293860-6kz0iws6	89	29	interference	interference	NN
cord-293860-6kz0iws6	89	30	with	with	IN
cord-293860-6kz0iws6	89	31	viral	viral	JJ
cord-293860-6kz0iws6	89	32	replication	replication	NN
cord-293860-6kz0iws6	89	33	.	.	.
cord-293860-6kz0iws6	90	1	To	to	IN
cord-293860-6kz0iws6	90	2	date	date	NN
cord-293860-6kz0iws6	90	3	,	,	,
cord-293860-6kz0iws6	90	4	the	the	DT
cord-293860-6kz0iws6	90	5	Cochrane	Cochrane	NNP
cord-293860-6kz0iws6	90	6	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	90	7	Study	Study	NNP
cord-293860-6kz0iws6	90	8	Register	Register	NNP
cord-293860-6kz0iws6	90	9	does	do	VBZ
cord-293860-6kz0iws6	90	10	not	not	RB
cord-293860-6kz0iws6	90	11	identify	identify	VB
cord-293860-6kz0iws6	90	12	any	any	DT
cord-293860-6kz0iws6	90	13	studies	study	NNS
cord-293860-6kz0iws6	90	14	exploring	explore	VBG
cord-293860-6kz0iws6	90	15	the	the	DT
cord-293860-6kz0iws6	90	16	clinical	clinical	JJ
cord-293860-6kz0iws6	90	17	benefits	benefit	NNS
cord-293860-6kz0iws6	90	18	of	of	IN
cord-293860-6kz0iws6	90	19	montelukast	montelukast	NNP
cord-293860-6kz0iws6	90	20	.	.	.
cord-293860-6kz0iws6	91	1	Whilst	whilst	IN
cord-293860-6kz0iws6	91	2	it	-PRON-	PRP
cord-293860-6kz0iws6	91	3	is	be	VBZ
cord-293860-6kz0iws6	91	4	unlikely	unlikely	JJ
cord-293860-6kz0iws6	91	5	that	that	IN
cord-293860-6kz0iws6	91	6	montelukast	montelukast	NN
cord-293860-6kz0iws6	91	7	would	would	MD
cord-293860-6kz0iws6	91	8	be	be	VB
cord-293860-6kz0iws6	91	9	effective	effective	JJ
cord-293860-6kz0iws6	91	10	at	at	IN
cord-293860-6kz0iws6	91	11	curing	cure	VBG
cord-293860-6kz0iws6	91	12	COVID-19	covid-19	VB
cord-293860-6kz0iws6	91	13	or	or	CC
cord-293860-6kz0iws6	91	14	reversing	reverse	VBG
cord-293860-6kz0iws6	91	15	severe	severe	JJ
cord-293860-6kz0iws6	91	16	immune	immune	NN
cord-293860-6kz0iws6	91	17	-	-	HYPH
cord-293860-6kz0iws6	91	18	modulated	modulate	VBN
cord-293860-6kz0iws6	91	19	multiorgan	multiorgan	NN
cord-293860-6kz0iws6	91	20	damage	damage	NN
cord-293860-6kz0iws6	91	21	,	,	,
cord-293860-6kz0iws6	91	22	it	-PRON-	PRP
cord-293860-6kz0iws6	91	23	could	could	MD
cord-293860-6kz0iws6	91	24	have	have	VB
cord-293860-6kz0iws6	91	25	a	a	DT
cord-293860-6kz0iws6	91	26	powerful	powerful	JJ
cord-293860-6kz0iws6	91	27	role	role	NN
cord-293860-6kz0iws6	91	28	in	in	IN
cord-293860-6kz0iws6	91	29	preventing	prevent	VBG
cord-293860-6kz0iws6	91	30	disease	disease	NN
cord-293860-6kz0iws6	91	31	progression	progression	NN
cord-293860-6kz0iws6	91	32	when	when	WRB
cord-293860-6kz0iws6	91	33	used	use	VBN
cord-293860-6kz0iws6	91	34	at	at	IN
cord-293860-6kz0iws6	91	35	an	an	DT
cord-293860-6kz0iws6	91	36	early	early	JJ
cord-293860-6kz0iws6	91	37	stage	stage	NN
cord-293860-6kz0iws6	91	38	in	in	IN
cord-293860-6kz0iws6	91	39	the	the	DT
cord-293860-6kz0iws6	91	40	disease	disease	NN
cord-293860-6kz0iws6	91	41	,	,	,
cord-293860-6kz0iws6	91	42	reducing	reduce	VBG
cord-293860-6kz0iws6	91	43	the	the	DT
cord-293860-6kz0iws6	91	44	need	need	NN
cord-293860-6kz0iws6	91	45	for	for	IN
cord-293860-6kz0iws6	91	46	hospital	hospital	NN
cord-293860-6kz0iws6	91	47	admission	admission	NN
cord-293860-6kz0iws6	91	48	,	,	,
cord-293860-6kz0iws6	91	49	or	or	CC
cord-293860-6kz0iws6	92	1	the	the	DT
cord-293860-6kz0iws6	92	2	requirement	requirement	NN
cord-293860-6kz0iws6	92	3	for	for	IN
cord-293860-6kz0iws6	92	4	the	the	DT
cord-293860-6kz0iws6	92	5	care	care	NN
cord-293860-6kz0iws6	92	6	of	of	IN
cord-293860-6kz0iws6	92	7	hospitalised	hospitalise	VBN
cord-293860-6kz0iws6	92	8	patients	patient	NNS
cord-293860-6kz0iws6	92	9	to	to	TO
cord-293860-6kz0iws6	92	10	be	be	VB
cord-293860-6kz0iws6	92	11	escalated	escalate	VBN
cord-293860-6kz0iws6	92	12	up	up	RP
cord-293860-6kz0iws6	92	13	to	to	TO
cord-293860-6kz0iws6	92	14	level	level	VB
cord-293860-6kz0iws6	92	15	3	3	CD
cord-293860-6kz0iws6	92	16	critical	critical	JJ
cord-293860-6kz0iws6	92	17	care	care	NN
cord-293860-6kz0iws6	92	18	.	.	.
cord-293860-6kz0iws6	93	1	It	-PRON-	PRP
cord-293860-6kz0iws6	93	2	may	may	MD
cord-293860-6kz0iws6	93	3	shorten	shorten	VB
cord-293860-6kz0iws6	93	4	the	the	DT
cord-293860-6kz0iws6	93	5	course	course	NN
cord-293860-6kz0iws6	93	6	of	of	IN
cord-293860-6kz0iws6	93	7	mild	mild	JJ
cord-293860-6kz0iws6	93	8	to	to	TO
cord-293860-6kz0iws6	93	9	moderate	moderate	JJ
cord-293860-6kz0iws6	93	10	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	93	11	with	with	IN
cord-293860-6kz0iws6	93	12	the	the	DT
cord-293860-6kz0iws6	93	13	attendant	attendant	JJ
cord-293860-6kz0iws6	93	14	social	social	JJ
cord-293860-6kz0iws6	93	15	,	,	,
cord-293860-6kz0iws6	93	16	economic	economic	JJ
cord-293860-6kz0iws6	93	17	and	and	CC
cord-293860-6kz0iws6	93	18	healthcare	healthcare	NN
cord-293860-6kz0iws6	93	19	system	system	NN
cord-293860-6kz0iws6	93	20	benefits	benefit	NNS
cord-293860-6kz0iws6	93	21	that	that	WDT
cord-293860-6kz0iws6	93	22	would	would	MD
cord-293860-6kz0iws6	93	23	bring	bring	VB
cord-293860-6kz0iws6	93	24	.	.	.
cord-293860-6kz0iws6	94	1	Furthermore	furthermore	RB
cord-293860-6kz0iws6	94	2	,	,	,
cord-293860-6kz0iws6	94	3	it	-PRON-	PRP
cord-293860-6kz0iws6	94	4	has	have	VBZ
cord-293860-6kz0iws6	94	5	a	a	DT
cord-293860-6kz0iws6	94	6	good	good	JJ
cord-293860-6kz0iws6	94	7	safety	safety	NN
cord-293860-6kz0iws6	94	8	profile	profile	NN
cord-293860-6kz0iws6	94	9	.	.	.
cord-293860-6kz0iws6	95	1	But	but	CC
cord-293860-6kz0iws6	95	2	perhaps	perhaps	RB
cord-293860-6kz0iws6	95	3	most	most	RBS
cord-293860-6kz0iws6	95	4	importantly	importantly	RB
cord-293860-6kz0iws6	95	5	,	,	,
cord-293860-6kz0iws6	95	6	if	if	IN
cord-293860-6kz0iws6	95	7	montelukast	montelukast	NNP
cord-293860-6kz0iws6	95	8	was	be	VBD
cord-293860-6kz0iws6	95	9	shown	show	VBN
cord-293860-6kz0iws6	95	10	to	to	TO
cord-293860-6kz0iws6	95	11	be	be	VB
cord-293860-6kz0iws6	95	12	of	of	IN
cord-293860-6kz0iws6	95	13	clinical	clinical	JJ
cord-293860-6kz0iws6	95	14	benefit	benefit	NN
cord-293860-6kz0iws6	95	15	in	in	IN
cord-293860-6kz0iws6	95	16	well	well	RB
cord-293860-6kz0iws6	95	17	-	-	HYPH
cord-293860-6kz0iws6	95	18	conducted	conduct	VBN
cord-293860-6kz0iws6	95	19	studies	study	NNS
cord-293860-6kz0iws6	95	20	it	-PRON-	PRP
cord-293860-6kz0iws6	95	21	is	be	VBZ
cord-293860-6kz0iws6	95	22	a	a	DT
cord-293860-6kz0iws6	95	23	widely	widely	RB
cord-293860-6kz0iws6	95	24	applicable	applicable	JJ
cord-293860-6kz0iws6	95	25	treatment	treatment	NN
cord-293860-6kz0iws6	95	26	,	,	,
cord-293860-6kz0iws6	95	27	accessible	accessible	JJ
cord-293860-6kz0iws6	95	28	to	to	IN
cord-293860-6kz0iws6	95	29	all	all	DT
cord-293860-6kz0iws6	95	30	patients	patient	NNS
cord-293860-6kz0iws6	95	31	,	,	,
cord-293860-6kz0iws6	95	32	and	and	CC
cord-293860-6kz0iws6	95	33	at	at	IN
cord-293860-6kz0iws6	95	34	just	just	RB
cord-293860-6kz0iws6	95	35	over	over	RB
cord-293860-6kz0iws6	95	36	£	£	$
cord-293860-6kz0iws6	95	37	4	4	CD
cord-293860-6kz0iws6	95	38	per	per	IN
cord-293860-6kz0iws6	95	39	month	month	NN
cord-293860-6kz0iws6	95	40	21	21	CD
cord-293860-6kz0iws6	95	41	,	,	,
cord-293860-6kz0iws6	95	42	not	not	RB
cord-293860-6kz0iws6	95	43	just	just	RB
cord-293860-6kz0iws6	95	44	available	available	JJ
cord-293860-6kz0iws6	95	45	to	to	IN
cord-293860-6kz0iws6	95	46	those	those	DT
cord-293860-6kz0iws6	95	47	who	who	WP
cord-293860-6kz0iws6	95	48	live	live	VBP
cord-293860-6kz0iws6	95	49	in	in	IN
cord-293860-6kz0iws6	95	50	nations	nation	NNS
cord-293860-6kz0iws6	95	51	with	with	IN
cord-293860-6kz0iws6	95	52	firstworld	firstworld	NNP
cord-293860-6kz0iws6	95	53	healthcare	healthcare	NN
cord-293860-6kz0iws6	95	54	resources	resource	NNS
cord-293860-6kz0iws6	95	55	that	that	WDT
cord-293860-6kz0iws6	95	56	can	can	MD
cord-293860-6kz0iws6	95	57	afford	afford	VB
cord-293860-6kz0iws6	95	58	highly	highly	RB
cord-293860-6kz0iws6	95	59	expensive	expensive	JJ
cord-293860-6kz0iws6	95	60	new	new	JJ
cord-293860-6kz0iws6	95	61	drugs	drug	NNS
cord-293860-6kz0iws6	95	62	.	.	.
cord-293860-6kz0iws6	96	1	Neither	neither	DT
cord-293860-6kz0iws6	96	2	of	of	IN
cord-293860-6kz0iws6	96	3	the	the	DT
cord-293860-6kz0iws6	96	4	authors	author	NNS
cord-293860-6kz0iws6	96	5	have	have	VBP
cord-293860-6kz0iws6	96	6	any	any	DT
cord-293860-6kz0iws6	96	7	conflicting	conflict	VBG
cord-293860-6kz0iws6	96	8	interests	interest	NNS
cord-293860-6kz0iws6	96	9	and	and	CC
cord-293860-6kz0iws6	96	10	neither	neither	CC
cord-293860-6kz0iws6	96	11	receive	receive	VBP
cord-293860-6kz0iws6	96	12	funding	funding	NN
cord-293860-6kz0iws6	96	13	from	from	IN
cord-293860-6kz0iws6	96	14	any	any	DT
cord-293860-6kz0iws6	96	15	third	third	JJ
cord-293860-6kz0iws6	96	16	party	party	NN
cord-293860-6kz0iws6	96	17	or	or	CC
cord-293860-6kz0iws6	96	18	external	external	JJ
cord-293860-6kz0iws6	96	19	source	source	NN
cord-293860-6kz0iws6	96	20	.	.	.
cord-293860-6kz0iws6	97	1	Professor	Professor	NNP
cord-293860-6kz0iws6	97	2	Kerrigan	Kerrigan	NNP
cord-293860-6kz0iws6	97	3	was	be	VBD
cord-293860-6kz0iws6	97	4	the	the	DT
cord-293860-6kz0iws6	97	5	original	original	JJ
cord-293860-6kz0iws6	97	6	creator	creator	NN
cord-293860-6kz0iws6	97	7	of	of	IN
cord-293860-6kz0iws6	97	8	the	the	DT
cord-293860-6kz0iws6	97	9	hypothesis	hypothesis	NN
cord-293860-6kz0iws6	97	10	linking	link	VBG
cord-293860-6kz0iws6	97	11	potential	potential	JJ
cord-293860-6kz0iws6	97	12	therapeutic	therapeutic	JJ
cord-293860-6kz0iws6	97	13	benefits	benefit	NNS
cord-293860-6kz0iws6	97	14	of	of	IN
cord-293860-6kz0iws6	97	15	montelukast	montelukast	NNP
cord-293860-6kz0iws6	97	16	in	in	IN
cord-293860-6kz0iws6	97	17	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	97	18	,	,	,
cord-293860-6kz0iws6	97	19	with	with	IN
cord-293860-6kz0iws6	97	20	the	the	DT
cord-293860-6kz0iws6	97	21	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	97	22	state	state	NN
cord-293860-6kz0iws6	97	23	associated	associate	VBN
cord-293860-6kz0iws6	97	24	with	with	IN
cord-293860-6kz0iws6	97	25	obesity	obesity	NN
cord-293860-6kz0iws6	97	26	.	.	.
cord-293860-6kz0iws6	98	1	Both	both	DT
cord-293860-6kz0iws6	98	2	authors	author	NNS
cord-293860-6kz0iws6	98	3	were	be	VBD
cord-293860-6kz0iws6	98	4	involved	involve	VBN
cord-293860-6kz0iws6	98	5	in	in	IN
cord-293860-6kz0iws6	98	6	background	background	NN
cord-293860-6kz0iws6	98	7	research	research	NN
cord-293860-6kz0iws6	98	8	and	and	CC
cord-293860-6kz0iws6	98	9	the	the	DT
cord-293860-6kz0iws6	98	10	writing	writing	NN
cord-293860-6kz0iws6	98	11	of	of	IN
cord-293860-6kz0iws6	98	12	the	the	DT
cord-293860-6kz0iws6	98	13	manuscript	manuscript	NN
cord-293860-6kz0iws6	98	14	.	.	.
cord-293860-6kz0iws6	99	1	This	this	DT
cord-293860-6kz0iws6	99	2	paper	paper	NN
cord-293860-6kz0iws6	99	3	did	do	VBD
cord-293860-6kz0iws6	99	4	not	not	RB
cord-293860-6kz0iws6	99	5	require	require	VB
cord-293860-6kz0iws6	99	6	ethics	ethic	NNS
cord-293860-6kz0iws6	99	7	approval	approval	NN
cord-293860-6kz0iws6	99	8	.	.	.
cord-293860-6kz0iws6	100	1	Regulation	regulation	NN
cord-293860-6kz0iws6	100	2	of	of	IN
cord-293860-6kz0iws6	100	3	adipose	adipose	JJ
cord-293860-6kz0iws6	100	4	tissue	tissue	NN
cord-293860-6kz0iws6	100	5	inflammation	inflammation	NN
cord-293860-6kz0iws6	100	6	by	by	IN
cord-293860-6kz0iws6	100	7	interleukin	interleukin	NN
cord-293860-6kz0iws6	100	8	6	6	CD
cord-293860-6kz0iws6	100	9	Circulating	circulate	VBG
cord-293860-6kz0iws6	100	10	levels	level	NNS
cord-293860-6kz0iws6	100	11	of	of	IN
cord-293860-6kz0iws6	100	12	MCP-1	MCP-1	NNP
cord-293860-6kz0iws6	101	1	and	and	CC
cord-293860-6kz0iws6	101	2	IL-8	IL-8	NNP
cord-293860-6kz0iws6	101	3	are	be	VBP
cord-293860-6kz0iws6	101	4	elevated	elevate	VBN
cord-293860-6kz0iws6	101	5	in	in	IN
cord-293860-6kz0iws6	101	6	human	human	JJ
cord-293860-6kz0iws6	101	7	obese	obese	JJ
cord-293860-6kz0iws6	101	8	subjects	subject	NNS
cord-293860-6kz0iws6	101	9	and	and	CC
cord-293860-6kz0iws6	101	10	associated	associate	VBN
cord-293860-6kz0iws6	101	11	with	with	IN
cord-293860-6kz0iws6	101	12	obesity	obesity	NN
cord-293860-6kz0iws6	101	13	-	-	HYPH
cord-293860-6kz0iws6	101	14	related	relate	VBN
cord-293860-6kz0iws6	101	15	parameters	parameter	NNS
cord-293860-6kz0iws6	101	16	Inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	101	17	cytokines	cytokine	NNS
cord-293860-6kz0iws6	101	18	in	in	IN
cord-293860-6kz0iws6	101	19	general	general	JJ
cord-293860-6kz0iws6	101	20	and	and	CC
cord-293860-6kz0iws6	101	21	central	central	JJ
cord-293860-6kz0iws6	101	22	obesity	obesity	NN
cord-293860-6kz0iws6	101	23	and	and	CC
cord-293860-6kz0iws6	101	24	modulating	modulate	VBG
cord-293860-6kz0iws6	101	25	effects	effect	NNS
cord-293860-6kz0iws6	101	26	of	of	IN
cord-293860-6kz0iws6	101	27	physical	physical	JJ
cord-293860-6kz0iws6	101	28	activity	activity	NN
cord-293860-6kz0iws6	101	29	Features	feature	NNS
cord-293860-6kz0iws6	101	30	of	of	IN
cord-293860-6kz0iws6	101	31	16,749	16,749	CD
cord-293860-6kz0iws6	101	32	hospitalised	hospitalise	VBN
cord-293860-6kz0iws6	101	33	UK	UK	NNP
cord-293860-6kz0iws6	101	34	patients	patient	NNS
cord-293860-6kz0iws6	101	35	with	with	IN
cord-293860-6kz0iws6	101	36	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	101	37	using	use	VBG
cord-293860-6kz0iws6	101	38	the	the	DT
cord-293860-6kz0iws6	101	39	ISARIC	ISARIC	NNP
cord-293860-6kz0iws6	102	1	WHO	who	WP
cord-293860-6kz0iws6	102	2	Clinical	Clinical	NNP
cord-293860-6kz0iws6	102	3	Characterisation	Characterisation	NNP
cord-293860-6kz0iws6	102	4	Protocol	Protocol	NNP
cord-293860-6kz0iws6	102	5	Are	be	VBP
cord-293860-6kz0iws6	102	6	more	more	RBR
cord-293860-6kz0iws6	102	7	black	black	JJ
cord-293860-6kz0iws6	102	8	,	,	,
cord-293860-6kz0iws6	102	9	Asian	asian	JJ
cord-293860-6kz0iws6	102	10	and	and	CC
cord-293860-6kz0iws6	102	11	minority	minority	NN
cord-293860-6kz0iws6	102	12	ethnic	ethnic	JJ
cord-293860-6kz0iws6	102	13	people	people	NNS
cord-293860-6kz0iws6	102	14	dying	die	VBG
cord-293860-6kz0iws6	102	15	with	with	IN
cord-293860-6kz0iws6	102	16	Covid-19	covid-19	NN
cord-293860-6kz0iws6	102	17	than	than	IN
cord-293860-6kz0iws6	102	18	might	may	MD
cord-293860-6kz0iws6	102	19	be	be	VB
cord-293860-6kz0iws6	102	20	expected	expect	VBN
cord-293860-6kz0iws6	102	21	?	?	.
cord-293860-6kz0iws6	103	1	Southall	Southall	NNP
cord-293860-6kz0iws6	103	2	And	and	CC
cord-293860-6kz0iws6	103	3	Brent	Brent	NNP
cord-293860-6kz0iws6	103	4	REvisited	REvisited	NNP
cord-293860-6kz0iws6	103	5	:	:	:
cord-293860-6kz0iws6	104	1	Cohort	cohort	NN
cord-293860-6kz0iws6	104	2	profile	profile	NN
cord-293860-6kz0iws6	104	3	of	of	IN
cord-293860-6kz0iws6	104	4	SABRE	SABRE	NNP
cord-293860-6kz0iws6	104	5	,	,	,
cord-293860-6kz0iws6	104	6	a	a	DT
cord-293860-6kz0iws6	104	7	UK	UK	NNP
cord-293860-6kz0iws6	104	8	population	population	NN
cord-293860-6kz0iws6	104	9	-	-	HYPH
cord-293860-6kz0iws6	104	10	based	base	VBN
cord-293860-6kz0iws6	104	11	comparison	comparison	NN
cord-293860-6kz0iws6	104	12	of	of	IN
cord-293860-6kz0iws6	104	13	cardiovascular	cardiovascular	JJ
cord-293860-6kz0iws6	104	14	disease	disease	NN
cord-293860-6kz0iws6	104	15	and	and	CC
cord-293860-6kz0iws6	104	16	diabetes	diabetes	NN
cord-293860-6kz0iws6	104	17	in	in	IN
cord-293860-6kz0iws6	104	18	people	people	NNS
cord-293860-6kz0iws6	104	19	of	of	IN
cord-293860-6kz0iws6	104	20	European	european	JJ
cord-293860-6kz0iws6	104	21	,	,	,
cord-293860-6kz0iws6	104	22	Indian	indian	JJ
cord-293860-6kz0iws6	104	23	Asian	asian	JJ
cord-293860-6kz0iws6	104	24	and	and	CC
cord-293860-6kz0iws6	104	25	African	african	JJ
cord-293860-6kz0iws6	104	26	Caribbean	caribbean	JJ
cord-293860-6kz0iws6	104	27	origins	origin	NNS
cord-293860-6kz0iws6	105	1	Is	be	VBZ
cord-293860-6kz0iws6	105	2	ethnicity	ethnicity	NN
cord-293860-6kz0iws6	105	3	linked	link	VBN
cord-293860-6kz0iws6	105	4	to	to	IN
cord-293860-6kz0iws6	105	5	incidence	incidence	NN
cord-293860-6kz0iws6	105	6	or	or	CC
cord-293860-6kz0iws6	105	7	outcomes	outcome	NNS
cord-293860-6kz0iws6	105	8	of	of	IN
cord-293860-6kz0iws6	105	9	covid-19	covid-19	NN
cord-293860-6kz0iws6	105	10	?	?	.
cord-293860-6kz0iws6	106	1	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	106	2	,	,	,
cord-293860-6kz0iws6	106	3	a	a	DT
cord-293860-6kz0iws6	106	4	leukotriene	leukotriene	NN
cord-293860-6kz0iws6	106	5	receptor	receptor	NN
cord-293860-6kz0iws6	106	6	antagonist	antagonist	NN
cord-293860-6kz0iws6	106	7	,	,	,
cord-293860-6kz0iws6	106	8	inhibits	inhibit	VBZ
cord-293860-6kz0iws6	106	9	the	the	DT
cord-293860-6kz0iws6	106	10	late	late	JJ
cord-293860-6kz0iws6	106	11	airway	airway	NN
cord-293860-6kz0iws6	106	12	response	response	NN
cord-293860-6kz0iws6	106	13	to	to	IN
cord-293860-6kz0iws6	106	14	antigen	antigen	NN
cord-293860-6kz0iws6	106	15	,	,	,
cord-293860-6kz0iws6	106	16	airway	airway	NN
cord-293860-6kz0iws6	106	17	eosinophilia	eosinophilia	NN
cord-293860-6kz0iws6	106	18	,	,	,
cord-293860-6kz0iws6	106	19	and	and	CC
cord-293860-6kz0iws6	106	20	IL-5-expressing	il-5-expressing	NN
cord-293860-6kz0iws6	106	21	cells	cell	NNS
cord-293860-6kz0iws6	106	22	in	in	IN
cord-293860-6kz0iws6	106	23	Brown	Brown	NNP
cord-293860-6kz0iws6	106	24	Norway	Norway	NNP
cord-293860-6kz0iws6	106	25	rats	rat	NNS
cord-293860-6kz0iws6	106	26	Effect	Effect	NNP
cord-293860-6kz0iws6	106	27	of	of	IN
cord-293860-6kz0iws6	106	28	Montelukast	Montelukast	NNP
cord-293860-6kz0iws6	106	29	on	on	IN
cord-293860-6kz0iws6	106	30	Pro	pro	JJ
cord-293860-6kz0iws6	106	31	-	-	JJ
cord-293860-6kz0iws6	106	32	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	106	33	Cytokine	cytokine	NN
cord-293860-6kz0iws6	106	34	Production	production	NN
cord-293860-6kz0iws6	106	35	During	during	IN
cord-293860-6kz0iws6	106	36	Naturally	naturally	RB
cord-293860-6kz0iws6	106	37	Acquired	acquire	VBN
cord-293860-6kz0iws6	106	38	Viral	Viral	NNP
cord-293860-6kz0iws6	106	39	Upper	Upper	NNP
cord-293860-6kz0iws6	106	40	Respiratory	respiratory	JJ
cord-293860-6kz0iws6	106	41	Infections	infection	NNS
cord-293860-6kz0iws6	106	42	(	(	-LRB-
cord-293860-6kz0iws6	106	43	vURIs	vuris	NN
cord-293860-6kz0iws6	106	44	)	)	-RRB-
cord-293860-6kz0iws6	107	1	in	in	IN
cord-293860-6kz0iws6	107	2	Adults	Adults	NNP
cord-293860-6kz0iws6	107	3	Analysis	Analysis	NNP
cord-293860-6kz0iws6	107	4	of	of	IN
cord-293860-6kz0iws6	107	5	therapeutic	therapeutic	JJ
cord-293860-6kz0iws6	107	6	targets	target	NNS
cord-293860-6kz0iws6	107	7	for	for	IN
cord-293860-6kz0iws6	107	8	SARS	SARS	NNP
cord-293860-6kz0iws6	107	9	-	-	HYPH
cord-293860-6kz0iws6	107	10	CoV-2	CoV-2	NNP
cord-293860-6kz0iws6	107	11	and	and	CC
cord-293860-6kz0iws6	107	12	discovery	discovery	NN
cord-293860-6kz0iws6	107	13	of	of	IN
cord-293860-6kz0iws6	107	14	potential	potential	JJ
cord-293860-6kz0iws6	107	15	drugs	drug	NNS
cord-293860-6kz0iws6	107	16	by	by	IN
cord-293860-6kz0iws6	107	17	computational	computational	JJ
cord-293860-6kz0iws6	107	18	methods	method	NNS
cord-293860-6kz0iws6	107	19	Identification	identification	NN
cord-293860-6kz0iws6	107	20	of	of	IN
cord-293860-6kz0iws6	107	21	FDA	FDA	NNP
cord-293860-6kz0iws6	107	22	approved	approve	VBD
cord-293860-6kz0iws6	107	23	drugs	drug	NNS
cord-293860-6kz0iws6	107	24	targeting	target	VBG
cord-293860-6kz0iws6	107	25	COVID-19	covid-19	JJ
cord-293860-6kz0iws6	107	26	virus	virus	NN
cord-293860-6kz0iws6	107	27	by	by	IN
cord-293860-6kz0iws6	107	28	structure	structure	NN
cord-293860-6kz0iws6	107	29	-	-	HYPH
cord-293860-6kz0iws6	107	30	based	base	VBN
cord-293860-6kz0iws6	107	31	drug	drug	NN
cord-293860-6kz0iws6	107	32	repositioning	repositioning	NN
cord-293860-6kz0iws6	107	33	(	(	-LRB-
cord-293860-6kz0iws6	107	34	Pre	pre	JJ
cord-293860-6kz0iws6	107	35	-	-	JJ
cord-293860-6kz0iws6	107	36	print	print	JJ
cord-293860-6kz0iws6	107	37	)	)	-RRB-
cord-293860-6kz0iws6	107	38	Dysregulation	dysregulation	NN
cord-293860-6kz0iws6	107	39	of	of	IN
cord-293860-6kz0iws6	107	40	immune	immune	JJ
cord-293860-6kz0iws6	107	41	response	response	NN
cord-293860-6kz0iws6	107	42	in	in	IN
cord-293860-6kz0iws6	107	43	patients	patient	NNS
cord-293860-6kz0iws6	107	44	with	with	IN
cord-293860-6kz0iws6	107	45	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	107	46	in	in	IN
cord-293860-6kz0iws6	107	47	Wuhan	Wuhan	NNP
cord-293860-6kz0iws6	107	48	,	,	,
cord-293860-6kz0iws6	107	49	China	China	NNP
cord-293860-6kz0iws6	107	50	.	.	.
cord-293860-6kz0iws6	108	1	Clin	Clin	NNP
cord-293860-6kz0iws6	108	2	Infect	infect	NN
cord-293860-6kz0iws6	108	3	Dis	Dis	NNP
cord-293860-6kz0iws6	108	4	Clinical	clinical	JJ
cord-293860-6kz0iws6	108	5	features	feature	NNS
cord-293860-6kz0iws6	108	6	of	of	IN
cord-293860-6kz0iws6	108	7	patients	patient	NNS
cord-293860-6kz0iws6	108	8	infected	infect	VBN
cord-293860-6kz0iws6	108	9	with	with	IN
cord-293860-6kz0iws6	108	10	2019	2019	CD
cord-293860-6kz0iws6	108	11	novel	novel	JJ
cord-293860-6kz0iws6	108	12	coronavirus	coronavirus	NN
cord-293860-6kz0iws6	108	13	in	in	IN
cord-293860-6kz0iws6	108	14	Wuhan	Wuhan	NNP
cord-293860-6kz0iws6	108	15	Clinical	Clinical	NNP
cord-293860-6kz0iws6	108	16	Features	Features	NNPS
cord-293860-6kz0iws6	108	17	of	of	IN
cord-293860-6kz0iws6	108	18	69	69	CD
cord-293860-6kz0iws6	108	19	Cases	case	NNS
cord-293860-6kz0iws6	108	20	with	with	IN
cord-293860-6kz0iws6	108	21	Coronavirus	Coronavirus	NNP
cord-293860-6kz0iws6	108	22	Disease	Disease	NNP
cord-293860-6kz0iws6	108	23	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	108	24	:	:	:
cord-293860-6kz0iws6	108	25	consider	consider	VB
cord-293860-6kz0iws6	108	26	cytokine	cytokine	JJ
cord-293860-6kz0iws6	108	27	storm	storm	NN
cord-293860-6kz0iws6	108	28	syndromes	syndrome	NNS
cord-293860-6kz0iws6	108	29	and	and	CC
cord-293860-6kz0iws6	108	30	immunosuppression	immunosuppression	NN
cord-293860-6kz0iws6	108	31	Pathogenic	pathogenic	JJ
cord-293860-6kz0iws6	108	32	human	human	JJ
cord-293860-6kz0iws6	108	33	coronavirus	coronavirus	NN
cord-293860-6kz0iws6	108	34	infections	infection	NNS
cord-293860-6kz0iws6	108	35	:	:	:
cord-293860-6kz0iws6	108	36	causes	cause	NNS
cord-293860-6kz0iws6	108	37	and	and	CC
cord-293860-6kz0iws6	108	38	consequences	consequence	NNS
cord-293860-6kz0iws6	108	39	of	of	IN
cord-293860-6kz0iws6	108	40	cytokine	cytokine	NN
cord-293860-6kz0iws6	108	41	storm	storm	NN
cord-293860-6kz0iws6	108	42	and	and	CC
cord-293860-6kz0iws6	108	43	immunopathology	immunopathology	NN
cord-293860-6kz0iws6	108	44	Cysteinyl	Cysteinyl	NNP
cord-293860-6kz0iws6	108	45	leukotrienes	leukotriene	NNS
cord-293860-6kz0iws6	108	46	and	and	CC
cord-293860-6kz0iws6	108	47	their	-PRON-	PRP$
cord-293860-6kz0iws6	108	48	receptors	receptor	NNS
cord-293860-6kz0iws6	108	49	:	:	:
cord-293860-6kz0iws6	108	50	cellular	cellular	JJ
cord-293860-6kz0iws6	108	51	distribution	distribution	NN
cord-293860-6kz0iws6	108	52	and	and	CC
cord-293860-6kz0iws6	108	53	function	function	NN
cord-293860-6kz0iws6	108	54	in	in	IN
cord-293860-6kz0iws6	108	55	immune	immune	JJ
cord-293860-6kz0iws6	108	56	and	and	CC
cord-293860-6kz0iws6	108	57	inflammatory	inflammatory	JJ
cord-293860-6kz0iws6	108	58	responses	response	NNS
cord-293860-6kz0iws6	108	59	Cysteinyl	Cysteinyl	NNP
cord-293860-6kz0iws6	108	60	leukotrienes	leukotriene	NNS
cord-293860-6kz0iws6	108	61	:	:	:
cord-293860-6kz0iws6	108	62	multifunctional	multifunctional	JJ
cord-293860-6kz0iws6	108	63	mediators	mediator	NNS
cord-293860-6kz0iws6	108	64	in	in	IN
cord-293860-6kz0iws6	108	65	allergic	allergic	JJ
cord-293860-6kz0iws6	108	66	rhinitis	rhinitis	NN
cord-293860-6kz0iws6	108	67	Leukotriene	Leukotriene	NNP
cord-293860-6kz0iws6	108	68	E4	E4	NNP
cord-293860-6kz0iws6	108	69	and	and	CC
cord-293860-6kz0iws6	108	70	granulocytic	granulocytic	JJ
cord-293860-6kz0iws6	108	71	infiltration	infiltration	NN
cord-293860-6kz0iws6	108	72	into	into	IN
cord-293860-6kz0iws6	108	73	asthmatic	asthmatic	JJ
cord-293860-6kz0iws6	108	74	airways	airway	NNS
cord-293860-6kz0iws6	108	75	Singulair	Singulair	NNP
cord-293860-6kz0iws6	108	76	(	(	-LRB-
cord-293860-6kz0iws6	108	77	montelukast	montelukast	NNP
cord-293860-6kz0iws6	108	78	sodium	sodium	NN
cord-293860-6kz0iws6	108	79	)	)	-RRB-
cord-293860-6kz0iws6	109	1	US	US	NNP
cord-293860-6kz0iws6	109	2	FDA	FDA	NNP
cord-293860-6kz0iws6	109	3	Label	Label	NNP
cord-293860-6kz0iws6	109	4	Coronaviruses	Coronaviruses	NNP
cord-293860-6kz0iws6	109	5	-drug	-drug	NNP
cord-293860-6kz0iws6	109	6	discovery	discovery	NN
cord-293860-6kz0iws6	109	7	and	and	CC
cord-293860-6kz0iws6	109	8	therapeutic	therapeutic	JJ
cord-293860-6kz0iws6	109	9	options	option	NNS
cord-293860-6kz0iws6	110	1	Structural	structural	JJ
cord-293860-6kz0iws6	110	2	insights	insight	NNS
cord-293860-6kz0iws6	110	3	into	into	IN
cord-293860-6kz0iws6	110	4	coronavirus	coronavirus	NN
cord-293860-6kz0iws6	110	5	entry	entry	NN
cord-293860-6kz0iws6	110	6	A	a	DT
cord-293860-6kz0iws6	110	7	pneumonia	pneumonia	NN
cord-293860-6kz0iws6	110	8	outbreak	outbreak	NN
cord-293860-6kz0iws6	110	9	associated	associate	VBN
cord-293860-6kz0iws6	110	10	with	with	IN
cord-293860-6kz0iws6	110	11	a	a	DT
cord-293860-6kz0iws6	110	12	new	new	JJ
cord-293860-6kz0iws6	110	13	coronavirus	coronavirus	NN
cord-293860-6kz0iws6	110	14	of	of	IN
cord-293860-6kz0iws6	110	15	probable	probable	JJ
cord-293860-6kz0iws6	110	16	bat	bat	NN
cord-293860-6kz0iws6	110	17	origin	origin	NN
cord-293860-6kz0iws6	110	18	Structure	structure	NN
cord-293860-6kz0iws6	110	19	,	,	,
cord-293860-6kz0iws6	110	20	Function	Function	NNP
cord-293860-6kz0iws6	110	21	,	,	,
cord-293860-6kz0iws6	110	22	and	and	CC
cord-293860-6kz0iws6	110	23	Antigenicity	Antigenicity	NNP
cord-293860-6kz0iws6	110	24	of	of	IN
cord-293860-6kz0iws6	110	25	the	the	DT
cord-293860-6kz0iws6	110	26	SARS	SARS	NNP
cord-293860-6kz0iws6	110	27	-	-	HYPH
cord-293860-6kz0iws6	110	28	CoV-2	CoV-2	NNP
cord-293860-6kz0iws6	110	29	Spike	Spike	NNP
cord-293860-6kz0iws6	110	30	Glycoprotein	Glycoprotein	NNP
cord-293860-6kz0iws6	110	31	ZINC	zinc	NN
cord-293860-6kz0iws6	110	32	:	:	:
cord-293860-6kz0iws6	110	33	a	a	DT
cord-293860-6kz0iws6	110	34	free	free	JJ
cord-293860-6kz0iws6	110	35	tool	tool	NN
cord-293860-6kz0iws6	110	36	to	to	TO
cord-293860-6kz0iws6	110	37	discover	discover	VB
cord-293860-6kz0iws6	110	38	chemistry	chemistry	NN
cord-293860-6kz0iws6	110	39	for	for	IN
cord-293860-6kz0iws6	110	40	biology	biology	NN
cord-293860-6kz0iws6	111	1	A	a	DT
cord-293860-6kz0iws6	111	2	real	real	JJ
cord-293860-6kz0iws6	111	3	-	-	HYPH
cord-293860-6kz0iws6	111	4	time	time	NN
cord-293860-6kz0iws6	111	5	dashboard	dashboard	NN
cord-293860-6kz0iws6	111	6	of	of	IN
cord-293860-6kz0iws6	111	7	clinical	clinical	JJ
cord-293860-6kz0iws6	111	8	trials	trial	NNS
cord-293860-6kz0iws6	111	9	for	for	IN
cord-293860-6kz0iws6	111	10	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	111	11	Clinical	clinical	JJ
cord-293860-6kz0iws6	111	12	evidence	evidence	NN
cord-293860-6kz0iws6	111	13	does	do	VBZ
cord-293860-6kz0iws6	111	14	not	not	RB
cord-293860-6kz0iws6	111	15	support	support	VB
cord-293860-6kz0iws6	111	16	corticosteroid	corticosteroid	NN
cord-293860-6kz0iws6	111	17	treatment	treatment	NN
cord-293860-6kz0iws6	111	18	for	for	IN
cord-293860-6kz0iws6	111	19	2019-nCoV	2019-ncov	CD
cord-293860-6kz0iws6	111	20	lung	lung	NN
cord-293860-6kz0iws6	111	21	injury	injury	NN
cord-293860-6kz0iws6	111	22	Immunosuppression	Immunosuppression	NNP
cord-293860-6kz0iws6	111	23	for	for	IN
cord-293860-6kz0iws6	111	24	hyperinflammation	hyperinflammation	NN
cord-293860-6kz0iws6	111	25	in	in	IN
cord-293860-6kz0iws6	111	26	COVID-19	COVID-19	NNP
cord-293860-6kz0iws6	111	27	:	:	:
cord-293860-6kz0iws6	111	28	a	a	DT
cord-293860-6kz0iws6	111	29	double	double	RB
cord-293860-6kz0iws6	111	30	-	-	HYPH
cord-293860-6kz0iws6	111	31	edged	edged	JJ
cord-293860-6kz0iws6	111	32	sword	sword	NN
cord-293860-6kz0iws6	111	33	?	?	.
cord-293860-6kz0iws6	112	1	Can	Can	MD
cord-293860-6kz0iws6	112	2	we	-PRON-	PRP
cord-293860-6kz0iws6	112	3	use	use	VB
cord-293860-6kz0iws6	112	4	interleukin-6	interleukin-6	NNP
cord-293860-6kz0iws6	112	5	(	(	-LRB-
cord-293860-6kz0iws6	112	6	IL-6	IL-6	NNP
cord-293860-6kz0iws6	112	7	)	)	-RRB-
cord-293860-6kz0iws6	112	8	blockade	blockade	NN
cord-293860-6kz0iws6	112	9	for	for	IN
cord-293860-6kz0iws6	112	10	coronavirus	coronavirus	NN
cord-293860-6kz0iws6	112	11	disease	disease	NN
cord-293860-6kz0iws6	112	12	2019	2019	CD
cord-293860-6kz0iws6	112	13	(	(	-LRB-
cord-293860-6kz0iws6	112	14	COVID-19)-induced	covid-19)-induce	VBN
cord-293860-6kz0iws6	112	15	cytokine	cytokine	NN
cord-293860-6kz0iws6	112	16	release	release	NN
cord-293860-6kz0iws6	112	17	syndrome	syndrome	NN
cord-293860-6kz0iws6	112	18	(	(	-LRB-
cord-293860-6kz0iws6	112	19	CRS	CRS	NNP
cord-293860-6kz0iws6	112	20	)	)	-RRB-
cord-293860-6kz0iws6	112	21	?	?	.
cord-293860-6kz0iws6	113	1	Why	why	WRB
cord-293860-6kz0iws6	113	2	tocilizumab	tocilizumab	NN
cord-293860-6kz0iws6	113	3	could	could	MD
cord-293860-6kz0iws6	113	4	be	be	VB
cord-293860-6kz0iws6	113	5	an	an	DT
cord-293860-6kz0iws6	113	6	effective	effective	JJ
cord-293860-6kz0iws6	113	7	treatment	treatment	NN
cord-293860-6kz0iws6	113	8	for	for	IN
cord-293860-6kz0iws6	113	9	severe	severe	JJ
cord-293860-6kz0iws6	113	10	COVID-19	covid-19	NN
cord-293860-6kz0iws6	113	11	?	?	.